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Outline of the thesis 
Chapter 1: “General introduction on epilepsy”. This chapter provides a general introduction on 
epilepsy, refractory epilepsy and its treatment options. The animal models used in this thesis are 
described. 
Chapter 2: “Vagus nerve stimulation for refractory epilepsy”. This chapter provides an introduction 
on the cervical anatomy and physiology of the vagus nerve, the antiepileptic mechanism of action of 
vagus nerve stimulation (VNS), the VNS stimulation parameters and the efficacy and safety of the 
VNS therapy. 
Chapter 3: “Vagus nerve stimulation and the central noradrenergic pathway”. This chapter describes 
the central noradreneregic pathway as an important contributor in the antiepileptic effect of VNS. 
Chapter 4: “Rationale and research aims of the thesis”.  
Chapter 5: “Increased hippocampal noradrenaline is a biomarker for efficacy of vagus nerve 
stimulation in a limbic seizure model”. This study addresses the role of noradrenaline in the 
antiepileptic effect of VNS. VNS-induced changes in hippocampal noradrenaline levels are measured 
and its potential involvement in the antiepileptic action of VNS is determined in an animal model for 
limbic seizures. 
Chapter 6: “Intensity-dependent modulatory effects of vagus nerve stimulation on cortical 
excitability”. This study investigates the effect of various VNS output current intensities on cortical 
excitability in the motor cortex stimulation rat model. The hypothesis that output current intensities 
in the lower range are sufficient to affect cortical excitability is evaluated. 
Chapter 7: “Repeated assessment of larynx compound muscle action potentials using a self-sizing 
cuff electrode around the vagus nerve in experimental rats”. The goal of this study is to determine an 
objective parameter that can be used as an indicator of effective VNS-induced activation of the vagus 
nerve in rats.  
Chapter 8: “Electrophysiological responses from vagus nerve stimulation in rats”. In this study, 
stimulation-induced vagus nerve electrophysiological responses are measured using various 
stimulation parameters in rats, in order to determine a biological marker reflecting true vagal fiber 
activation when electrical stimulation is applied to the vagus nerve.  
Chapter 9: “Conclusion, discussion and future perspectives”. 
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Definition and epidemiology 
According to the definition of the International League Against Epilepsy (ILAE), epilepsy is a chronic 
neurological condition characterized by the occurrence of recurrent, usually unprovoked epileptic 
seizures (Fisher et al. 2005). An epileptic seizure represents the signs and symptoms that result from 
excessive, synchronous, abnormal firing patterns of groups of neurons which are usually, but not 
necessarily, located in the cerebral cortex (Seino 2006). The clinical manifestation consists of a 
sudden and transitory abnormal phenomenon which may include alterations of consciousness, 
motor, sensory, autonomic or psychic events (Engel 2006a). The occurrence of a single seizure does 
not make a person have epilepsy, but when two or more seizures occur, the diagnosis of epilepsy can 
be made (Boon et al. 1996). 
Epilepsy is the second most common serious neurological disorder following neurovascular diseases, 
with a worldwide prevalence of approximately 0.5-1% (Sander and Shorvon 1996; Banerjee and 
Hauser 2008). It is estimated that the annual incidence of new onset epilepsy in the general 
population is more than 80 per 100,000 (Hirose 2013). Epilepsy affects both sexes and the incidence 
rate is age related. The highest incidence rate is observed in the first year of life. Incidence is lowest 
during adult years and increases in the elderly as a result of the higher prevalence of cerebrovascular 
disorders (Hauser et al. 1996). 
Diagnosis and classification  
The initial diagnosis of epilepsy is based on clinical symptoms, the medical history and Electro-
Encephalo-Graphic (EEG) recordings. A correct diagnosis of epilepsy includes the identification of the 
epileptic focus in the brain cortex and the type(s) of epileptic seizure(s) the patient is suffering from. 
Different types of epileptic seizures can occur within a single epilepsy syndrome. Classifying epileptic 
seizures is challenging, as they are numerous and diverse in their presentation, underlying 
pathophysiology, age relationships, prevalence and triggering factors (Panayiotopoulos 2007). 
The most universally accepted classification of epileptic seizures is the International Classification of 
Seizures that was developed by the Commission on Classification of the ILAE (Commission on 
Classification 1981). Epileptic seizures can be divided into two main categories depending on their 
onset in the brain: those that are partial in onset and those that have a generalized onset. Partial or 
General introduction on epilepsy 
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focal seizures are the result of an abnormal paroxysmal discharge originating in one cerebral 
hemisphere. They can be subclassified as simple - with retention of consciousness - and complex - 
with impairment or complete loss of consciousness. The clinical presentation of a seizure depends on 
the localization of the ictal onset in the brain, as well as the pattern of propagation. Seizures can 
affect sensory, motor and autonomic function, consciousness, emotional state, memory, cognition 
and behaviour (Panayiotopoulos 2007). Both simple and complex partial seizures may gradually 
develop into secondary generalized seizures when epileptic activity spreads to the contralateral 
hemisphere. Primary generalized seizures differ from focal seizures in clinical presentation, aetiology, 
neuroanatomy and neurobiology. They result from abnormal paroxysmal discharges arising in both 
cerebral hemispheres and can be subclassified as tonic-clonic seizures, absences and myoclonic 
seizures. Tonic-clonic seizures are often preceded by an aura and are characterized by an intial tonic 
and a subsequent clonic phase. During the tonic phase, the patient’s muscles stiffen and they lose 
consciousness. During the subsequent clonic phase, the individual’s muscles begin to spasm and jerk. 
Postictally stupor, confusion, autonomic behaviour and sleep may occur (Zifkin and Dravet 2008). 
Absence seizures, sometimes referred to as petit mail seizures, are brief genezalized seizures of 
sudden onset and termination, characterized by loss of consciousness and bursts of spike-wave 
discharges on the EEG (Panayiotopoulos 2007). Children between 4-12 years old are most susceptible 
to absences seizures. Myoclonic seizures manifest as involuntary, shock-like and often arrhythmic 
unidirectional movements that can be focal, multifocal or generalized (Panayiotopoulos 2007). They 
usually occur without detectable loss of consciousness.  
The ILAE Commission on Classification also devised a classification of epilepsy syndromes 
(Commission on Classification 1989). According to the underlying presumptive cause, epilepsy 
syndromes can be divided into symptomatic, idiopathic and cryptogenic. Symptomatic epilepsy 
syndromes arise as a result of structural or metabolic abnormalities in the brain, which can be either 
acquired (e.g. infections, trauma), endogenous (e.g. neoplasm) or genetic (e.g. tuberous sclerosis) in 
origin. Idiopathic epilepsy syndromes are without an identifiable structural abnormality or aetiology, 
and are thought to be genetic in origin. Cryptogenic epilepsy syndromes are presumably symptomatic 
but currently of unknown aetiology.  
The ILAE has recently proposed a new categorization of epilepsy syndromes based on the aetiology 
(Berg et al. 2010). Instead of the terms symptomatic, idiopathic and cryptogenic, epilepsy syndromes 
can be divided into genetic, structural/metabolic and of unknown cause. The concept of genetic 
epilepsy is that the epilepsy is, as best as understood, the direct result of a known or presumed 
genetic defect in which seizures are the core symptom of the disorder. For structural/metabolic 
epilepsy, there is a distinct other structural or metabolic condition or disease that has been 
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demonstrated to be associated with a substantially increased risk of developing epilepsy in 
appropriately designed studies. The term unknown cause is used to designate that the nature of the 
underlying cause is as yet unknown. 
Once the initial diagnosis of epilepsy is made, additional tools such as long-term video-EEG 
monitoring, Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography 
(SPECT) and Positron Emission Tomography (PET) can help to discover the aetiology of the epilepsy, 
to determine the affected brain region, to (sub)classify the epilepsy syndrome and to determine an 
appropriate treatment, especially in patients with pharmacoresistant epilepsy. 
Pathophysiology 
Within the normal brain, a constant equilibrium exists between excitation and inhibition. Epileptic 
seizures are generally believed to arise as a result of an imbalance between excitation and inhibition 
(in favour of excitation), making the cortex prone to sudden hyperexcitable and uncontrolled 
electrical activity. Epileptogenesis refers to a dynamic process of pathological changes that 
progressively alters neuronal excitability and transforms a normal healthy brain into an epileptic 
brain (Pitkänen and Lukasiuk 2011). These pathological changes include neurodegeneration, 
neurogenesis, gliosis, axonal damage or sprouting, dendritic plasticity, blood brain barrier damage 
and recruitment of inflammatory cells into brain tissue.  
Treatment 
Uncontrolled epilepsy is associated with excess injury and mortality, and increased adverse 
psychosocial, behavioural and cognitive consequences, resulting in a low quality of life and an 
enormous burden of economic costs (Tomson et al. 2004; Wirrell 2006; Cardarelli and Smith 2010). 
Epilepsy treatment is generally initiated after a second unprovoked seizure. The goal of medical 
treatment in epilepsy is to achieve seizure freedom without inducing unwanted side-effects. 
Antiepileptic Drugs (AEDs) are the primary option for the management of epilepsy. Kwan and Brodie 
have shown that the first AED leads to seizure freedom in 47% of patients with newly diagnosed 
epilepsy. Thirteen percent of patients are seizure free with the second AED, and only 1% after 
switching to a third AED (Kwan and Brodie 2001). The ILAE defined pharmacoresistant or refractory 
epilepsy as “failure of adequate trials of two tolerated, appropriately chosen and used AED 
schedules, whether as monotherapy or in combination, to achieve sustained seizure freedom” (Kwan 
et al. 2010). Patients with refractory epilepsy require a thorough diagnostic and therapeutic 
evaluation in a specialized epilepsy center. For these patients, alternative treatment options include 
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the administration of newly developed AEDs, epilepsy surgery, gamma knife radiosugery, dietary 
treatments, immune-based therapies and neurostimulation.  
Newly developed AEDs 
The least invasive alternative treatment for refractory epilepsy consists of including patients in trails 
with newly developed AEDs. Administration of newly developed AEDs leads to seizure freedom in 
only 6% and to 50% seizure frequency reduction in only 21% of refractory patients (Fisher 1993; 
Beyenburg et al. 2010).  
Epilepsy surgery 
Epilepsy surgery is an invasive but often curative treatment option that involves the resection or 
disconnection of the epileptogenic zone, believed to be responsible for seizure occurrence, in order 
to eliminate seizures (Spencer 2002). Epilepsy surgery is considered when the epileptogenic zone can 
be identified and is located in a brain area that does not cause a functional deficit when removed. 
Epilepsy sugery is a successful treatment for patients with focal epilepsy with long-term seizure 
freedom of 40-75% (Wiebe et al. 2001; Engel et al. 2003; Cohen-Gadol et al. 2006; de Tisi et al. 2011). 
Gamma knife radiosurgery 
In gamma knife radiosurgery, specialized equipment focuses gamma radiation to well-defined small 
volumes of brain tissue, rendering it less seizure-prone (Romanelli and Anschel 2006). Cortical 
structures can be targeted with gamma knife radiosurgery with a stereotactic precision, without 
opening the skull. The precision of gamma knife radiosurgery results in minimal damage to healthy 
tissue surrounding the epileptogenic zone. Outcome in terms of seizure control is variable, but good 
safety profiles are reported (Regis et al. 2004; Chang et al. 2010; Romanelli et al. 2012).  
Dietary treatments 
The ketogenic diet encourages the intake of excessive amounts of fat (80% of daily meal), adequate 
amounts of protein (15% of daily meal) and low amounts of carbohydrate (5% of daily meal). The aim 
of the diet is to force the body to find an alternative energy source due to carbohydrate restriction. 
Stored body fat is metabolized in the liver and as a final product, ketones are released into the 
circulation and used in the brain as an alternative energy source (Huffman and Kossoff 2006). The 
presumed correlation between seizure reduction and ketone increase remains unproven. Acute side 
effects that can occur immediately upon starting the diet include nausea and vomiting, 
hypoglycemia, excessive ketosis and acidosis. Chronic implications include constipation, renal stones, 
cardiomyopathy, weight loss, retarded growth, high cholesterol levels, higher chances of infection, 
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specific vitamin and/or mineral deficiencies and rarely pancreatitis. But the most common reason for 
discontinuation of the diet is felt to be the “too restrictive nature” of the diet (Dhamija et al. 2013). 
Long-term prospective studies show a reduction of seizure frequency of more than 90% in one third 
of the patients who are able to continue the diet (Freeman et al. 1998, 2006). Because of the high 
chance of side effects, the ketogenic diet is only used for catastrophic childhood epilepsy, such as 
epileptic encephalopathies (Dhamija et al. 2013).  
The Atkins’diet is a variant of the ketogenic diet and was initially developed for the purpose of weight 
loss (Carrette et al. 2008). The Atkins’ diet also encourages the intake of fat and the restriction of 
carbohydrates, but the daily allowed amount of protein is higher compared to the ketogenic diet. 
The Atkins’ diet allows meals containing 60% fat, 30% protein and 10% carbohydrates. Because of 
strong carbohydrate restriction, patients following the Atkins’ diet also produce ketones. The main 
reasons why patients stop the Atkins’s diet are inefficacy, side effects and restrictiveness (Kossoff et 
al. 2008). 
Immune-based therapies 
Immune system dysfunction may play a role in epilepsy by triggering or maintaining epileptic 
seizures. Immunoglobulin treatment as a result may have a beneficial effect on epileptic seizures. 
The suggested mechanism of action of immunoglobulin treatment for refractory epilepsy has been 
related to (i) the compensation of possible immunoglobulin deficiencies, (ii) the suppression of 
infections, (iii) the neutralization of pathogenic autoantibodies and (iv) the interference with cytokine 
production (Villani and Avanzini 2002). Because of the lack of double-blind controlled clinical studies, 
no definite conclusions can be made concerning efficacy and safety of this approach. 
Treatment with corticosteroids is a primary treatment option for children with West Syndrome (Arya 
et al. 2012). This devastating epilepsy syndrome is characterized by infantile spasms and is poorly 
responsive to conventional antiepileptic medications. The exact mechanism of action of 
corticosteroid treatment is unknown, although many putative mechanisms have been reported. 
Corticosteroids have several regulatory effects on growth of neuroblasts, myelination and 
metabolism in the developing brain (Hrachovy and Frost 2008). In addition, corticosteroids have been 
demonstrated to influence important enzymes and growth factors in the developing cerebrum in 
animals (Molteni et al. 2001) and more than 200 steroid-responsive genes have been identified in the 
rat hippocampus involved in axonogenesis, synaptogenesis, cell adhesion and signal transduction 
(Vreugdenhil et al. 2001).  
Neurostimulation 
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Neurostimulation-based treatments for epilepsy have gained considerable interest in the last decade. 
Electrical pulses are administered directly to or in the vicinity of nervous tissue in order to prevent or 
suppress seizure occurrence. Various neurostimulation strategies have been developed targeting 
different parts of the nervous system in an invasive or non-invasive way (Bagary 2011; Bergey 2013; 
DeGiorgio and Krahl 2013). Among these are Deep Brain Stimulation (DBS), repetitive Transcranial 
Magnetic Stimulation (rTMS), transcranial Direct Current Stimulation (tDCS), Trigeminal Nerve 
Stimulation (TNS) and Vagus Nerve Stimulation (VNS). 
Deep Brain Stimulation 
DBS involves the intracranial implantation of one or more electrodes in a selected brain region. Via 
an implanted pulse generator and a subcutaneous lead, electrical pulses are sent to specific parts of 
the brain to interfere with the neural activity of the target site. DBS has clear therapeutic benefits for 
treatment-resistent movement disorders and is currently being explored for a variety of other 
neurological diseases, such as refractory epilepsy (Gwinn and Spencer 2004; Vonck et al. 2013). 
Despite the long history of DBS, its underlying principles and mechanisms remain to be elucidated.  
Repetitive Transcranial Magnetic Stimulation  
TMS is an extracranial, non-invasive and generally well-tolerated form of cortical stimulation. The 
basic principle of TMS is the application of short magnetic pulses over the scalp of the patient with 
the aim of inducing electrical currents in the neurons of the cortex. A typical TMS device consists of a 
stimulator that generates a strong electrical current, and a coil in which fluctuating electrical currents 
generate magnetic pulses. If the magnetic pulses are delivered in the proximity of a conductive 
medium, e.g. the brain, a secondary current in the conductive medium is induced (Kobayashi and 
Pascual-Leone 2003). Continuing progress on the technical aspects of TMS devices made it possible 
to deliver multiple pulses within a short time period, i.e. rTMS. rTMS produces effects that outlast 
the stimulation duration by increasing or decreasing the excitability of neuronal networks. Changes in 
rTMS frequency and stimulation patterns can result in varying long-term effects. High-frequency 
stimulation (> 3 Hz) generally results in a synaptic facilitation - an effect that shares similarities with 
Long-Term Potentiation (LTP), while low-frequency rTMS (≤ 1 Hz) induces a reduction of synaptic 
efficiency - an effect that shares similarities with Long-Term Depression (LTD) (Fitzgerald et al. 2006; 
Gersner et al. 2011). Antiepileptic properties of rTMS were previously studied, but results of 
randomized, double-blind and sham controlled studies show diverting results (Theodore et al. 2002; 
Cantello et al. 2007). For this reason, rTMS has not yet been widely adopted as a treatment for 
refractory epilepsy. 
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Transcranial Direct Current Stimulation 
tDCS is a form of neurostimulation in which electrical currents (1-2 mA) are delivered to the scalp via 
anodal or cathodal electrodes. tDCS selectively modulates cortical excitability and has been shown to 
affect a range of motor, somatosensory, visual, affective and cognitive functions (Been et al. 2007). 
Future research will point out whether this treatment can be used as a new neurostimulation 
treatment for refractory epilepsy. 
Trigeminal Nerve Stimulation 
TNS is an extracranial form of neurostimulation, in which the superfacial location of trigeminal nerve 
branches allows for minimally invasive stimulation approaches (DeGiorgio et al. 2009). Animal and 
human data demonstrate that stimulation of the trigeminal nerve inhibits seizures (Fanselow et al. 
2000; DeGiorgio et al. 2011). The presumed antiepileptic mechanism of action involves activation of 
the reticular-activating system in the brainstem, thereby causing a desynchronization of thalamic and 
cortical activity and a generalized arousal (Fanselow et al. 2000).  
Vagus Nerve Stimulation  
VNS is an extracranial form of neurostimulation developed in the 1980s, where the left vagus nerve is 
stimulated in the neck area by means of a helical stimulation electrode connected to a subclavicularly 
implanted pulse generator (Ben-Menachem 2002). Following two randomized, double-blind 
controlled studies showing short-term efficacy and safety of VNS (Ben-Menachem et al. 1994; 
DeGiorgio et al. 2000), the Food and Drug Administration (FDA, USA) approved this treatment in 
1997. Since then, over 60,000 patients have been implanted worldwide (Magdaleno-Madrigal et al. 
2014). Despite the established efficacy and safety, the large number of treated patients and more 
than 20 years of experience with VNS, some specific issues about this treatment remain unresolved. 
Better comprehension of the antiepileptic mechanism of action of VNS could lead to the 
identification of certain seizure types and epilepsy syndromes that respond best to VNS and to the 
identification of responder characteristics. In addition, it may guide the search for a more 
appropriate choice of stimulation parameters.  
A recently developed non-invasive alternative for VNS consists of stimulating the auricular branch of 
the vagus nerve and is called transcutaneous VNS (t-VNS). A recently performed pilot study of t-VNS 
for pharmacoresistant epilepsy indicates that t-VNS is safe, effective, well-tolerated and practicable 
for long-term treatment (Stefan et al. 2012). Based on these first promising clinical data concerning 
feasibility and safety, the t-VNS device received CE approval in 2012.  
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Temporal lobe epilepsy 
Introduction 
The term Temporal Lobe Epilepsy (TLE) is used to designate localization-related epilepsy syndromes 
of diverse aetiology, originating in the temporal lobe. Two main types can be distinguished: mesial 
TLE (MTLE) with seizure focus in medial temporal lobe structures (e.g. hippocampal formation) and 
the much rarer neocortical TLE with seizure focus in the neocortex. We will only describe MTLE.  
MTLE is characterized by simple and/or complex focal seizures, with or without secondary 
generalization. Prior to the onset of their habitual partial seizures, patients commonly have a 
previous history of an initial precipitating insult such as febrile seizures, head trauma, congenital 
brain malformation, central nervous system infection, brain tumor or Status Epilepticus (SE) (Tatum 
2012). Months or years following the initial neural damage, MTLE is developed (Arzimanoglou et al. 
2002). MTLE accounts for approximately 30-35% of all epilepsies, and is the most prevalent type of 
epilepsy in adults (Panayiotopoulos 2007). More than 30% of MTLE patients are medically refractory 
(Pascual 2007).  
Neuroanatomy of the hippocampal formation 
The hippocampal formation is located in the dorsomedial part of the temporal lobe, just posterior to 
the amygdala (Fig.1). The hippocampal formation plays a major role in higher order brain functions, 
such as memory, spatial navigation, mood and attention control (Eichenbaum 2004; Squire 2004).  
 
 
 
 
 
 
 
Figure 1| Location of the temporal lobe (red), amygdala (purple) and hippocampal formation (blue) (adapted from 
www.brainconnection.com). 
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The hippocampal formation can be divided into several distinct regions: the dentate gyrus, the Cornu 
Ammonis (CA) fields CA1, CA2, CA3 and CA4/hilus (which underlies the dentate gyrus), and the 
subiculum (Fig.2). The main input to the hippocampal formation, which includes neocortical, 
subcortical, limbic and brainstem afferents, originates from the pyramidal cells of the entorhinal 
cortex and enters the hippocampus via the perforant path, which densely projects to the granule 
cells of the dentate gyrus and to the apical dendrites of the CA3 cells. Information flow through the 
hippocampus proceeds from the dentate gyrus to the CA3 via the mossy fiber pathway. The CA3 cells 
are connected to the CA1 cells via CA2 cells. There are also direct projections from the CA3 to the 
CA1 cells. The CA1 cells eventually target the subiculum. The cingulum bundle and fornix receive the 
main output from the hippocampus. 
 
 
 
 
 
 
 
 
 
 
The intrinsic connectivity of the hippocampal formation is more complicated than the simple input - 
trisynaptic circuit - output scheme. One single hippocampal neuron typically projects to several other 
neurons in its target area (Andersen et al. 2007). Hippocampal connectivity is further refined by the 
presence of (mainly inhibitory) interneurons in all areas of the hippocampal formation. These 
interneurons receive input from neurons which are located in the same hippocampal region, as well 
as in other (typically more proximal) hippocampal regions (Amaral et al. 2007). In summary, a 
complex network of serial and parallel excitatory and inhibitory connections is formed, in which 
every neuron influences the state of many other neurons, and is itself under control of many 
neurons. 
Figure 2| Illustration of the different regions of the hippocampal formation and information flow. 
Neurons of the dentate gyrus receive input from the entorhinal cortex via the perforant pathway, and 
extend projections into the CA3 via the mossy fiber pathway. Subsequent information flows to CA1 and 
the subiculum, from which extra-hippocampal areas are targeted (adapted from (Lie et al. 2004)).  
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There is still a lot of debate about the mechanisms underlying the development and intractability of 
MTLE, but it is generally accepted that the hippocampal formation plays a crucial role. One of the 
reasons for this is the fact that surgical removal of the hippocampal formation in MTLE patients leads 
to seizure freedom in 70% of cases (Engel 1992; Foldvary et al. 2000; Spencer 2002). Also depth EEG 
recordings and neuroimaging studies show that seizures in MTLE typically originate in the 
hippocampal formation (King and Spencer 1995; Vossler et al. 2004). Histological studies on tissue, 
obtained surgically from patients with intractable and unilateral MTLE, reveal specific changes which 
could underlie hyperexcitability of the removed structures. In 70% of cases, the distinctive 
neuropathological feature of MTLE is hippocampal sclerosis (Burton 1988; de Lanerolle and Lee 
2005).  
Hippocampal sclerosis 
Hippocampal sclerosis is the most common type of neuropathological lesion identified in temporal 
lobectomy series in MTLE patients. Hippocampal sclerosis is frequently the result of a previous SE, 
encephalitis or an ischemic insult (French et al. 1993). However, also the seizures themselves can 
cause or aggravate hippocampal sclerosis (Sutula and Pitkänen 2001). Hippocampal sclerosis is 
characterized by selective neuronal loss and astrocytic gliosis in the CA1, CA3 and CA4 subfields, with 
relatively sparing of CA2 pyramidal cells and dentate granule cells (Burton 1988). Neuronal cell loss 
involves both glutamatergic excitatory neurons and GABAergic inhibitory interneurons. In response 
to this, disorganization and altered connectivity of hippocampal neurons are commonly observed - 
the axons of the mossy fibers that lost their targets innervate towards regions that they normally do 
not innervate. This process is called mossy fiber sprouting and is a presumed mechanism of increased 
excitability of the hippocampal circuit (Brandt et al. 2003). Mossy fiber sprouting was first observed 
in hippocampal tissue resected during epilepsy surgery in humans, but is also a typical feature of 
chronic animal models of MTLE (Scheibel et al. 1974; Cavazos et al. 1991; Mello et al. 1993; Mazarati 
et al. 2002).  
Animal models of epilepsy 
Introduction 
Because of the ethical and experimental limitations inherent to studies in humans, animal models 
have been and still are essential to the study of human disease processes, including epilepsy. In order 
to better understand the mechanisms involved in seizure-initiation, epileptogenesis and spontaneous 
seizures, different animal models, that replicate some features of epileptic seizures and syndromes in 
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humans, have been developed. These models are valuable tools in the ongoing search for new 
treatments. It should however be pointed out that animal models are never more than an 
approximation of the disease process they emulate, and data derived from experimental animal 
studies should be interpreted with this caveat in mind. This is especially true for in vitro animal 
models, as these studies are usually carried out on tissue samples which have been physically 
removed from the rest of the brain, thereby severely compromising neuronal connectivity. 
Different types of in vivo animal models of epilepsy exist. They can be subdivided into two main 
categories: (i) acute epilepsy models, which do not necessarily indicate the presence of an epileptic 
disorder and (ii) chronic epilepsy models, which are associated with permanent “epileptogenic” 
disturbances (Engel 2006b).  
In acute animal models, seizures are evoked by audiogenic, electrical or chemical stimuli. These 
models are preferably used as an initial screening test for antiseizure potency of newly developed 
treatment strategies. Two of the most frequently used acute models are the Maximal Electro Shock 
(MES) model and the Pentylenetetrazol (PTZ) model. The MES model, in which bilateral 
transauricular or corneal electrodes are used, is used to search for compounds with activity against 
generalized tonic-clonic seizures (Walker et al. 2002). The PTZ model involves systemic injection of 
the convulsant and is used to discover drugs with efficacy against non-convulsive absence or 
myoclonic seizures (Löscher 2002).  
Chronic epilepsy models more closely resemble the pathophysiology and epileptic state of human 
epilepsy (Mascott et al. 1994; Löscher 2002). Many chronic epilepsy models were created specifically 
to reproduce specific types of human epilepsy, particularly the most common form, i.e. MTLE 
(Wieser 2004). Some chronic epilepsy models are genetically predetermined to express spontaneous 
limbic seizures. One example is the Ihara epileptic rat, displaying neuronal microdysgenesis and 
gliosis in the hippocampus (Arai et al. 2003). In previously healthy rodents, spontaneous limbic 
seizures can be provoked by different types of insults such as brain infarction (Kelly et al. 2001), 
traumatic brain damage (Kharatishvili et al. 2006), febrile seizures (Dube et al. 2006), kindling 
(Goddard 1983) and SE. These chronic animal models of MTLE cover three phases: (i) the initial 
precipitating insult, (ii) a period of epileptogenesis during which molecular and structural changes 
occur and (iii) chronic epilepsy characterized by the occurrence of spontaneous, recurrent seizures 
(Morimito et al. 2004). 
While they are clearly more suited to the study of many - especially chronic - aspects of MTLE 
compared to acute models, chronic models have a number of practical disadvantages. Because of the 
latency period between the initial epileptogenic insult and the occurrence of spontaneous seizures, 
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and because they require long periods of EEG and video monitoring, chronic models are more labor 
intensive and technically demanding compared to acute models. Also, the timing of seizures in these 
models is unpredictable, which makes them less suitable for certain purposes.  
On the other hand, the most important shortcoming of acute seizure models is that seizures do not 
arise as a result of a pre-existing abnormality in the brain, but are artificially induced in normal brain 
tissue. A second shortcoming of acute seizure models is that they cannot be used to study chronic 
processes, such as epileptogenesis. Nevertheless, acute seizure models have proven to be very 
productive. Since seizures in acute models can be reliably induced at a time of the researcher’s 
choosing, precise measurements can be performed at the moment of seizure induction and during 
seizure activity. Because of their relative ease of use and reliability, acute models are the first models 
used to screen potential antiepileptic compounds. 
As a full review of all acute and chronic animal models of epilepsy is beyond the scope of this thesis, 
only the animal models used in this thesis will be described. 
The motor cortex stimulation model 
The motor cortex stimulation model is an acute, fast-screening animal model in which the threshold 
for evoking focal, motor seizures is determined by electrical stimulation of the motor cortex in 
unanaesthetized rats (Voskuyl et al. 1989; Liebetanz et al. 2006). Cortical stimulation typically is 
performed using a ramp-shaped pulse train with biphasic, rectangular pulses with increasing 
amplitude. The cortical stimulation train is interrupted when the first symptoms of a focal seizure are 
detected on visual inspection. The clinical expression of a focal seizure is typically a forelimb clonus. 
The motor seizure threshold (MST) is defined as the current intensity corresponding to the first 
clinical symptoms of a focal seizure. Compounds are considered to have an antiseizure effect when 
increasing the MST.  
The intrahippocampal pilocarpine model of acute limbic seizures 
The intrahippocampal pilocarpine model is an acute animal model of limbic seizures with or without 
secondary generalization (Millan et al. 1993; Smolders et al. 1997a,b,c), in which intrahippocampal 
microdialysis is used both as a tool for local drug delivery and as a sampling technique.  
Microdialysis 
Microdialysis is an invasive technique that is widely used in neuroscience research both as a drug 
delivery and sampling tool. A microdialysis probe is implanted in the tissue of interest and 
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continuously perfused with an aqueous solution that closely resembles the (ionic) composition of the 
surrounding tissue fluid. Not only the brain but various peripheral tissue types can be targeted.  
The main design of the microdialysis probe is illustrated in figure 3 and resembles a concentric tube 
where the perfusion fluid enters through the inner tube, flows to the distal end, exits the inner tube 
and enters the space between the inner tube and the outer semipermeable membrane. This is where 
the “dialysis” takes place - small molecules can cross the semipermeable membrane by passive 
diffusion between the extracellular tissue fluid and the perfusate. The direction of the analyte flow is 
determined by the respective concentration gradient and allows the usage of microdialyses probes as 
a local delivery as well as a sampling tool. The dialysate leaving the probe is collected at certain time 
intervals for analysis. 
  
 
 
 
 
 
 
 
 
 
The intrahippocampal pilocarpine model of acute limbic seizures 
Limbic seizures are evoked in awake, freely moving animals by intrahippocampal perfusion of the 
non-selective muscarinic receptor agonist pilocarpine via the microdialysis probe. Pilocarpine-
induced seizures are initiated via muscarinic receptors and maintained by NMDA receptor activation 
A B 
Figure 3| A: The main design of the microdialysis probe consists of (i) an inlet, via which the perfusion fluid 
enters the probe, (ii) a semi-permeable membrane, through which diffusion of molecules takes place 
between the perfusion fluid and the extracellular tissue fluid, and (iii) an outlet, via which the 
microdialysate is collected in a microvial to be analyzed. B: Detailed illustration of the microdialysis 
concentric tube (adapted from Wikipedia).  
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(Maslanski et al. 1994; Smolders et al. 1997a,b,c). Video-EEG monitoring is used to assess the 
pilocarpine-induced seizure activity. Behavioural changes indicative of limbic seizure activity are 
rated on a seizure severity scale based on Racine’s scale, which was adapted to include all 
behavioural changes observed in focal limbic seizure models: (0) normal, non-epileptic activity; (1): 
mouth and facial movements, hyperactivity, grooming, sniffing, scratching, wet dog shakes; (2) head 
nodding, staring, tremor; (3) forelimb clonus, forelimb extension; (4) rearing, salivating, tonic-clonic 
activity; (5) falling, status epilepticus. Typically, for each twenty minute interval following initiation of 
pilocarpine perfusion, the highest seizure severity score (SSS) is retained. Total seizure severity score 
(TSSS) is then calculated as the sum of the SSSs and used as a measure for seizure severity 
throughout the experiment. Hippocampal and cortical EEG recordings are used to determine the 
latency to occurrence of the first epileptiform activity (spikes) and the total duration of the 
epileptiform activity after the start of pilocarpine perfusion. Compounds, administered systemically 
or perfused simultaneously with pilocarpine through the microdialysis probe, are considered to have 
an antiepileptic effect when decreasing the TSSS, increasing the latency to occurrence of the first 
epileptiform activity and/or decreasing the total duration of the epileptiform activity.  
Besides local drug delivery, microdialysis in the intrahippocampal pilocarpine model is also used to 
monitor compound-related or seizure-related biochemical changes concomitantly as the site of 
seizure induction. The collected dialysates from the intrahippocampal extracellular space can be 
analysed for a wide range of endogenous substances such as amino acids, monoamines, histamine, 
neuropeptides, hormones, ions, cyclic nucleotides, oxidative stress components and metabolic 
markers. As such, microdialysis in the intrahippocampal pilocarpine model is an elegant tool to 
elucidate the mechanism of action of compounds against limbic seizures and to gain insights into 
neuronal circuits involved in the generation, spread and control of pilocarpine-induced seizures. 
Increases in extracellular glutamate, GABA, dopamine and serotonin have consistently been 
observed during pilocarpine-induced limbic seizures (Smolders et al. 1997a,b,c, 2002, 2004; Khan et 
al. 1999, 2000; Lindekens et al. 2000; Meurs et al. 2006; Stragier et al. 2006). 
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Cervical anatomy, brainstem and brain hemisphere projections of 
the vagus nerve 
The vagus nerve, or tenth cranial nerve, is the longest of the cranial nerves and a major component 
of the parasympathetic nervous system. The various branches of the vagus nerve mediate important 
visceral reflexes such as vomiting, coughing, swallowing and control of blood pressure and heart rate. 
Heart rate is mostly influenced by the right vagus nerve that has dense projections primarily to the 
atria of the heart (Saper et al. 1990). Sensory impulses from receptors in peripheral organs are 
transported via sensory vagal fibers to the central nervous system. The signals are processed within 
the central nervous system and postganglionic vagal efferent fibers are activated to target the 
appropriate effector organ. These autonomic reflexes occur unconsciously and guarantee normal 
daily functioning. The parasympathetic nervous system uses acetylcholine as its neurotransmitter 
and is considered to be protective, defensive and relaxing in its actions (Andrews and Lawes 1992). 
Figure 4 gives a schematic overview of the vagus nerve at the cervical level, its projection to the 
brainstem Nucleus Tractus Solitarius (NTS) and its target organs. At the cervical level, the vagus nerve 
is a mixed cranial nerve consisting of both afferent sensory fibers, transferring information from the 
internal organs to the central nervous system, and efferent motor fibers, providing innervation of the 
laryngeal and pharyngeal muscles (via the recurrent laryngeal nerve that branches off from the vagus 
nerve at the level of the aortic arch) and parasympathetic outflow to the heart, lungs and abdominal 
organs. The afferent fibers far outnumber the efferent fibers and comprise approximately 65-80% of 
all cervical vagal fibers (Foley and DuBois 1937; Agostini et al. 1957; Paintal 1973). Nerve fibers can 
be subdivided into α, β, γ and δ types according to a decreasing fiber diameter (Erlanger and Gasser 
1937). Alternatively, a classification in type ‘A’, ‘B’ and ‘C’ based on the conduction velocity and 
myelination has been proposed. Approximately 90% of the afferent and 70% of the efferent cervical 
vagal fibers are small, unmyelinated, high-threshold C-type fibers and a smaller portion are 
intermediate diameter, myelinated B-type fibers and large diameter, myelinated, low-threshold A-
type fibers (Asala and Bower 1986). The link between fiber diameter, conduction velocity and the 
various components of action potentials has always been the basis for nerve fiber classification 
(Erlanger and Gasser 1937). However, due to the slightly different fiber contents in various nerves 
and species, and taking into account the physiological functions, a more complex classification is 
currently in use: Aα, Aβ, Aγ, Aδ, B and C (Manzano 2008). The fiber diameter and conduction velocity 
Vagus nerve stimulation for refractory epilepsy 
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of the different fiber types are summarized in table 1. Aα fibers subserve large motor functions and 
proprioception, Aβ fibers small motor movements, touch and pressure sensations, Aγ fibers muscle 
tone and reflexes, Aδ fibers temperature and sharp pain transmission, B fibers preganglionic 
autonomic control and C fibers postganglionic autonomic control, and nociception, temperature, 
pain, touch and pressure sensations. 
 
Table 1| Fiber diameter (µm) and conduction velocity (m/s) of the different fiber types at the cervical level of the vagus 
nerve. 
 Aα Aβ Aγ Aδ B C 
Fiber diameter (µm) 12-22 5-12 2-8 1-5 < 3 0.1-1.3 
Conduction velocity (m/s) 70-120 30-70 15-30 5-30 3–15 0.6–2.0 
 
Each nerve fiber is wrapped in a protective fibrous tissue sheath, the endoneurium. Different nerve 
fibers are bundled in fascicles, again surrounded by a protective fibrous tissue sheath, the 
perineurium. Several fascicles are bundled together with blood vessels within another sheath, the 
epineurium. At the cervical level, the vagus nerve is characterized by structural heterogeneity. Both 
the afferent and efferent A, B and C fibers are randomly organized within the fascicles and the 
fascicles are randomly organized within the nerve bundles (Krasteva et al. 2003; Vuckovic et al. 
2008). Furthermore, the organization of the nerve fibers and fascicles at the cervical level of the 
vagus nerve is different from person to person.  
The cell bodies of the efferent fibers are located in the dorsal motor nucleus and the nucleus 
ambiguous in the brainstem (Fig.4). Upon leaving the medulla, the efferent fibers extend through the 
jugular foramen and pass into the carotid sheath between the internal carotid artery and the internal 
jugular vein to provide innervation of their target organs. The afferent fibers run alongside the 
efferent fibers in the carotid sheet and have their cell bodies in the small jugular and the much larger 
nodose ganglion, located inside the tympano-occipital fissure and protruding peripherally from the 
jugular foramen, respectively. The afferent fibers pass through the jugular foramen and the 
tympano-occipital fissure and enter the lateral medulla as intracranial fiber bundles. Subsequently, 
they continue rostrocaudally as the tractus solitarius and terminate bilaterally in the rostral and 
caudal NTS (Kiernan 2009; Krahl and Clark 2012), a nuclear formation located in the dorsal lower 
brainstem (Koutcherov et al. 2004). The projections of the vagal afferent fibers to the NTS are 
predominantly ipsilateral (Norman and Bower 1982; Bohotin et al. 2003). The medial, ventral and 
lateral parts of the NTS predominantly receive input from visceral afferent A and B fibers (Kalia and 
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Sullivan 1982), whereas the caudal part of the NTS is a target for aortic, carotid sinus, cardiac, 
pharyngeal and pulmonary afferent B and C fibers (Andresen and Kunze 1994; Deuchars et al. 2000; 
Corbett et al. 2005; Bailey et al. 2006; Kubin et al. 2006). 
 
The NTS is connected to a large number of brainstem and intracerebral structures (Fig.5). The NTS 
sends out short monosynaptic projections to many bulbo-ponto-mesencephalic structures, such as 
the hypoglossal and trigeminal brainstem nuclei, the parabrachial nucleus, the reticular formation, 
the Dorsal Raphe Nucleus (DRN), the Nucleus Paragigantocellularis (PGi), the perifascicular area of 
the Nucleus Prepositus Hypoglossi (PrH), and the respiratory and cardiovascular centers (Bystrzycka 
and Nail 1985). The noradrenergic brainstem nucleus, the Locus Coeruleus (LC), receives both 
Figure 4| Schematic overview of the vagus nerve at the cervical level, its projection to the brainstem nucleus 
tractus solitarius and its target organs (adapted from (Amaral 1999)).  
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monosynaptic and disynaptic projections from the NTS (Aston-Jones et al. 1991; Van Bockstaele et al. 
1999). The disynaptic NTS-LC projections pass through the PGi and PrH. The caudal part of the NTS 
specifically projects to the nucleus ambiguous and the dorsal motor nucleus of the vagus nerve, areas 
where cardiac vagal preganglionic neurons are primarily located (Andresen and Kunze 1994; 
Deuchars et al. 2000; Corbett et al. 2005; Bailey et al. 2006; Kubin et al. 2006). Forebrain and limbic 
structures also receive monosynaptic NTS projections, in addition to the cerebellum, hypothalamus, 
thalamus and amygdala (Barnes et al. 2003).  
 
Mechanism of action 
In VNS therapy for refractory epilepsy, a bipolar, helical stimulation electrode is implanted around 
the left vagus nerve at the cervical level. Electrical pulses are administered to the afferent and 
efferent fibers of the vagus nerve via a subclavicularly implanted pulse generator and a subcutaneous 
lead (Fig.6).  
 
 
 
 
Figure 5| Schematic overview of the nucleus tractus solitarius (NTS) and its brainstem and intracerebral projection 
structures. The nuclei containing cell bodies of the efferent vagal fibers are presented in green (adapted from (Amaral 
1999)).  
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As for many AEDs, clinical application of VNS preceded the research into its antiepileptic mechanism 
of action. Following a limited number of animal experiments in cats, dogs and monkeys, investigating 
safety and efficacy, the first human trial was performed in 1990 (Uthman et al. 1990). The basic 
hypothesis on the mechanism of action was based on the knowledge that the tenth cranial nerve 
afferents have numerous projections within the central nervous system and that in this way action 
potentials generated in vagal afferents have the potential to affect the entire organism (Berthoud 
and Neuhuber 2000). To date, the precise mechanism of action of VNS for refractory epilepsy 
remains to be elucidated.  
Research on the mechanism of action of VNS occurs at different levels. The role of the different fiber 
types that constitute the vagus nerve at the cervical level in the antiepileptic effect of VNS requires 
further investigation. A next step is to identify the potential role of central nervous system structures 
that are located on the anatomical pathways from the cervical part of the vagus nerve up to the 
cortex. Within these central nervous system structures, the identification of specific 
neurotransmitter systems involved in the antiepileptic effect of VNS is an essential step in VNS 
research. Over the last few years, researchers have dedicated increasing attention to the role of the 
immune system in epilepsy and to the hypothesis that VNS could interfere with this process. The 
vagus nerve indeed plays a critical role in the signalization and modulation of inflammatory processes 
Figure 6| A: A programmable pulse generator is connected to a helical stimulation electrode via a lead. B: 
The programmable pulse generator is subcutaneously implanted at the level of the left clavicle. C: The 
bipolar, helical stimulation electrode is implanted around the left vagus nerve at the cervical level. D: 
Electrical pulses of sufficient strength induce action potentials in the vagus nerve fibers (adapted from 
(George and Aston-Jones 2010)). 
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(Borovikova et al. 2000; Hosoi et al. 2000) and this could thus represent a new modality in the 
mechanism of action of VNS for epilepsy. 
Stimulation parameters 
The vagus nerve is stimulated with biphasic, charge-balanced pulses. Programmable parameters of 
the pulse generator are output current, frequency, pulse width and ON/OFF times (Labiner and 
Ahern 2007) (Fig.7).  
The output current of the pulse generator ranges between 0 and 3.5 mA. The output current is 
typically set at 0.25 mA at the start of the VNS therapy, and increased in 0.25-0.5 mA steps every 2-4 
weeks as patient tolerability permits. The frequency of the pulse generator ranges from 1 to 30 Hz 
and is typically set at 30 Hz. The pulse width setting affects the level of output current required to 
stimulate the vagus nerve, and higher output currents may be needed for shorter pulse widths (Heck 
et al. 2002). The pulse width of the pulse generator ranges between 130 and 1000 µs. Typical values 
are 250 µs and 500 µs. Stimulation is administered intermittently, with alternating periods of 
programmed signal ON and OFF times. Signal ON time values range between 7-60 s. For signal OFF 
times, the range is 0.2-180 min. The choice of intermittent stimulation is based upon safety studies 
with regard to stimulation of neural tissue (Agnew and McCreery 1990), upon efficacy studies 
showing that the effect of stimulation outlasts the stimulus duration (Zabara 1992; Takaya et al. 
1996; Santiago-Rodriguez et al. 2006; Carrette et al. 2007) and upon the knowledge that intermittent 
stimulation is associated with a longer battery life. Stimulation with an ON time longer than OFF time 
has resulted in degenerative nerve damage in laboratory animals (Agnew and McCreery 1990). An 
ON/OFF time of 30 s/5 min is typically used.  
All output parameters of the pulse generator can be modified in order to reach maximum 
therapeutic efficacy, while minimizing treatment-emergent side effects and preserving battery life 
(Heck et al. 2002). 
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The stimulation parameters currently used in clinical practice are not evidence based and vary 
considerably. There is incomplete understanding of the neurobiological effects of different VNS 
parameters and there is a clear need for identification of the most optimal VNS parameter settings. 
Several preclinical and clinical studies suggest that lower current density might be sufficient to 
achieve clinical efficacy. These data may be relevant for VNS patients because these “new” 
parameters could minimize or prevent side effects and increase the battery life of the pulse 
generator. 
Clinical efficacy  
Following promising animal studies on the efficacy of VNS for epilepsy (Zabara 1992; McLachlan 
1993), clinical trials were initiated in the early ninetees. Initial results from multicenter, single-blind 
pilot clinical trials (phase-1 trials EO1 and EO2) in a small group of patients (n=14) with refractory 
complex partial seizures showed a seizure reduction of at least 50% in 9/14 patients treated for 3-22 
months (Uthman et al. 1990; Penry and Dean 1990; Wilder et al. 1991). It was noticed that a 
reduction in seizure frequency, duration and intensity lagged 4-8 weeks after initiation of VNS 
treatment (Uhman et al. 1990). Three years later, Uthman and coworkers published the long-term 
results from the EO1 and EO2 studies (Uthman et al. 1993). VNS treatment for 14-35 months resulted 
in a mean seizure reduction of 46%. Five out of 14 patients had a seizure reduction of at least 50%. 
In the meantime, two prospective, multicenter, randomized, double-blind clinical studies (EO3 and 
EO5) were initiated (Handforth et al. 1998). In these studies, large patient groups (EO3: n=114, EO5: 
n=196) were divided in a “high” (1.3 mA, 30 Hz, 500 µsec, 30 s ON/5 min OFF) and “low” (1.3 mA, 1 
Figure 7| Pulse generator output parameters. 
44 Chaper 2| VNS for refractory epilepsy  
 
Hz, 130 µsec, 30 s ON/3 h OFF) stimulation group in terms of frequency, pulse width and duty cycle. 
The parameters in the “high” stimulation group were those believed to be efficacious based on 
previous animal data. In both studies, patients enrolled in the “high” stimulation group experienced 
seizure reducing effects ranging between 24-28%. Patients in the “low” stimulation group had a 
seizure reduction of maximal 15%.  
The results of the EO3 and EO5 studies led to a FDA approval and were followed by open label 
extension trials, demonstrating that the antiepileptic effects of VNS clearly increased over time to 
values between 35-44% after 2 years of follow-up (Holder et al. 1992; George et al. 1994; Salinsky et 
al. 1996; Morris et al. 1999; DeGiorgio et al. 2000). In the following years, a growing amount of 
clinical data confirmed efficacy of VNS. In a retrospective study by our group, an overall seizure 
frequency reduction of 51% was observed in 138 patients with a minimal follow-up of 1 year (De 
Herdt et al. 2007). VNS, ranging from 10 days to 11 years, in a consecutive series of 436 adults and 
children with treatment-resistent epilepsy led to ≥ 90% seizure frequency reduction in 90 patients 
(22,5%), ≥ 75% seizure control in 162 patients (40,5%), ≥ 50% improvement in 255 patients (63,8%) 
and < 50% improvement in 145 patients (36,3%) (Elliott et al. 2011a). The same group analyzed the 
efficacy of VNS over time in 65 patients with refractory epilepsy: the overall seizure frequency 
reduction improved from 35,7% after 1 year of follow-up to 75,5% after 8 years, eventually followed 
by a stabilization (Elliott et al. 2011b). Recently, Englot et al. performed the first meta-analysis of VNS 
efficacy in epilepsy, identifying 74 clinical studies with 3321 patients suffering from intractable 
epilepsy (Englot et al. 2011). Mean seizure frequency reduction increased from 36% at 3-12 months 
following surgery to 51% after > 1 year of VNS therapy. The data of the 65 refractory epilepsy 
patients in the study of Elliott and coworkers were not included in this meta-analysis (Elliott et al. 
2011b).  
Vonck et al. and Boon et al. concluded that the mean VNS-induced seizure frequency reduction 
ranges between 25-55% with a large inter-patient variability in efficacy (Vonck et al. 2003; Boon et al. 
2007). Efficacy has a tendency to improve with longer duration of treatment. Treatment with VNS 
(especially long-term treatment) reduces seizures with ≥ 50% in 50% of patients. In about 30% of 
patients, there is little or no effect. In the other 20% of patients, seizure frequency reduction ranges 
between 30-50%. It is still unclear why some patients do and others do not respond to the VNS 
therapy.  
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Safety, side effects and tolerability 
Acute side effects 
Perioperative complications occur infrequently. Fluid accumulation at the level of the subclavicularly 
implanted pulse generator occurs in 1-2% of patients. Postoperative infections occur in 3-6% of 
patients. These side effects are usually treatable with oral antibiotics (Ben-Menachem 2001). 
Ventricular asystole has been observed during perioperative testing of the VNS device, even in 
patients without any history of cardiac dysfunction (Lanska 2000; Ali et al. 2004; Ardesch et al. 2007). 
As the left vagus nerve contains less sinoatrial fibers compared to the right vagus nerve, VNS is 
typically administered to the left vagus nerve, in order to provoke less cardiac side effects. In case of 
severe postoperative infections, intraoperative bleeding in the approach of the left vagus nerve or 
mechanical dysfunction due to fibrosis and high impedance of the electrode-nerve interface, the VNS 
device should be explanted. Implantation of the right vagus nerve could be a good alternative, as 
several studies report no cardiac side effects and similar antiepileptic effects of left and right VNS 
(McGregor et al. 2005; Spuck et al. 2008; Navas et al. 2010).  
Side effects related to long-term use and tolerability 
The most common side effects are coughing, throat pain and hoarseness. These side-effects are 
stimulus-related, dose-dependent, tend to improve over time and are due to secondary stimulation 
of the recurrent laryngeal nerve, which carries Aα motor fibers to the laryngeal muscles (Morris and 
Mueller 1999; Banzett et al. 1999; Ben-Menachem 2001). Less often reported side effects are 
dyspnea and vomiting (Uthman et al. 1993). Psychiatric side effects have been described. In patients 
with pre-existing psychiatric disorders decreased sedation and increased alertness may manifest 
itself as psychosis (Blumer et al. 2001; De Herdt et al. 2003). Unwanted side effects are easy to 
control by reducing the output current.  
VNS at therapeutic levels does not cause central nervous system side effects, such as tiredness, 
psychomotor slowing, irritation and nervousness, which are all common in AED treatment (Ben-
Menachem 2001). VNS also has no effect on the heart rate and gastrointestinal system, and does not 
affect AED serum levels. A notable increase of the perceived well-being, arousal and attention during 
VNS treatment is frequently reported (Sherman et al. 2008; Helmers et al. 2012). Relative contra-
indications include progressive neurologic or systemic diseases, cardiac arrhythmia, asthma, chronic 
obstructive pulmonary disease, active peptic ulcer and insulin dependent diabetes mellitus (Elliot 
2009).  
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This chapter focuses on the central noradrenergic pathway as an important contributor in the 
antiepileptic effect of VNS. Preclinical and clinical studies demonstrate a role for vagal afferent A and 
B fibers at the cervical level running to the brainstem NTS. Data obtained from in vitro studies show a 
frequency-dependent inhibition of the NTS with VNS. Our hypothesis further considers the 
predominantly inhibitory influence of the NTS on the noradrenergic neurons of the LC. VNS as a 
result causes a disinhibition of the LC. The activity of the LC and its widespread noradrenergic 
modulation are now increased. This noradrenergic modulation is believed to be responsible, at least 
in part, for the antiepileptic effect of VNS.  
Vagal fibers involved in the antiepileptic effect of VNS 
The role of afferent A and B fibers at the cervical level 
In 1992, Zabara reported for the first time that the antiepileptic actions of VNS are not mediated by 
vagal efferent fibers at the cervical level. This conclusion was based on the demonstration that the 
antiepileptic effect of VNS in dogs was preserved after transection of the vagus nerve distally to the 
site of cervical vagal stimulation (Zabara 1992). In 1993, McLachlan et al. demonstrated that VNS-
induced abolishment of penicillin-induced focal interictal spikes in rats disappeared after cooling of 
the vagus nerve proximal to the point of stimulation, further supporting the hypothesis that VNS 
exerts its effect on seizures through cervical afferent fiber activation (McLachlan 1993). 
It remains incompletely understood which afferent fibers precisely induce the antiepileptic effect of 
VNS. Further research in this field may support a more rational choice of stimulation parameters and 
increase knowledge on the central mechanism of action of VNS. Early animal studies on the 
therapeutic mechanisms of VNS suggested that the antiepileptic potential of VNS was directly related 
to the fraction of cervical vagal afferent C fibers stimulated. This was based on a maximal evoked 
response from A, B and C fibers in an isolated vagus nerve in anaesthetized rats induced by 
parameters required to suppress seizures in awake rats (Woodbury and Woodbury 1990, 1991). The 
theory supporting C fiber involvement was discarded after Krahl et al. demonstrated seizure 
suppression in awake rats following selective destruction of C fibers using capsaicin (Krahl et al. 
2001). The discrepancy between the former and latter studies is probably due to the fact that 
Vagus nerve stimulation and the central noradrenergic pathway 
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compound action potentials (CAPs) in the former studies were recorded in anaesthetized animals 
and may therefore not be relevant to VNS in awake rats. Stimulation in a chronically implanted, 
awake animal produces electrical shunting through the body, which is not modeled accurately by an 
acute isolated nerve preparation. The clinical relevance of this finding is that A and B fibers have 
much lower activation thresholds and that output current intensities required for C fiber activation 
would unnecessarily induce side effects and shorten battery life. Data from clinical trials support the 
idea of Krahl et al. (2001) that efficient antiepileptic stimulation levels are subthreshold for the 
recruitment of C fibers (Binks et al. 2001). In order to determine the vagal A fiber threshold, patients 
were asked to speak as monotonically and steadily as possible during each output current intensity 
increment. Increases in stimulus strength were continued until A fiber stimulation was achieved as 
judged by an audible change in the subject’s voice quality, caused by contraction of the vocal cords. 
In order to determine the vagal C fiber threshold, cardiopulmonary parameters were measured. 
None of the patients however showed cardiopulmonary changes or sensations expected to be 
associated with vagal C fiber stimulation even at the highest possible stimulus current the VNS device 
could deliver. For all patients, the stimulus strength at which seizures were reduced was as such 
subthreshold for C fiber activation (Binks et al. 2001). Recently, Helmers et al. developed a 
mathematical model to explore how full activation of the myelinated A and B fibers at the cervical 
level of the vagus nerve can be achieved through changes in output current intensity and pulse width 
(Helmers et al. 2012). The model incorporated acute and chronic stimulation conditions in order to 
study the effect of tissue encapsulation at the site of electrode placement. In the future, the model 
can be refined to include additional factors that may influence the effectiveness of the VNS therapy, 
such as duty cycle and frequency of stimulation. Information retained from such a mathematical 
model could guide clinicians on how to optimize the VNS therapy. 
Fiber type selective stimulation and directional selectivity 
VNS for epilepsy requires the selective generation and propagation of action potentials in cervical 
vagal afferent A and/or B fibers. Efferent fibers of larger diameter innervating the laryngeal muscles 
are unnecessarily stimulated and this results in stimulation-related coughing, throat pain and/or 
hoarseness. Avoiding stimulation of these larger diameter motor fibers would reduce these side 
effects. Two techniques that could be used for this purpose are fiber type selective stimulation and 
directional selectivity.  
Fiber type selective stimulation 
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The potential of fiber type selective stimulation mainly relies on the knowledge that fiber activation 
and fiber blocking thresholds are inversely proportional to the square of the fiber diameter (Rozman 
et al. 1993). Activating or blocking the largest fibers requires the least energy or electrical current 
density. When an axon is electrically activated, action potentials propagate in both directions away 
from the point of activation, in both the afferent and efferent fibers. Fiber type selective stimulation 
involves stimulation of all the nerve fibers and then adjusting a conduction block at both sides of the 
stimulation point in such a way that the action potentials would not propagate further in the fibers 
with the largest diameter. The theoretical result is a selective activation of smaller diameter fibers 
(Rozman et al. 1993; Bugbee et al. 2001).  
Directional selectivity 
A variation on fiber type selective stimulation is directional selectivity. A conduction block placed on 
the distal side of the stimulation point can ensure that propagation in the large diameter motor 
fibers takes place in one direction only (Ungar et al. 1986). Application of this technique would be 
sufficient to avoid VNS-related side effects (coughing, throat pain and/or hoarseness).  
Blocking techniques 
To obtain fiber type selective stimulation or directional selectivity, a number of conduction block 
techniques has been developed. One strategy is ‘anodal hyperpolarization’, which consists of 
electrically hyperpolarizing the nerve membrane at such a level that the depolarizing cathodic 
currents from an action potential are no longer strong enough to depolarize the corresponding 
region to the excitation threshold (Rijkhoff et al. 1994). A conduction block based on anodal 
hyperpolarization can theoretically be obtained by application of a triangular or quasi-trapezoidal 
stimulus pulse. Such a pulse consists of a square leading edge and a plateau phase, followed by an 
exponential decay (Ungar et al. 1986). Another physiological mechanism used to block a nerve is 
‘accommodation’. The depolarization phase of an action potential is the result of sodium ions flowing 
into the cell through voltage-gated sodium channels. The inwards sodium flow subsequently opens 
even more sodium channels, resulting in a further depolarization. This process proceeds explosively 
until all the available ion channels are open. The rapid influx of sodium ions causes the polarity of the 
plasma membrane to reverse, and the ion channels then rapidly inactivate. Together with the 
activation of voltage-gated potassium channels, through which potassium ions are transported out of 
the cell, the inactivation of sodium channels brings the membrane potential back to the resting state. 
Accommodation refers to the inactivation of sodium channels, while keeping the channel opening 
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rate low enough, not to trigger an action potential. Accommodation can be achieved by means of 
exponentially rising waveforms and depolarizing prepulses (Joseph and Butera 2011). When a nerve 
fiber is stimulated with a subthreshold current, close to the excitation threshold, the membrane 
accommodates in such a way that the excitation threshold increases, which is attributed to the 
inactivation of the voltage-gated sodium channels.  
Limitations of the blocking techniques 
Both fiber type selective stimulation and directional selectivity are theoretical concepts with 
limitations for practical implementation. Blocking techniques require relatively high power (Vuckovic 
et al. 2008). Long pulse durations are required as the blocking pulse must comprise the latency of the 
action potential arrival and the duration of the action potential itself. This often leads to large power 
consumptions and current densities that are incompatible with chronic use in clinical implants. In 
addition, an accurate timing is essential and dependent on anatomical or geometric factors as well as 
the fiber conduction velocity itself. Apart from the power consumption and timing issues, the 
application of anodal current typically creates virtual cathodes for example at the electrode 
extremities. These virtual cathodes are able to activate nerve fibers beyond the blocked region. The 
pseudo-trapezoidal pulses mentioned above are supposed to reduce this secondary stimulation 
effect (Ungar et al. 1986). The practical result of the timing and virtual cathode problems is that 
many fibers escape the expected blocking effect and conduct action potentials anyway, so that 
neither fiber type selective stimulation nor directional selectivity works very efficiently in clinical 
applications. In current VNS therapy, co-activation of large diameter Aα motor fibers innervating the 
laryngeal muscles is not prevented, resulting in stimulation-related coughing, throat pain and/or 
hoarseness.  
The nucleus tractus solitarius 
Vagal afferent A and B fibers arrive in the medial, ventral and lateral parts of the brainstem NTS 
(Kalia and Sullivan 1982). They convey information on the status of visceral organs by releasing the 
excitatory neurotransmitter glutamate, which acts on postsynaptic AMPA receptors to excite the NTS 
neurons (Fig.8) (Andresen et al. 2013). At baseline physiological firing rates ranging from 0.1 to 16 Hz 
depending on the species and the vagal afferent fiber type involved (Mathis et al. 1998; Brundson 
and Grundy 1999; Lynn and Blackshaw 1999; Niijima 2000; Horn and Friedman 2003; Sengupta et al. 
2004; Peiris et al. 2011) most of the released glutamate binds to postsynaptic AMPA receptors on 
NTS neurons. At higher firing rates of vagal afferent fibers, glutamate diffuses outside the synaptic 
cleft and binds to presynaptic glutamatergic autoreceptors (i.e. mGluRs type II and III), which reduces 
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glutamate release and further activation of postsynaptic NTS receptors (Fig.8). The result is a 
frequency-dependent depression in the NTS with increasing vagal afferent input. Andresen and Yang 
studied the dynamics of sensory transmission on the NTS neurons in a horizontal brainstem slice 
preparation of the rat (Andresen and Yang 1995). The amplitude of the excitatory post-synaptic 
potential (EPSP) in NTS neurons was maximal at < 0.5 Hz of vagal afferent stimulation for 2 minutes. 
EPSP amplitude declined to an average of 57.5% at 10 Hz of stimulation. Within 1 minute of 100 Hz 
stimulation, EPSP amplitude declined to nearly zero. The role of the mGluRs type II and III is 
evidenced by the observation that the frequency-dependent depression in the NTS with increasing 
vagal afferent input is abolished by mGluR blockade (Liu et al. 1998). Furthermore, administration of 
a selective agonist of the mGluR type II and III in brainstem slices has been shown to reduce the EPSP 
amplitude in NTS neurons evoked by low-frequency stimulation (0.1-0.2 Hz) of vagal afferent fibers, 
and this reduction in EPSP amplitude was attenuated by co-administration of a selective antagonist 
of the mGluR type II and III (Chen et al. 2002). The antagonist data further showed that the inhibitory 
effect of mGluRs type II and III on synaptic transmission in the NTS in response to electrical 
stimulation of vagal afferent fibers was negligible at stimulation frequencies < 9 Hz and was 
increasingly prominent with higher stimulation frequencies (up to 48 Hz). The NTS findings 
correspond to those in other central nervous system regions regarding the contribution of 
presynaptic mGluRs type II and III to frequency-dependent synaptic depression (Dubé and Marshall 
2000).  
In addition, mGluRs are also expressed presynaptically by GABAergic terminals that are interspersed 
throughout the NTS (Fig.8) (Fernandes et al. 2011). Some of these GABAergic terminals originate 
from local interneurons, whereas others may well arise from outside the NTS (Jordan et al. 1988; 
Fong et al. 2005). Binding of released glutamate on these presynaptic mGluRs can either activate or 
inhibit GABA release, depending on the receptor subtype (Fig.8) (Jin et al. 2004; Fong et al. 2005; 
Bailey et al. 2008). mGluR type II and III is a Gi-protein coupled receptor and inhibits GABA release, 
mGluR type I is a Gq-protein coupled receptor and promotes GABA release. GABA on its turn 
heterosynaptically modulates the release of glutamate by acting on GABAA or GABAB receptors on 
vagal glutamatergic terminals in the NTS (Fig.8) (Bailey et al. 2008; Kang et al. 2012). The GABAA 
receptor on vagal terminals in the NTS is a Na+K+Cl2--cotransporter that strongly promotes glutamate 
release. The binding of GABA on GABAA receptors normally results in an influx of chloride ions, 
thereby hyperpolarizing the cell membrane and inhibiting the firing of new action potentials. Upon 
binding of GABA on the Na+K+Cl2-cotransporter on vagal glutamatergic terminals in the NTS, one 
sodium ion and one potassium ion is transported into the cell, while two chloride ions are 
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transported out of the cell. The net result is a postsynaptic depolarization and increased release of 
glutamate (Kang et al. 2012). Such GABAA receptors are expressed by numerous glutamatergic 
terminals in the brainstem. These glutamatergic terminals are characterized by a developmental high 
intracellular chloride concentration, which is up to five times higher then in their soma (Price and 
Trussel 2006). The GABAB receptor is a Gi-protein coupled receptor and strongly inhibits glutamate 
release. The precise mechanism remains poorly understood but in vitro studies suggest a possible 
involvement of GABA in signal transmission in the NTS (Glaum and Brook 1995; Glaum and Brooks 
1996; Kang et al. 2012). The sustained synaptic depression in the NTS induced by brief periods of 
high-frequency (50 Hz) vagal afferent stimulation in a slice preparation of the rat medulla was 
blocked by GABAB receptor antagonism (Glaum and Brook 1995; Glaum and Brooks 1996). In a more 
recent study, GABAA and GABAB receptor agonists facilitated and reduced the EPSP frequency in 
isolated mechanically dispersed NTS neurons, respectively. Local application of GABAA and GABAB 
receptor antagonists had opposite effects (Kang et al. 2012). Other mechanisms that could 
contribute to the synaptic depression in the NTS with increasing vagal afferent input include 
desensitization of the postsynaptic AMPA receptors and depletion of synaptic vesicles in the vagal 
glutamatergic terminals (Liu et al. 1998).  
It should be noted that the described frequency-dependent inhibition of the NTS with VNS is only 
based on in vitro studies and this should be evidenced by in vivo studies in future. Only a few in vivo 
studies evaluated the effect of VNS on the NTS. These studies demonstrated an increased nuclear c-
fos expression in the NTS in response to VNS in rats (Naritoku et al. 1995; Osharina et al. 2006; 
Cunningham et al. 2008). C-fos is the product of the immediate early gene c-fos and it is commonly 
acknowledged that the expression of c-fos is a valuable marker of increased neuronal activity. These 
data indicate that the NTS is indeed addressed by VNS, but do not reveal which neuronal population 
is triggered by VNS. The heterosynaptic crosstalk between glutamatergic and GABAergic terminals in 
the NTS implies that both terminals are in very close proximity to each other and to the NTS (Bailey 
et al. 2008). C-fos may therefore stain the nucleus of both the glutamatergic and GABAergic fibers. 
Osharina et al. demonstrated a frequency-dependent c-fos expression in the NTS with VNS (Osharina 
et al. 2006). VNS at 10 Hz stained the NTS more intense compared to VNS at 1 Hz. We hypothesize 
that at 10 Hz, more GABAergic nuclei are stained.  
In summary, in vitro studies in which the vagal afferent fibers are electrically stimulated have shown 
that (i) the NTS is maximally active at stimulation frequencies < 0.5 Hz, and (ii) the overall inhibitory 
effect on glutamatergic synaptic signaling in the NTS is negligible at stimulation frequencies below 9 
Hz while becoming prominent at higher stimulation frequencies. The most common VNS frequency 
applied in clinical practice is 30 Hz. We therefore hypothesize that clinical VNS reduces the activity of 
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the NTS neurons. The demonstration in rats that local injection of GABA agonists or glutamate 
antagonists in the NTS reduces susceptibility to limbic motor seizures provides direct evidence that 
an inhibition of the NTS can have antiepileptic effects (Walker et al. 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8| Schematic representation of the heterosynaptic crosstalk between presynaptically released glutamate and 
GABA to influence glutamatergic signaling onto neurons in the medial, ventral and lateral NTS. The neurotransmitters 
glutamate and GABA are shown as black and grey dots, respectively. Afferent activity in vagal afferent A and B fibers 
activates the release of glutamate, which binds to postsynaptic AMPA receptors on NTS neurons (A). In addition, 
released glutamate can activate mGluRs type II and III on the vagal terminals to reduce subsequent glutamate release 
(B). Glutamate may also bind to mGluRs on local GABAergic terminals. mGluR type II and III is negatively coupled and 
inhibits GABA release (C), mGluR type I is positively coupled and stimulates GABA release (D). Released GABA reaches 
GABAA and/or GABAB receptors on the vagal terminals. GABAA receptors strongly promote glutamate release (E), in 
contrast to GABAB receptors which strongly inhibit glutamate release (F). As a result of this complex heterosynaptic 
interaction, afferent glutamate weighs on both sites of the excitatory and inhibitory balance and this balance 
determines the outcome of afferent information within the medial, ventral and lateral NTS. (mGluR = metabotropic 
glutamate receptor) 
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The locus coeruleus  
As a relay station for vagal afferent fibers, the NTS probably plays a key role in connecting the 
electrical stimulation of cervical vagal afferent A and B fibers to central antiepileptic brain circuits. 
Identifying structures upstream of the NTS that are engaged by VNS is a further essential step in 
understanding the antiepileptic effect of VNS. The LC is a strong candidate. The LC is a nucleus of the 
pontine tegmentum containing a homogeneous compact noradrenergic cell group (Maeda 2000). 
There are anatomical connections between the NTS and the LC (Fig.9a) (Aston-Jones et al. 1991; Van 
Bockstaele et al. 1999; Halliday 2004). The LC provides innervation of the entire cortex and is the 
major source of brain noradrenaline, a neuromodulator with strong antiepileptic effects (Foote et al. 
1983). Electrophysiological studies demonstrated that the LC is activated by acute and chronic VNS 
(Groves et al. 2005; Dorr and Debonnel 2006; Manta et al. 2009).  
The noradrenergic LC receives both monosynaptic and disynaptic projections from the NTS (Fig.9a) 
(Aston-Jones et al. 1991; Van Bockstaele et al. 1999; Halliday 2004). Cell bodies located in the LC 
have an extensive dendritic network in the pericoerulear region and the monosynaptic projections 
originating in the NTS influence LC activity through both excitatory and inhibitory synapses with the 
LC dendrites (Van Bockstaele et al. 1999). Tract-tracing and electrophysiological studies have 
revealed that the LC proper receives afferents from remarkably few brain loci (Aston-Jones et al. 
1991). Major inputs to the LC proper are found in the PGi and the PrH only, which are located in the 
ventrolateral and dorsomedial rostral medulla, respectively (Aston-Jones et al. 1991). Both the PGi 
and PrH receive glutamatergic projections from the NTS (Kihara and Kubo 1991; Aston-Jones et al. 
1991; Van Bockstaele et al. 1999; Halliday 2004). LC-projecting neurons of the PGi stain positive on 
markers for adrenalin, enkephalin, corticotropin-releasing factor and glutamate (Aston-Jones et al. 
1991). Neuropharmacological and electrophysiological experiments have revealed that the PGi 
provides a potent excitatory glutamatergic input to the LC, acting primarily on non-NMDA receptors 
(Ennis and Aston-Jones 1988). Adrenergic as well as non-adrenergic inhibition of the LC could be 
detected in a minority of PGi cells tested (Aston-Jones et al. 1986). The PrH potently and consistently 
inhibits LC neurons via GABAergic projections, acting on GABAA receptors (Aston-Jones et al. 1991). 
Large proportions of the PrH neurons also stain positive on markers for met-enkephalin. A third 
disynaptic pathway involves the inhibitory action of GABAergic interneurons surrounding the LC 
(Aston-Jones et al. 2004). As the NTS efferents to upstream brain structures which among other 
project to the LC are mainly glutamatergic (Kihara and Kubo 1991; Aston-Jones et al. 1991; Van 
Bockstaele et al. 1999; Halliday 2004) and ultra-structural analysis has revealed that ± 77% of LC 
afferents are GABAergic, we hypothesize that the NTS effect on the LC is predominantly inhibitory. By 
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reducing the activity of the NTS, VNS results in a disinhibition of the LC and a subsequent increased 
release of noradrenaline (Fig.9b). 
Role of the locus coeruleus and noradrenaline in the antiepileptic 
effect of VNS 
LC neurons have an enormous network of noradrenergic projections throughout the brain (Fig.9) 
(Ungerstedt 1971; Jones and Moore 1977). LC fibers run within two main ascending fiber systems: 
the dorsal bundle, which ascends through the central tegmental tract in the pons and midbrain, and 
the much smaller dorsal periventricular pathway, which is a component of the dorsal longitudinal 
fasciculus, a white matter fiber tract located within the brainstem (Giorgi et al. 2004). The dorsal 
bundle provides noradrenergic innervation of the telencephalon and diencephalon. The dorsal 
periventricular pathway projects to medial and midline thalamic, pretectal and hypothalamic regions 
(Krahl et al. 2012). The LC axons are characterized by profuse terminal branching and varicosities 
Figure 9| A. Anatomical projections from the NTS to the LC. The green and red arrows represent excitatory and 
inhibitory projections, respectively. Note the smaller number of inhibitory projections (dotted red arrow) from the PGi 
to the LC compared to its excitatory projections. The majority of LC afferents are coming from GABAergic interneurons 
(bold red arrow). B. We hypothesize that, by reducing the NTS output, VNS results in a disinhibition of the LC and a 
subsequent increased release of noradrenaline (adapted from (Nelson 2007)). (NTS = nucleus tractus solitarius, LC = 
locus coeruleus, PGi = nucleus paragigantocellularis, PrH = nucleus prepositus hypoglossi, NA = noradrenaline) 
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(Fornai et al. 2011). The varicosities do not represent a classic synaptic site with a pre- and 
postsynaptic component, but noradrenaline directly diffuses into the extracellular space to modulate 
the activity of neurons, glial cells and blood vessels. This paracrine noradrenaline diffusion is quite 
generalized and can affect the entire cortical activity. Noradrenaline interacts with three families of 
G-protein coupled adrenergic receptors (α1, α2 and β receptors) which are further divided into 
different subtypes (α1A-B, α1D, α2A-C and β1-3 receptors) (Ramos and Arnsten 2007). It has highest 
affinity for the α2 adrenergic receptors, which are generally coupled to Gi proteins. The α2 adrenergic 
receptor subtype is considered to be the most prominent antiepileptic adrenoreceptor (Weinshenker 
and Szot 2002). Noradrenaline exerts a variety of central functions and is involved in modulating EEG 
activity, regulating the sleep-waking cycle by anticipating fluctuations of EEG activity, promoting a 
state of vigilance, monitoring environmental stimuli with a specific emphasis on alerting stimuli and 
orienting to novelty (Giorgi et al. 2004).  
The noradrenergic system has been implicated in the control of seizure activity (Weinshenker and 
Szot 2002; Giorgi et al. 2004). When the LC is damaged or the noradrenergic system is genetically 
impaired, animals demonstrate a higher susceptibility to experimentally evoked seizures. Amygdala 
and hippocampal kindling were accelerated after noradrenaline depletion with 6-hydroxydopamine 
in rats (McIntyre and Edson 1981; Bortolotto and Cavalheiro 1986; Corcoran 1988). Genetically 
engineered mice that lack noradrenaline are shown to have higher susceptibility to different 
convulsant stimuli (Szot et al. 1999). Other studies demonstrated that seizure susceptibility in these 
animals can be reduced by restoring the noradrenergic activity. Audiogenic seizures in genetically 
epilepsy-prone rats were suppressed by intracerebral injections of noradrenaline (Mishra et al. 1993; 
Yan et al. 1998) and grafted noradrenergic neurons suppressed seizure development in the kindling 
model (Barry et al. 1987; Bengzon et al. 1990). Also, electrical stimulation of the LC inhibited seizure 
activity induced by administration of chemoconvulsants (Ferraro et al. 1994). Recently, it was shown 
that mutations in the α2B adrenoreceptor are involved in autosomal dominant cortical myoclonus and 
epilepsy (De Fusco et al. 2014). Further evidence for the antiepileptic properties of noradrenaline is 
related to the ability of several antiepileptic drugs to increase the noradrenergic activity. Valproate 
and phenytoin increase noradrenaline levels in various brain regions (Baf et al. 1994) and 
carbamazepine produces a dose-dependent increase in the firing rate of LC neurons (Olpe and Jones 
1983), concomitant with higher noradrenaline levels in various brain regions (Baf et al. 1994).  
The first evidence for a prominent role of the LC in the antiepileptic activity induced by VNS dates 
back to 1998, when Krahl et al. showed that the permanent loss or functional inactivation of LC 
neurons abolished the antiepileptic effects of VNS (Krahl et al. 1998). Results from 
electrophysiological studies in the rat brain showed that the activity of LC neurons is increased upon 
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acute and chronic stimulation of the vagus nerve (Groves et al. 2005; Dorr and Debonnel 2006; 
Manta et al. 2009). Confirming the recruitment of LC neurons during VNS, immediate-early gene 
mRNAs or their protein transcripts increase within LC neurons, in both rats (Naritoku et al. 1995) and 
rabbits (Gieroba and Blessing 1994; Cunningham et al. 2008). Increases in extracellular noradrenaline 
concentrations have been measured by microdialysis in projection areas of the LC, such as the 
prefrontal cortex (Roosevelt et al. 2006; Follesa et al. 2007; Manta et al. 2013), hippocampus 
(Roosevelt et al. 2006; Manta et al. 2013) and amygdala (Hassert et al. 2004) in VNS-treated rats.  
In addition to noradrenaline, axons pertaining to the LC synthesize a rich spectrum of 
neuromodulators known to be co-released. The LC neurons store and release a variety of 
neuropeptides, such as enkephalin, neurotensin, vasopressin, somatostatin, neuropeptide Y and 
galanin (Olpe and Steinmann 1991). Among these, neuropeptide Y and galanin have shown strong 
antiepileptic properties when applied locally in the rat hippocampus (Gundlach et al. 1990; Xu et al. 
1998; Mazarati and Wasterlain 2002; Meurs et al. 2007). In addition, administration of a galanin 
receptor antagonist accelerates the development of status epilepticus (Mazarati et al. 1998) and 
galanin knock-out mice are more susceptible to seizures (Mazarati et al. 2000). It remains to be 
established to what extent the activity of these noradrenaline co-transmitters contributes to the 
antiepileptic effect of VNS.  
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Rationale 
Every year, more than 80 new cases of epilepsy occur per 100,000 persons, making it the second 
most common neurological disorder following neurovascular diseases (Sander and Shorvon 1996; 
Banerjee and Hauser 2008; Hirose 2013). More than 30% of all epilepsy patients suffer from 
uncontrolled seizures or experience unacceptable medication-related side effects despite adequate 
pharmacological treatment (Blume 2008). The inability to adequately treat all patients with 
refractory epilepsy provides a continuous impetus to investigate novel forms of treatment. One novel 
treatment option is neurostimulation. This thesis focuses on VNS. 
Despite the fact that VNS is an efficacious, safe and worldwide accepted treatment option for 
patients who are considered unsuitable for resective surgery or in whom surgery failed, specific 
issues remain to counteract its full therapeutic application.  
Mechanism of action 
The precise mechanism of action of VNS for refractory epilepsy remains to be elucidated, but the 
central noradrenergic pathway has been shown to play a key role in the circuitry required for the 
antiepileptic effects of VNS. The first evidence for a prominent role of the noradrenergic LC in the 
antiepileptic activity induced by VNS dates back to 1998, when Krahl et al. showed that the 
permanent loss or functional inactivation of LC neurons abolished the antiepileptic effects of VNS in 
the MES model (Krahl et al. 1998). Results from electrophysiological studies in the rat brain showed 
that the activity of LC neurons is increased upon acute and chronic stimulation of the vagus nerve 
(Groves et al. 2005; Dorr and Debonnel 2006; Manta et al. 2009). Confirming the recruitment of LC 
neurons during VNS, immediate-early gene mRNAs or their protein transcripts increase within LC 
neurons, in both rats (Naritoku et al. 1995) and rabbits (Gieroba and Blessing 1994; Cunningham et 
al. 2008). Increases in extracellular noradrenaline concentrations have been measured by 
microdialysis in projection areas of the LC, such as the prefrontal cortex (Roosevelt et al. 2006; 
Follesa et al. 2007; Manta et al. 2013), hippocampus (Roosevelt et al. 2006; Manta et al. 2013) and 
amygdala (Hassert et al. 2004) in VNS-treated rats. Although these studies show VNS-induced 
noradrenaline increases, no correlations were made with antiepileptic effects of VNS. One aim of this 
thesis was therefore to evaluate whether VNS-induced changes in extracellular hippocampal 
noradrenaline levels are involved in the antiepileptic mechanism of action of VNS. 
Rationale and research aims  
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Stimulation parameters 
The stimulation parameters currently used in clinical practice are not evidence based and vary 
considerably. It is routine clinical practice to uptitrate the output current intensity in order to reach 
seizure control over several weeks/months. Several preclinical and clinical studies however do 
suggest that lower current density might be sufficient to achieve clinical efficacy (Woodbury and 
Woodbury 1990; Zagon and Kemeny 2000; Van Laere et al. 2000; Vonck et al. 2008; Cunningham et 
al. 2008). A second aim of this thesis was therefore to test the hypothesis that output current 
intensities in the lower range are sufficient to obtain seizure-suppressing effects.  
Predictive factors for response 
Clinical response to VNS is variable and unpredictable (Boon et al. 2007). Treatment with VNS 
reduces seizures with ≥ 50% in 50% of patients. These patients are defined as responders. In about 
30% of patients, there is little or no effect. These patients are defined as non-responders. In the 
other 20% of patients, seizure frequency reduction ranges between 30-50%. These patients are 
defined as partial responders. So far, no predictive criteria for success have been identified - it is still 
unclear why some patients do and others do not respond to the VNS therapy. In current clinical 
practice, physicians are unable to assess true VNS-induced vagal nerve fiber activation. Apart from 
unravelling and understanding the effect of VNS in the brain, research on activation of the vagus 
nerve itself remains a key point, as adequate activation of the vagus nerve is ultimately necessary to 
achieve any positive effects. A third aim of this thesis was therefore to identify a biomarker reflecting 
true VNS-induced activation of the vagus nerve. Recording CAPs would be a good biomarker. 
Research aims 
The aims of this thesis are  
(i) to investigate whether VNS-induced changes in extracellular hippocampal noradrenaline 
levels are involved in the antiepileptic mechanism of action of VNS in the 
intrahippocampal pilocarpine rat model of acute limbic seizures, 
(ii) to investigate the effect of various VNS output current intensities on cortical excitability 
in the motor cortex stimulation rat model, and 
(iii) to identify and characterize a neurophysiological parameter reflecting true VNS-induced 
activation of the vagus nerve. 
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Abstract 
Introduction: Vagus nerve stimulation (VNS) is an effective adjunctive treatment for medically 
refractory epilepsy. In this study, we measured VNS-induced changes in hippocampal 
neurotransmitter levels and determined their potential involvement in the anticonvulsive action of 
VNS, in order to elucidate the mechanism of action responsible for the seizure suppressing effect of 
VNS in an animal model for limbic seizures. 
Methods: We used in vivo intracerebral microdialysis to measure VNS-induced changes in 
hippocampal extracellular concentrations of noradrenaline, dopamine, serotonin and GABA in freely 
moving, male Wistar rats. During the same experiment, the effect of VNS on pilocarpine-induced 
limbic seizures was assessed using video-EEG monitoring. The involvement of VNS-induced increases 
in hippocampal noradrenaline in the mechanims of action of VNS was evaluated by blocking 
hippocampal α2 receptors. 
Results: VNS produced a significant increase in hippocampal noradrenaline concentration (69 ± 16% 
above baseline levels). VNS also increased the latency between pilocarpine infusion and the onset of 
epileptiform discharges, and reduced the duration and severity of pilocarpine-induced limbic 
seizures. A strong positive correlation was found between the noradrenergic and anticonvulsive 
effects of VNS. Blockade of hippocampal α2 receptors reversed the seizure-suppressing effect of VNS. 
Increased hippocampal noradrenaline is a biomarker for efficacy of vagus 
nerve stimulation in a limbic seizure model 
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Conclusion: VNS induces increases in extracellular hippocampal noradrenaline, which are at least 
partly responsible for its seizure-suppressing effect in a model for limbic seizures, and constitute a 
potential biomarker for the efficacy of VNS in temporal lobe epilepsy. 
Introduction 
Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy in patients who are 
unsuitable candidates for epilepsy surgery (Ben-Menachem 2002). Worldwide, more than 50,000 
epilepsy patients have been treated with VNS. Several studies, including two large double-blind 
randomized clinical trials (Ben-Menachem et al. 1994; DeGiorgio et al. 2000), have confirmed the 
efficacy of VNS in different types of epilepsy. Seizure reduction as a result of VNS ranges from 25% to 
55%, and varies considerably from patient to patient. In responders, VNS causes either a rapid or a 
delayed reduction in seizure frequency. However, a significant fraction (approximately one third) of 
patients does not respond to VNS. Because the mechanism of action of VNS in epilepsy is currently 
unknown, it is not clear which factors determine the patient’s response to the treatment, nor what 
the most optimal stimulation parameters are. 
The vagus nerve is a mixed nerve consisting of 20% efferent (motor) and 80% afferent (sensory) 
fibers. The nucleus of the solitary tract (NTS) receives the largest number of vagal afferents. The NTS 
in turn projects to pontine nuclei, the cerebellum and the mesencephalon, but also to regions which 
are frequently involved in the generation of seizures such as the cortex, thalamus and amygdala. The 
vagus nerve also projects directly to the raphe nucleus and indirectly to the locus coeruleus (LC). 
These nuclei are the major sources of serotonergic and noradrenergic neurons in the brain, 
respectively (Henry 2002). Both send direct projections to the hippocampus, a brain structure that is 
frequently involved in the generation of epileptic seizures in temporal lobe epilepsy (TLE) (Castle et 
al. 2005).  
Interestingly, bilateral destruction of the LC has been found to reverse the seizure-suppressing effect 
of VNS in the maximal electroshock model (Krahl et al. 1998). Single-unit recording experiments have 
shown that the activity of noradrenergic neurons in the LC is increased upon stimulation of the vagus 
nerve (Dorr and Debonnel 2006a; Groves et al. 2005). Presumably as a result of enhancement of the 
activity of LC neurons, increases in extracellular noradrenaline concentration have been measured in 
projection areas of the LC such as the hippocampus and cortex in VNS-treated rats (Roosevelt et al. 
2006). 
The noradrenergic system has been convincingly implicated in the control of seizure activity, 
especially for seizures that spread along the limbic system (Giorgi et al. 2004; Weinshenker and Szot 
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2002a). Animals in which the noradrenergic system has been damaged (McIntyre and Edson 1981; 
Corcoran 1988; Bortolotto and Cavalheiro 1986) or is genetically impaired (Mishra et al. 1993; Yan et 
al. 1998; Szot et al. 1999) generally have a higher susceptibility to experimentally evoked seizures 
and seizure susceptibility in these models can be reduced by restoring noradrenergic activity (Barry 
et al. 1987; Bengzon et al. 1990; Kokaia et al. 1994; Mishra et al. 1993; Yan et al. 1998; Kokaia et al. 
1989; Gross and Ferrendelli 1982). Loss of noradrenaline also attenuates the efficacy of a number of 
anticonvulsant therapies including the ketogenic diet and valproic acid (Weinshenker 2008; Schank et 
al. 2005). Conversely, activation of the noradrenergic system can inhibit seizure activity induced by 
electrical stimulation (McIntyre et al. 1982) or administration of chemoconvulsants (Ferraro et al. 
1994). Noradrenaline interacts with three families of G-protein coupled adrenergic receptors (α1, α2, 
β receptors) which are further divided into different subtypes (α1A-B, α1D, α2A-C, β1-3 receptors) (Ramos 
and Arnsten 2007). It has highest affinity for α2 adrenergic receptors, which are generally coupled to 
Gi proteins. The α2 adrenergic receptor subtype is considered to be the most promiscuous 
anticonvulsant adrenoreceptor (Weinshenker and Szot 2002).  
Recent work by our group provides further insight into the relative contribution of different 
adrenergic receptor subtypes to the anticonvulsive action of noradrenaline. Administation of 
maprotiline, a selective noradrenaline reuptake inhibitor, in the intrahippocampal pilocarpine model 
for limbic seizures resulted in increased levels of brain noradrenaline and potent suppression of 
pilocarpine-induced limbic seizures. Administration of a threshold anticonvulsive dose of maprotiline 
resulted in a 70% increase of hippocampal noradrenaline levels. Using selective agonists and 
antagonists for the different adrenergic receptor subtypes, we then showed that seizure suppression 
was mediated by combined activation of α2 and β2 adrenergic receptors. Application of an antagonist 
of either α2 (SKF-86466) or β2 adrenergic receptors (ICI-118551) reversed the anticonvulsive effect of 
increased hippocampal noradrenaline. On the other hand, combined application of an α2 
(medetomidine) and β2 adrenoreceptor agonist (salmeterol) was necessary to obtain seizures 
suppression (Clinckers et al. 2010). 
Given the established role of increased noradrenergic transmission in the control of limbic seizures, it 
is conceivable that VNS produces its anticonvulsive effect by increasing noradrenaline levels in 
structures that are critically involved in the generation of limbic seizures, such as the hippocampus. 
To test this hypothesis would require that the noradrenergic and anticonvulsive effects of VNS are 
measured concomitantly in the same group of animals. This experiment has not been performed to 
date.  
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The aim of this study was to evaluate whether VNS-induced changes in hippocampal 
neurotransmitter levels, particularily those of noradrenaline, are involved in the mechanism of action 
of VNS in TLE. In a first series of experiments, we determined the effect of VNS on hippocampal 
noradrenaline, dopamine, serotonin and GABA levels and on pilocarpine-induced limbic seizures in 
the same group of animals. Subsequently, we tested the hypothesis that increases in hippocampal 
noradrenaline mediate the anticonvulsive effect of VNS. To this end, we studied the effect of 
blockade of hippocampal adrenoreceptors on the seizure suppressing action of VNS. We chose to use 
a selective α2 adrenoreceptor antagonist in these experiments, given that hippocampal α2 
adrenoreceptor blockade was previously found to be sufficient to completely reverse the 
anticonvulsive effect of a noradrenaline reuptake inhibitor in the same animal model (Clinckers et al. 
2010). 
Methods 
Chemicals and Reagents 
Pilocarpine HCL and SKF-86466 HCl were purchased from Sigma (St. Louis, MO, USA). All other 
chemicals were analytical reagent grade or better and were obtained from Merck (Darmstadt, 
Germany). Aqueous solutions were made with purified water (Seralpur pro 90 CN, Belgolabo, 
Overijse, Belgium) and filtered through a 0.2 μm membrane filter. The aqueous perfusion solution for 
the microdialysis experiments, subsequently referred to as modified Ringer’s solution, consisted of 
147 mM NaCl, 2.3mM CaCl2 and 4mM KCl. An antioxidant solution containing 3.3 mM L-cystein, 0.27 
mM Na2EDTA, 12.5 μM ascorbic acid and 100 mM glacial acetic acid was used to stabilize collected 
monoamines in the dialysates. All compounds were dissolved in modified Ringer’s solution and 
administered via the microdialysis probe. 
Animals 
Thirty-seven male Wistar rats (Charles River Laboratories, Belgium) weighing 250-275g were used. 
Animals were treated according to guidelines approved by the European Ethics Committee (decree 
86/609/EEC). The study protocol was approved by the Animal Experimental Ethical Committee of 
Ghent University Hospital (ECP 08/47). All animals were kept under environmentally controlled 
conditions (12h light/dark cycles, 20-23°C and 50% relative humidity) with food and water intake ad 
libitum. 
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Surgery 
Rats were anesthetized with isoflurane (induction: 5%; maintenance:1-2% ) and implanted with two 
epidural recording electrodes in the right and left os frontale, a ground (reference) electrode close to 
the sutura lambdoidea and four anchor screws bilaterally in the os frontale and parietale. A bipolar 
depth electrode was fixed to a microdialysis guide cannula (CMA/Microdialysis; Solna; Sweden), and 
both were stereotactically implanted in the left hippocampus (coordinates relative to bregma: 
rostrocaudal -5.6 mm; medio-lateral -4.6 mm; dorso-ventral -4.6 mm, i.e. 3 mm above final 
microdialysis probe membrane position). A custom-made silicone spiral cuff-electrode with platinum 
contacts was implanted around the left vagus nerve. To minimize post-operative pain, 
buprenorphine (1 mg/kg) was intraperitonally administrated and a 2% xylocaine gel was applied to 
the incision wounds. Animals were allowed to recover from surgery under an infrared lamp. Correct 
positioning of the microdialysis probe in the left hippocampus and the cuff electrode around the left 
vagus nerve was verified post-mortem. Animals with aberrant probe or cuff electrode localization 
were excluded from the study. 
Video-EEG monitoring and intracerebral microdialysis 
One week after surgery, rats were placed in specialized neuromonitoring cages equipped for 
simultaneous performance of VNS, video-EEG monitoring and microdialysis sampling in freely moving 
conditions. Rats were connected to (i) a custom-built digital video-EEG monitoring system, and (ii) an 
external current stimulator (NCP, model 100; Cyberonics Inc., Houston, TX, USA) via an electrical 
swivel (Plastics One, Roanoke, USA). The microdialysis cannula obturator was replaced by a 
microdialysis probe (CMA12; 3 mm membrane length; theoretical cut-off 20 kDa; CMA/Microdialysis, 
Solna, Sweden). The microdialysis probe was continuously perfused with modified Ringer’s solution 
at a flow rate of 2 μl/min. A 15 - 20 h interval between probe implantation and the beginning of the 
experiment was respected to ensure integrity of the blood-brain barrier (Benveniste 1989), absence 
of excessive reactive gliosis in the tissue surrounding the microdialysis probe (Georgieva et al. 1993) 
and stable basal neurotransmitter dialysate concentrations (Clapp-Lilly et al. 1999). 
Experimental design 
In all animals, limbic seizures were evoked by intrahippocampal perfusion of the muscarinic agonist 
pilocarpine (10 mM) via the microdialysis probe. This rodent model for acute limbic seizures (Millan 
et al. 1993) has been extensively used in our laboratory (Smolders et al. 1997; Meurs et al. 2008), and 
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is characterized by the sequential development of typical behavioural patterns, electrographic 
activity and neurochemical alterations (Meurs et al. 2008).  
In a first series of experiments, we studied the effects of VNS on hippocampal neurotransmitter 
levels and pilocarpine-induced limbic seizure activity. Based on the results of these experiments, we 
conducted a second series of experiments in which we tested whether the effects of VNS on 
pilocarpine-induced seizure activity could be reversed by intrahippocampal application of a selective 
α2 adrenoreceptor antagonist.  
During each experiment, the microdialysis probe was continuously perfused at a flow-rate of 2 μl / 
min and hippocampal dialysate samples (40 μl) were collected every 20 minutes. Protocols for each 
experimental group are shown in figure 1 and detailed below: 
Effect of VNS on limbic seizure activity and hippocampal neurotransmitter levels 
- SHAM group (n=7): the probe was perfused with modified Ringer’s solution (R) during the first 15 
collection periods. During collection periods 16 and 17, 10 mM pilocarpine was added to the 
perfusion fluid. Subsequently, perfusion fluid was switched back to modified Ringer’s solution and 
samples were collected for another five collection periods (collection periods 18-22). 
- VNS group (n=12): protocol as for the SHAM rats except but VNS was performed from the beginning 
of collection period 10 until the end of the experiment (i.e. collection period 22). VNS was delivered 
with the following stimulation parameters: frequency = 30 Hz; intensity = 1 mA; pulse width = 250 
μsec; duty cycle = 7 sec on - 18 sec off. 
Effect of α2 adrenoreceptors antagonism on the seizure-suppressing effect of VNS 
- SHAM-SKF group (n=10): from collection period 7 until the end of the experiment, 1 nM SKF-86466 
was added to the perfusion fluid. During collection period 16 and 17, perfusion was switched to a 
mixture of 10 mM pilocarpine and 1 nM SKF-86466. Subsequently, perfusion fluid was switched back 
to the 1 nM SKF-86466 solution and samples were collected for another five collection periods 
(collection periods 18-22). The SKF-86166 perfusate concentration was selected based on the 
published affinity constant (Ki= 6nM) (Heal et al. 1995). This concentration was compensated for 
expected probe recovery (approximately 10%) and multiplied by 2 to obtain full receptor 
antagonism. 
- VNS-SKF group (n=8): protocol as for the SHAM-SKF group, but VNS (frequency = 30 Hz; intensity = 
1 mA; pulse width = 250 μsec; duty cycle = 7 sec on - 18 sec off) was delivered from collection period 
10 onwards. 
   
Chapter 5| VNS, noradrenaline and seizure suppression 83 
 
 
 
 
 
 
 
 
 
 
 
 
Video-EEG recording 
All rats were monitored with continuous video-EEG recording throughout the experiment. 
Behavioural changes indicative of seizure activity were scored by reviewing video recordings. For 
each collection period, behavioural changes were rated on a seizure severity scale based on Racine’s 
scale, which was adapted to include all behavioural changes observed in focal limbic seizure models: 
(0) normal, non-epileptic activity; (1) mouth and facial movements, hyperactivity, grooming, sniffing, 
scratching, wet dog shakes; (2) head nodding, staring, tremor; (3) forelimb clonus; forelimb 
extension; (4) rearing, salivating, tonic-clonic activity; (5) falling, status epilepticus. For each of the 
seven collection periods following the start of the pilocarpine administration (i.e. collection periods 
16 to 22) the highest seizure severity score (SSS) was retained. Total seizure severity score (TSSS) for 
each animal was calculated as the sum of the seizure severity scores (SSS), and used as a measure for 
seizure severity throughout the experiment. Hippocampal and cortical EEG recordings were reviewed 
to determine the latency to occurrence of the first epileptiform activity (spikes) and the total 
duration of the epileptiform activity after the start of the pilocarpine infusion (collection periods 16 
to 22). 
Figure 1| Schematic representation of experimental protocols: Every square represents a 20-min 
perfusion of the microdialysis probe with: R = modiﬁed Ringer’s solution; RP = 10 mM pilocarpine 
dissolved in modiﬁed Ringer’s solution; S = 1 nM SKF-86466 (α2 receptor antagonist) dissolved in modiﬁed 
Ringer’s solution and SP = 10 mM pilocarpine and 1 nM SKF-86466 dissolved in modiﬁed Ringer’s 
solution. 
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Microdialysate analysis 
Dialysate samples were split for analysis of monoamines (dopamine, serotonin, noradrenaline) (25μL) 
and GABA (15μL). For monoamine analysis, we performed an off-line microbore liquid 
chromatography assay (C8, 5 μm; 100 x 1 mm) based on ion-pair reversed phase chromatography, 
coupled to single-channel electrochemical detection with a low oxidation potential (+450 mV vs. 
Ag/AgCl) (Decade, Antec, Leiden, The Netherlands), as has previously been described in detail 
(Smolders et al. 2008). For the analysis of GABA, we performed pre-column derivatisation with 
ophtalaldehyde/ 2-methyl-2-propanethiol and iodoacetamide followed by reversed-phase isocratic 
microbore liquid chromatography (C8, 5 μm; 100x1 mm; Unijet, Bioanalytical Systems) and 
amperometric detection, as has previously been described in detail (Smolders et al. 1995). 
Data analysis 
All statistical analyses were performed using SPSS 15 for Windows. Data are expressed as mean ± 
standard error of the mean. The significance level for demonstrating differences between groups was 
set at α=0.05. To evaluate VNS-induced changes in hippocampal neurotransmitter levels, a Student’s 
T-test for paired comparison was used. In the VNS group, mean neurotransmitter levels during 
baseline collections 4 to 9 were compared to the mean neurotransmitter levels during the six 
collection periods after the start of VNS and prior to pilocarpine perfusion (collection periods 10-15). 
In the VNS-SKF group, mean neurotransmitter levels in the three collections during SKF infusion 
(collection periods 7-9) were compared to the mean neurotransmitter levels during the six collection 
periods in which VNS and SKF were co-administered prior to pilocarpine infusion (collection periods 
10-15). The effect of VNS on pilocarpine-induced seizure activity was determined by comparing SSS 
and TSSS (Mann-Whitney U test), and latency to epileptiform discharges and duration of epileptiform 
discharges on the hippocampal EEG (Student’s T test for comparison of independent samples) 
between the SHAM and VNS group. Pearson correlation tests were performed to analyze correlation 
between VNS-induced increase of hippocampal NAD levels and seizure parameters (severity, 
duration and latency).  
The effect of hippocampal α2 adrenoreceptors antagonism on pilocarpine-induced seizures and on 
the seizure-suppresing effect of VNS were assessed by comparing TSSS (Kruskal-Wallis ANOVA 
followed by Mann-Whitney U post-hoc tests using adjusted P-levels after Bonferroni correction), and 
latency and duration of epileptiform discharges on hippocampal EEG (one-way ANOVA followed by 
Bonferroni-Dunn post-hoc tests for pairwise comparison) between the relevant groups. 
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Results 
Effect of VNS on limbic seizure activity and hippocampal neurotransmitter 
levels 
In the SHAM-treated group, perfusion of a 10 mM pilocarpine solution through the hippocampal 
microdialysis probe during 40 min elicited a host of behavioural changes including increased 
exploratory behaviour, wet dog shakes and excessive grooming, beginning 15-20 min after the start 
of pilocarpine administration. Approximately 30 to 60 min following pilocarpine, these changes 
progressively evolved into recurring bouts of staring, mouth and facial movements, forelimb clonus, 
rearing, salivation and rarely falling. Individual behavioural seizures typically lasted between 5 s and 1 
min. EEG showed continuous epileptic spikes and intermittent rhythmic epileptiform discharges in 
the hippocampus, which occasionally generalized to the cortex (fig. 2A). None of the animals 
developed a status epilepticus or died.  
 
 
 
 
 
 
 
 
 
 
Figure 2| Representative sample of EEG recorded from SHAM- (A) and VNS-treated rats (B). The upper 
traces represent EEG recorded from the left hippocampal depth electrode. The lower traces represent 
EEG recorded from an epidural electrode positioned over the right frontal cortex. EEG recordings are 
shown from the start of intrahippocampal pilocarpine infusion until the end of the experiment (i.e. 
collection periods 16–22, 140 min). The ﬁrst vertical line represents the onset of epileptiform activity on 
hippocampal EEG. The second vertical line represents the end of epileptiform activity on hippocampal 
EEG. Both in SHAM- and VNS-treated rats, intrahippocampal infusion of pilocarpine-induced epileptic 
spikes and intermittent rhythmic epileptiform discharges, visible on hippocampal EEG and occasionally 
also on cortical EEG. In VNS-treated animals (B), the latency to ﬁrst epileptiform activity was signiﬁcantly 
increased and the total duration of epileptiform activity was signiﬁcantly decreased compared with 
SHAM-treated animals (A). 
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In the VNS-treated group, pilocarpine-induced behavioural changes indicative of seizure activity were 
significantly less severe than in the SHAM group (table 1). Overall seizure severity was significantly 
lower in the VNS-treated group (TSSS = 5 +/- 1) compared to the SHAM group (TSSS = 14 +/- 2) (p < 
0.01). The latency between the start of pilocarpine administration and the occurrence of epileptiform 
activity on the hippocampal EEG was significantly prolonged in VNS-treated rats (26 +/- 4 min) 
compared to SHAM-treated rats (12 +/- 4 min) (p < 0.05, table 1). Moreover, the total duration of 
epileptiform activity on the hippocampal EEG was significantly shorter in VNS-treated rats (67 +/- 12 
min) compared to SHAM-treated rats (111 +/- 8 min) (p < 0.05, table 1). A representative sample of 
the EEG recorded from hippocampus and cortex in SHAM- and VNS-treated rats is shown in fig.2. 
 
During VNS, the mean dialysate concentration of noradrenaline increased by 69% +/- 16% (0.122 +/- 
0.012 nM) compared to baseline (0.075 +/- 0.008 nM) (p < 0.01). VNS had no significant effect on the 
dialysate concentration of serotonin, dopamine and GABA (fig 3). VNS-induced increases in the 
dialysate concentration of noradrenaline were positively correlated with the latency to epileptiform 
activity on hippocampal EEG (R2=0.82; p < 0.01), and negatively correlated with the total duration of 
epileptiform activity on hippocampal EEG (R2=0.62; p < 0.01) and TSSS (R2=0.81; p < 0.01) (fig. 4 A-C). 
Animals could be divided into two distinct groups on the basis of the noradrenergic and 
anticonvulsive effects of VNS. Rats with a VNS-induced increase in hippocampal noradrenaline 
concentration of at least 70% (7 out of 12 rats, subsequently referred to as “responders”) had a 
pronounced reduction in seizure severity. Conversely, animals with a VNS-induced increase in 
hippocampal noradrenaline concentration of less than 70% (5 out of 12 rats, subsequently referred 
to as “non-responders”) were not protected from pilocarpine induced seizures. No significant 
correlation was found between baseline hippocampal NAD levels and seizure parameters (severity, 
latency and duration). 
Table 1| Overview of seizure parameters (severity, latency and duration) in all experimental groups. In VNS and VNS-
SKF group, a subdivision was made between non-responders and responders based on VNS-induced noradrenaline 
increase. In the VNS-SKF group, noradrenaline levels prior to VNS were already increased compared with baseline 
because of intrahippocampal infusion of 1 nM SKF-86466. 
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Effect of α2 adrenoreceptor antagonism on the seizure suppressing effect of 
VNS 
Intrahippocampal infusion of 1 nM SKF-86466 alone induced an increase in mean noradrenaline 
dialysate concentration of 97 ± 14% in the VNS-SKF group and 84 +/- 28% in the SKF group (table 1). 
VNS-induced increases in noradrenaline in the VNS-SKF group were determined by comparing mean 
noradrenaline concentration in the three collections during SKF infusion (collection periods 7- 9) to 
the mean noradrenaline concentration during the six dialysate collections in which VNS and SKF were 
co-administered prior to pilocarpine infusion (collection periods 10-15). VNS produced an additional 
increase in mean noradrenaline dialysate concentration of 57 +/- 12% compared noradrenaline 
contrations during administration of SKF alone. Out of a total of 8 rats, 4 had a VNSinduced increase 
in hippocampal noradrenaline of ≥ 70% (further defined as responders).  
 
Figure 3| Effect of VNS on hippocampal levels of GABA, serotonin (5HT), dopamine (DA) and 
noradrenaline (NAD). In the VNS group, mean neurotransmitter levels during baseline collections 4–9 
were compared with the mean neurotransmitter levels during the six collection periods after the start of 
VNS and prior to pilocarpine perfusion (collection periods 10–15). Average dialysate concentrations are 
presented in the table under the graph (in nM). No signiﬁcant changes could be demonstrated for GABA, 
5HT and DA. VNS did induce a signiﬁcant increase of hippcampal NAD levels. *Statistical signiﬁcant 
difference (p < 0.05). 
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Because the aim of these experiments was to determine the involvement of increased hippocampal 
noradrenaline in the seizure-suppressing effect of VNS, only responders were included in the 
statistical analysis of seizure activity.  
In responders, intrahippocampal administration of the selective α2 adrenoreceptor antagonist SKF- 
86466 completely reversed the seizure-suppressing effect of VNS. Latency to epileptiform discharges, 
Figure 4| Correlation between VNS-induced changes in hippocampal noradrenaline levels and seizure-
suppressing effects. (A) VNS-induced increases in hippocampal noradrenaline levels were positively 
correlated with the latency to epileptiform activity on hippocampal EEG after starting the pilocarpine 
infusion. VNS-induced increases in hippocampal noradrenaline levels were negatively correlated with (B) 
the total duration of epileptiform activity on hippocampal EEG and (C) clinical seizure severity 
represented by TSSS. 
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total duration of epileptiform activity and TSSS were similar for VNS-SKF- and SHAM-SKF-treated rats 
(fig. 5). Seizure duration and severity in the VNS-SKF group were significantly increased compared to 
VNS-treated rats, and were comparable to what was observed in SHAM-treated rats (fig.5B-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5| Effect of α2 adrenoreceptor antagonism on the seizuresuppressive effects of VNS. 
Intahippocampal infusion of the selective α2 adrenoreceptor antagonist SKF-86466 completely blocked 
VNSinduced effects on latency to epileptiform discharges (A), total duration of epileptiform activity (B) 
and clinical seizure severity represented by TSSS (C) because these outcome parameters were similar for 
VNSSKF and SHAM-SKF rats. *Statistical signiﬁcant difference (p < 0.05). 
90 Chaper 5| VNS, noradrenaline and seizure suppression 
 
Discussion 
The main findings of this study are (i) that VNS induces an increase in the extracellular hippocampal 
concentration of noradrenaline, but not of dopamine, serotonin and GABA; (ii) that VNS prevents the 
development of pilocarpine-induced limbic seizures only in those rats in which hippocampal 
noradrenaline increased by at least 70%; and (iii) that selective α2 adrenoreceptor antagonism in 
proximity of the seizure focus abolishes the seizure-suppressing effect of VNS. Taken together, these 
findings provide convincing evidence for the existence of a strong causal link between the 
seizuresuppressing effect of VNS and increased hippocampal noradrenergic signaling.  
Roosevelt and co-workers have previously reported a bilateral increase in noradrenaline levels in the 
cortex (39%) and the hippocampus (28%) in response to one hour of VNS (20 Hz, 1 mA, 500 μsec, 30 
sec ON - 10 min OFF) (Roosevelt et al. 2006). In our hands, VNS produced a more than two-fold 
higher increase (69%) in extracellular hippocampal noradrenaline. This may be due to the fact that 
we used a more intensive stimulation protocol (30 Hz, 1 mA, 250 μsec, 7 sec ON - 18 sec OFF), 
resulting in the delivery of a total of 30,240 electrical pulses to the vagus nerve compared to 3,600 
pulses in the study by Roosevelt and colleagues. The duty cycle used in our experiments (7 sec ON - 
18 sec OFF) is referred to as ‘rapid cycling’, and is used to treat patients in whom VNS with a duty 
cycle of 30 sec ON - 10 min OFF did not sufficiently improve seizure control (Labar 2004; Liporace et 
al. 2001). In our hands, VNS suppressed pilocarpine-induced limbic seizures most strongly in those 
rats with the largest increase in hippocampal noradrenaline. Conversely, rats in which VNS did not 
increase hippocampal noradrenaline exhibited the most severe seizures. A noradrenaline increase of 
at least 70% seems to be associated with suppression of limbic seizures. Interestingly, in previous 
work, we found that hippocampal extracellular noradrenaline increased by 70% in rats that were 
treated with the selective noradrenaline reuptake inhibitor, maprotiline, at the minimal dose 
required to suppress pilocarpine-induced seizures (Clinkers et al. 2010).  
Based on these observations, we hypothesized that VNS prevents the development of limbic seizures 
by increasing hippocampal noradrenaline. To test this hypothesis, we verified whether blockade of 
adrenoreceptors in proximity of the seizure focus would reverse the anticonvulsive effect of VNS. We 
chose to use a selective α2 adrenoreceptor antagonist in these experiments, based on previous work 
in which we showed that application of this antagonist was sufficient to completely reverse the 
anticonvulsive effect of increased hippocampal noradrenaline (Clinckers et al. 2010).  
We found that in rats with a VNS-induced increase in hippocampal noradrenaline of ≥ 70%, 
concomitant intrahippocampal administration of the selective α2 adrenoreceptor antagonist SKF- 
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86466 abolished the anticonvulsive action of VNS. This finding strongly supports the hypothesis that 
the seizure suppressing effect of VNS is at least partly mediated by increased hippocampal 
noradrenaline concentration and increased hippocampal α2 adrenoreceptor activation. 
In our hands, only a subset of animals (7 out of 12) exhibited a VNS-induced increase in hippocampal 
noradrenaline that was sufficient to produce an anticonvulsant effect. This “responderrate” is 
remarkably similar to what has been observed in clinical trials with VNS.  
One small open-label study in patients with TLE and seizures originating independently from the 
leftand right temporal lobes showed that VNS reduced seizure frequency by at least 50% in 6 out of 
10 patients (Alsaadi et al. 2001). Larger clinical trials that have evaluated the efficacy of VNS in 
various types of refractory epilepsy have consistently shown that VNS is ineffective at reducing 
seizures in approximately one third of patients (Ben-Menachem et al. 1994; De Herdt et al. 2007; 
Handforth et al. 1998; Vonck et al. 2004).  
Several, though not necessarily similar, factors could account for the inter-subject variablility of the 
response to VNS in our experiments and in patients suffering from TLE. First, there could be a 
difference in vagus nerve activation in response to VNS. Although an electrode lead break and 
stimulator defect was excluded by measuring impedance, it is possible that VNS does not activate 
vagus nerve fibers due to injury of the nerve induced by induced electrode implantation. Temporary 
nerve damage could explain the delayed effect of VNS in some patients with epilepsy implanted with 
a VNS system. Second, genetic variability and differences in external and/or internal environment 
could lead to differences in the number of noradrenergic neurons, their afferent and/or efferent 
projections and synaptic strengths within these noradrenergic neuronal networks. This intrinsic 
variation in the noradrenergic neural network could underlie the variable release of noradrenaline in 
response to VNS. One argument against this second hypothesis is that our study shows that 
differences in baseline noradrenaline levels do not explain the variation in clinical response to VNS. 
indicating that baseline hippocampal NAD level is no critical indicator of VNS mediated 
anticonvulsant effect. 
Given the causal relationship between increased hippocampal noradrenaline and suppression of 
limbic seizures in response to VNS in rats, VNS-induced increases in hippocampal noradrenaline may 
be a useful biomarker for the efficacy of VNS in human TLE. If used in combination with a non-
invasive technique to deliver VNS (f.i. transcutaneous activation of the vagus nerve (Dietrich et al. 
2008)), a biomarker for the efficacy of VNS could help clinicians to reliably identify responders prior 
to surgical implantation of a VNS device, and to determine optimal stimulation parameters in a 
rational way. 
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Conclusion 
The main findings of this study are (i) that VNS induces an increase in the extracellular hippocampal 
concentration of noradrenaline, but not of dopamine, serotonin and GABA; (ii) that VNS prevents the 
development of pilocarpine-induced limbic seizures only in those rats with VNS-induced increases in 
hippocampal noradrenaline of at least 70%; and (iii) that selective α2 adrenoreceptor antagonism in 
proximity of the seizure focus abolishes the seizure-suppressing effect of VNS. Taken together, these 
findings provide convincing evidence for the existence of a strong causal link between increased 
noradrenergic signaling and the anticonvulsant effect of VNS. 
Acknowledgements 
We acknowledge the excellent technical assistance of Ria Berckmans and Gino De Smet, laboratory 
technicians at the VUB. Robrecht Raedt is a post-doctoral fellow supported by the Special Research 
Fund of Ghent University. Ralph Clinckers is a post-doctoral fellow of the Fund for Scientific Research-
Flanders (FWO Vlaanderen). Kristl Vonck is supported by a grant from the BOF fund of Ghent 
University Hospital. Paul Boon is supported by grants from the Fund for Scientific Research- Flanders 
and Ghent University Research Fund and by the Clinical Epilepsy Grant from Ghent University 
Hospital.  
References 
Alsaadi TM, Laxer KD, Barbaro NM, Marks WJ, Jr., Garcia PA. Vagus nerve stimulation for the treatment of 
bilateral independent temporal lobe epilepsy. Epilepsia 2001;42:954-956. 
Aston-Jones G, Shipley MT, Chouvet G et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology 
and pharmacology. Prog Brain Res 1991;88:47-75. 
Barry DI, Kikvadze I, Brundin P, Bolwig TG, Bjorklund A, Lindvall O. Grafted noradrenergic neurons suppress 
seizure development in kindling-induced epilepsy. Proc Natl Acad Sci U S A 1987;84:8712-8715. 
Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002;1:477-82. 
Ben-Menachem E, Manon-Espaillat R, Ristanovic R et al. Vagus nerve stimulation for treatment of partial 
seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. 
Epilepsia 1994;35:616-626. 
Bengzon J, Kokaia M, Brundin P, Lindvall O. Seizure suppression in kindling epilepsy by intrahippocampal locus 
coeruleus grafts: evidence for an alpha-2-adrenoreceptor mediated mechanism. Exp Brain Res 1990;81:433-
437. 
Benveniste H. Brain microdialysis. J Neurochem 1989;52:1667-1679. 
Bohning DE, Lomarev MP, Denslow S, Nahas Z, Shastri A, George MS. Feasibility of vagus nerve stimulation-
synchronized blood oxygenation level-dependent functional MRI. Investigative Radiology 2001;36:470-479. 
   
Chapter 5| VNS, noradrenaline and seizure suppression 93 
 
Bonham AC, Chen CY. Synaptic transmission in nucleus tractus solitarius (NTS). In: Undem BJ, Weinreich D, 
editors. Advances in vagal afferent neurobiology. Boca Raton: CRC Press; 2005. p. 193-208. 
Bortolotto ZA, Cavalheiro EA. Effect of DSP4 on hippocampal kindling in rats. Pharmacol Biochem Behav 
1986;24:777-779. 
Castle M, Comoli E, Loewy AD. Autonomic brainstem nuclei are linked to the hippocampus. Neuroscience 
2005;134:657-669. 
Clapp-Lilly KL, Roberts RC, Duffy LK, Irons KP, Hu Y, Drew KL. An ultrastructural analysis of tissue surrounding a 
microdialysis probe. J Neurosci Methods 1999;90:129-142. 
Clinckers R, Zgavc T, Vermoesen K, Meurs A, Michotte Y, Smolders I. Pharmacological and neurochemical 
characterization of the involvement of hippocampal adrenoreceptor subtypes in the modulation of acute limbic 
seizures. J Neurochem 2010;115:1595-607. 
Contreras RJ, Beckstead RM, Norgren R. The central projections of the trigeminal, facial, glossopharyngeal and 
vagus nerves: an autoradiographic study in the rat. J Auton Nerv Syst 1982;6:303-322. 
Corcoran ME. Characteristics of accelerated kindling after depletion of noradrenaline in adult rats. 
Neuropharmacology 1988;27:1081-1084. 
Cunningham JT, Mifflin SW, Gould GG, Frazer A. Induction of c-Fos and DeltaFosB immunoreactivity in rat brain 
by Vagal nerve stimulation. Neuropsychopharmacology 2008;33:1884-1895. 
De Herdt V, Boon P, Ceulemans B et al. Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter 
study. Eur J Paediatr Neurol 2007;11:261-269. 
DeGiorgio CM, Schachter SC, Handforth A et al. Prospective long-term study of vagus nerve stimulation for the 
treatment of refractory seizures. Epilepsia 2000;41:1195-1200. 
Dietrich S, Smith J, Scherzinger C et al. A novel transcutaneous vagus nerve stimulation leads to brainstem and 
cerebral activations measured by functional MRI. Biomedizinische Technik 2008;53:104-111. 
Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J 
Pharmacol Exp Ther 2006b;318:890-898. 
Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J 
Pharmacol Exp Ther 2006a;318:890-898. 
Ferraro G, Sardo P, Sabatino M, La G, V. Locus coeruleus noradrenaline system and focal penicillin hippocampal 
epilepsy: neurophysiological study. Epilepsy Res 1994;19:215-220. 
Georgieva J, Luthman J, Mohringe B, Magnusson O. Tissue and microdialysate changes after repeated and 
permanent probe implantation in the striatum of freely moving rats. Brain Res Bull 1993;31:463-470. 
Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F. The role of norepinephrine in epilepsy: from the bench to the 
bedside. Neurosci Biobehav Rev 2004;28:507-524. 
Gross RA, Ferrendelli JA. Relationships between norepinephrine and cyclic nucleotides in brain and seizure 
activity. Neuropharmacology 1982;21:655-661. 
Groves DA, Bowman EM, Brown VJ. Recordings from the rat locus coeruleus during acute vagal nerve 
stimulation in the anaesthetised rat. Neurosci Lett 2005;379:174-179. 
Handforth A, DeGiorgio CM, Schachter SC et al. Vagus nerve stimulation therapy for partial-onset seizures: a 
randomized active-control trial. Neurology 1998;51:48-55. 
94 Chaper 5| VNS, noradrenaline and seizure suppression 
 
Heal DJ, Cheetham SC, Butler SA, Gosden J, Prow MR, Buckett WR. Receptor binding and functional evidence 
suggest that postsynaptic alpha 2-adrenoceptors in rat brain are of the alpha 2D subtype. Eur J Pharmacol 
1995;277:215-221. 
Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002;59:S3-14. 
Henry TR, Bakay RA, Votaw JR et al. Brain blood flow alterations induced by therapeutic vagus nerve stimulation 
in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia 1998;39:983-990. 
Kokaia M, Bengzon J, Kalen P, Lindvall O. Noradrenergic mechanisms in hippocampal kindling with rapidly 
recurring seizures. Brain Res 1989;491:398-402. 
Kokaia M, Cenci MA, Elmer E et al. Seizure development and noradrenaline release in kindling epilepsy after 
noradrenergic reinnervation of the subcortically deafferented hippocampus by superior cervical ganglion or 
fetal locus coeruleus grafts. Exp Neurol 1994;130:351-361. 
Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the seizureattenuating effects of 
vagus nerve stimulation. Epilepsia 1998;39:709-714. 
Krahl SE, Senanayake SS, Handforth A. Destruction of peripheral C-fibers does not alter subsequent vagus nerve 
stimulation-induced seizure suppression in rats. Epilepsia 2001;42:586-9. 
Labar D. Vagus nerve stimulation for 1 year in 269 patients on unchanged antiepileptic drugs. Seizure 
2004;13:392-398. 
Levitt P, Moore RY. Noradrenaline neuron innervation of the neocortex in the rat. Brain Res 1978;139:219-231. 
Liporace J, Hucko D, Morrow R et al. Vagal nerve stimulation: adjustments to reduce painful side effects. 
Neurology 2001;57:885-886. 
McIntyre DC, Edson N. Facilitation of amygdala kindling after norepinephrine depletion with 6- 
hydroxydopamine in rats. Exp Neurol 1981;74:748-757. 
McIntyre DC, Edson N, Chao G, Knowles V. Differential effect of acute vs chronic desmethylimipramine on the 
rate of amygdala kindling in rats. Exp Neurol 1982;78:158-166. 
Meurs A, Clinckers R, Ebinger G, Michotte Y, Smolders I. Seizure activity and changes in hippocampal 
extracellular glutamate, GABA, dopamine and serotonin. Epilepsy Res 2008;78:50-59. 
Millan MH, Chapman AG, Meldrum BS. Extracellular amino acid levels in hippocampus during pilocarpine-
induced seizures. Epilepsy Res 1993;14:139-148. 
Mishra PK, Kahle EH, Bettendorf AF, Dailey JW, Jobe PC. Anticonvulsant effects of intracerebroventricularly 
administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure 
genetically epilepsy-prone rats (GEPR-9s). Life Sci 1993;52:1435-1441. 
Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant 
stimulation of the vagus nerve. Epilepsy Res 1995;22:53-62. 
Nieuwenhuis S, Aston-Jones G, Cohen JD. Decision making, the P3, and the locus coeruleusnorepinephrine 
system. Psychol Bull 2005;131:510-532. 
Olejniczak PW, Fisch BJ, Carey M, Butterbaugh G, Happel L, Tardo C. The effect of vagus nerve stimulation on 
epileptiform activity recorded from hippocampal depth electrodes. Epilepsia 2001;42:423-429. 
Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 
2007;113:523-536. 
Rhoton AL, Jr., O'Leary JL, Ferguson JP. The trigeminal, facial, vagal, and glossopharyngeal nerves in the 
monkey. Afferent connections. Arch Neurol 1966;14:530-540. 
   
Chapter 5| VNS, noradrenaline and seizure suppression 95 
 
Roosevelt RW, Smith DC, Clough RW, Jensen RA, Browning RA. Increased extracellular concentrations of 
norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. Brain Res 
2006;1119:124-132. 
Schank JR, Liles LC, Weinshenker D. Reduced anticonvulsant efficacy of valproic acid in dopamine beta-
hydroxylase knockout mice. Epilepsy Res 2005;65:23-31. 
Shaw GY, Sechtem P, Searl J, Dowdy ES. Predictors of laryngeal complications in patients implanted with the 
Cyberonics vagal nerve stimulator. Ann Otol Rhinol Laryngol 2006;115:260-267. 
Smolders I, Clinckers R, Meurs A et al. Direct enhancement of hippocampal dopamine or serotonin levels as a 
pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 
2008;54:1017-1028. 
Smolders I, Sarre S, Michotte Y, Ebinger G. The analysis of excitatory, inhibitory and other amino acids in rat 
brain microdialysates using microbore liquid chromatography. J Neurosci Methods 1995;57:47-53. 
Smolders I, Van BK, Ebinger G, Michotte Y. Hippocampal and cerebellar extracellular amino acids during 
pilocarpine-induced seizures in freely moving rats. Eur J Pharmacol 1997;319:21-29. 
Szot P, Weinshenker D, White SS et al. Norepinephrine-deficient mice have increased susceptibility to seizure-
inducing stimuli. J Neurosci 1999;19:10985-10992. 
Van Bockstaele EJ, Peoples J, Telegan P. Efferent projections of the nucleus of the solitary tract to peri-locus 
coeruleus dendrites in rat brain: evidence for a monosynaptic pathway. J Comp Neurol 1999;412:410-428. 
Vonck K, De H, V, Bosman T, Dedeurwaerdere S, Van LK, Boon P. Thalamic and limbic involvement in the 
mechanism of action of vagus nerve stimulation, a SPECT study. Seizure 2008;17:699-706. 
Vonck K, Thadani VY, Gilbert K et al. Vagus nerve stimulation for refractory epilepsy: A transatlantic experience. 
Journal of Clinical Neurophysiology 2004;21:283-289. 
Weinshenker D. The contribution of norepinephrine and orexigenic neuropeptides to the anticonvulsant effect of 
the ketogenic diet. Epilepsia 2008;49 Suppl 8:104-107. 
Weinshenker D, Szot P. The role of catecholamines in seizure susceptibility: new results using genetically 
engineered mice. Pharmacol Ther 2002;94:213-233. 
Yan QS, Dailey JW, Steenbergen JL, Jobe PC. Anticonvulsant effect of enhancement of noradrenergic 
transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study. Brain 
Res 1998;780:199-209. 
Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia 1992;33:1005-
12. 
Zalvan C, Sulica L, Wolf S, Cohen J, Gonzalez-Yanes O, Blitzer A. Laryngopharyngeal dysfunction from the 
implant vagal nerve stimulator. Laryngoscope 2003;113:221-225.  
  
 
  
 
 
 
 
 
Chapter 6  
Intensity-dependent modulatory effects of vagus nerve stimulation 
on cortical excitability  
 
  
 Chapter 6| Effects of VNS on cortical excitability 99 
 
 
 
Mollet L.a, Grimonprez A.a, Raedt R.a, Delbeke J.b, El Tahry R.a, De Herdt V.a, Meurs A.a, Wadman W.c, 
Boon P.a, Vonck K.a 
 
a
 Laboratory for Clinical and Experimental Neurophysiology, Neurobiology and Neuropsychology (LCEN3), Department of 
Neurology, Institute for Neuroscience, Ghent University Hospital, Belgium 
b
 Institute of Neuroscience, Université catholique de Louvain, Medical School, Brussels, Belgium 
c
 Swammerdam Institute of Life Sciences, Department of Neurobiology, University of Amsterdam, Amsterdam, The 
Netherlands 
 
Acta Neurologica Scandinavica 2013;128(6):391-396. 
 
 
Abstract 
Objectives: Vagus nerve stimulation (VNS) is an effective treatment for refractory epilepsy. It remains 
unknown whether VNS efficacy is dependent on output current intensity. The present study 
investigated the effect of various VNS output current intensities on cortical excitability in the motor 
cortex stimulation rat model. The hypothesis was that output current intensities in the lower range 
are sufficient to significantly affect cortical excitability. 
Material and methods: VNS at 4 output current intensities (0 mA, 0.25 mA, 0.5 mA and 1 mA) was 
randomly administered in rats (n=15) on 4 consecutive days. Per output current intensity, the 
animals underwent 5 one-hour periods: (1) baseline, (2) VNS1, (3) wash-out1, (4) VNS2 and (5) wash-
out2. After each one-hour period, the motor seizure threshold (MST) was measured and compared 
to baseline (i.e. ∆MSTbaseline, ∆MSTVNS1, ∆MSTwash-out1, ∆MSTVNS2 and ∆MSTwash-out2). Finally, the mean 
∆MSTbaseline, mean ∆MSTwash-out1, mean ∆MSTwash-out2 and mean ∆MSTVNS per VNS output current 
intensity were calculated.  
Results: No differences were found between the mean ∆MSTbaseline, mean ∆MSTwash-out1 and mean 
∆MSTwash-out2 within each VNS output current intensity. The mean ∆MSTVNS at 0 mA, 0.25 mA, 0.5 mA 
and 1 mA was 15.3 ± 14.6 µA, 101.8 ± 23.5 µA, 108.1 ± 24.4 µA and 85.7 ± 18.1 µA respectively. The 
mean ∆MSTVNS at 0.25 mA, 0.5 mA and 1 mA were significantly larger compared to the mean ∆MSTVNS 
at 0 mA (p=0.002 for 0.25 mA; p=0.001 for 0.5 mA; p=0.011 for 1 mA). 
Conclusions: This study confirms efficacy of VNS in the motor cortex stimulation rat model and 
indicates that, of the output current intensities tested, 0.25 mA is sufficient to decrease cortical 
excitability and higher output current intensities may not be required.  
Intensity-dependent modulatory effects of vagus nerve stimulation on 
cortical excitability 
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Introduction 
Vagus nerve stimulation (VNS) is an efficacious and widely applied neurostimulation modality for 
patients with medically or surgically refractory epilepsy (Boon et al. 2001; Ben-Menachem 2002). The 
left vagus nerve is stimulated in the neck area by means of a helical stimulation electrode connected 
to a subclavicular implanted pulse generator. The clinically available stimulation parameters include 
output current intensity (range: 0.25-3.5 mA), frequency (range: 20-30 Hz), pulse width (range: 250-
500 µsec) and duty cycle (range ON time (sec)/OFF time (min): 30/5, 30/3, 30/1.8, 30/1.1, 21/0.8, 
14/0.5) which can all be modified in order to reach maximum therapeutic efficacy (Heck et al. 2002). 
It has been demonstrated that VNS has both an acute effect on seizures, i.e. it is able to interrupt 
ongoing seizure activity, as well as having a more chronic seizure preventative effect following long-
term treatment (Ben-Menachem 2002; Henry 2002; Elliott et al. 2011).  
The antiepileptic mechanism of VNS remains incompletely understood. Previous experimental 
research showed that VNS exerts its antiepileptic effect by stimulating the afferent fibers of the 
vagus nerve (Woodbury and Woodbury 1990, 1991; Krahl et al. 2001). The afferent fibers originate 
from the nodose and jugular ganglion and primarily project to the nucleus of the solitary tract (NTS). 
The NTS in turn has widespread projections to numerous areas in the brain including the locus 
coeruleus (LC), which is the major brain source of noradrenaline, and important areas for 
epileptogenesis such as the amygdala and the thalamus. Furthermore the NTS, LC and thalamus have 
many diffuse cortical connections. Different neurochemical and neuromodulatory changes affecting 
cortical excitability seem to play a role in the mode of action of the acute and chronic effects of VNS 
(Naritoku et al. 1992; Henry et al. 1999; De Herdt et al. 2010; Raedt et al. 2011). 
One clinical drawback of current VNS therapy is the variable therapeutic outcome (Uthman et al. 
1993; Ben-Menachem et al. 1994; Handforth et al. 1998; Koo et al. 2001). Currently, VNS is succesfull 
in only one third of the treated patients (Boon et al. 2007). It is routine clinical practice to uptitrate 
output current intensity in order to reach seizure control over several weeks/months. So far, analysis 
of large patient series have not demonstrated a correlation between output current intensities and 
seizure control. Several experimental studies in animals and humans using functional imaging and c-
fos however do suggest that lower output current intensities are sufficient to induce significant 
intracerebral effects (Van Laere et al. 2000; Vonck et al. 2008; Cunningham et al. 2008). 
A study by De Herdt et al. showed efficacy of acute VNS in the motor cortex stimulation rat model 
using an output current intensity of 0.75 mA (De Herdt et al. 2010). In this rat model, the threshold 
for evoking focal, motor seizures is determined by electrical stimulation of the motor cortex in 
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unanaesthetized rats (Voskuyl et al. 1989; Liebetanz et al. 2006). VNS significantly increased the 
threshold for evoking focal, motor seizures.  
The present study investigated the effect of various VNS output current intensities on cortical 
excitability in the motor cortex stimulation rat model. The hypothesis was that output current 
intensities in the lower range are sufficient to significantly affect cortical excitability. 
Material and methods 
Animals 
Fifteen male Wistar rats (Harlan, The Netherlands) weighing 250-275 g were used. Animals were 
treated according to the guidelines approved by the European Ethics Committee (decree 
86/609/EEC). The study protocol was approved by the Animal Experimental Ethical Committee of 
Ghent University Hospital (ECP 08/47). All animals were kept under environmentally controlled 
conditions (12h light/dark cycles, 20-23°C and 50% relative humidity) with food and water intake ad 
libitum. 
Surgery 
Rats were anesthetized with isoflurane (induction: 5%; maintenance: 1-2%). An incision was made 
over the left anterior cervical region. The left cervical vagus nerve was carefully dissected from the 
aortic sheet and a custom-made silicone spiral cuff-electrode with two platinum contacts (3 mm² 
area each, with 1 mm space between them) was implanted around the vagus nerve with the anode 
placed caudally and the cathode placed rostrally. The cuff-electrode leads were tunneled under the 
skin over the back of the neck towards an incision made over the skull. Animals were then placed in a 
stereotactic frame (Bilaney Consultants, Düsseldorf, Germany), the skull was exposed and eight holes 
were drilled to insert electrodes and anchor screws. For stimulation of the motor cortex, two 
epidural stainless steel screw electrodes were stereotactically positioned over the motor area of the 
left and right frontal cortex (coordinates relative to bregma: dorsoventral -1.0 mm; mediolateral ±3.0 
mm). Four epidural stainless steel screw electrodes were implanted bilaterally on the parietal cortex; 
three of them were used for electroencephalogram (EEG) recording, the fourth was used as a 
reference/ground electrode. Two anchor screws were implanted bilaterally on the parietal cortex. 
The leads of the epidural electrodes and the leads of the cuff-electrode were assembled in a head 
cap on the skull of the rat using acrylic cement. To minimize post-operative pain, buprenorphine 
(Temgesic®, 0.03 mg/kg) was subcutaneously administered and a 2% xylocaine gel was applied to the 
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incision wounds. Animals were allowed to recover from surgery under an infrared lamp. Correct 
positioning of the cuff-electrode around the left vagus nerve was verified post-mortem.  
EEG monitoring, cortical stimulation and VNS 
One week after surgery, rats were placed in neuromonitoring cages. Rats were connected via an 
electrical swivel (Plastics One, Roanoke, USA) to (i) a custom-made digital EEG monitoring system for 
EEG recording, which was used to confirm the focal character of the induced seizures and (ii) two 
external constant-current stimulators (DS4, Digitimer Ltd., Hertfordshire, England) for cortical 
stimulation and for delivering VNS. Rats were allowed to move freely in their cages. 
- Cortical stimulation 
Cortical stimulation was performed using a ramp-shaped pulse train with biphasic, rectangular pulses 
(1000 µs, 50 Hz) with increasing amplitude (0-10 mA). The maximum duration of the cortical 
stimulation train was 150 s (i.e. 1.3 µA increments every pulse). The cortical stimulation train was 
interrupted when the first symptoms of a focal seizure were detected on visual inspection. The 
clinical expression of a focal seizure was typically a forelimb clonus. The motor seizure threshold 
(MST) was then defined as the current intensity corresponding to the first clinical symptoms of a 
focal seizure.  
- VNS 
The effect of one hour of VNS (30 Hz, 250 µsec, 30 sec ON/1.8 min OFF) at 4 different output current 
intensities (0.0 mA, 0.25 mA, 0.5 mA and 1.0 mA) on the MST was evaluated. These VNS parameters 
are typically used in clinical practice. 
Experimental design 
The experimental design is represented in figure 1 and detailed below. VNS was administered in each 
rat on 4 consecutive days. On each day, VNS was given at one of the 4 output current intensities (see 
higher) in a random order. Per VNS output current intensity, the animals underwent 5 one-hour 
periods: (1) baseline, (2) VNS 1, (3) wash-out 1, (4) VNS 2 and (5) wash-out 2 (on any given day, VNS1 
and VNS2 represent the same VNS intensity). Immediately after each one-hour period ended, the 
MST was measured (i.e MSTbaseline, MSTVNS1, MSTwash-out1, MSTVNS2 and MSTwash-out2). Prior to baseline, 
the impedance between the two vagus nerve electrode contacts was measured. 
- Part 1: Outlasting effect of VNS 
 Chapter 6| Effects of VNS on cortical excitability 103 
 
Per rat and per VNS output current intensity, the ∆MSTbaseline (i.e. MSTbaseline minus MSTbaseline), 
∆MSTwash-out1 (i.e. MSTwash-out1 minus MSTbaseline) and ∆MSTwash-out2 (i.e. MSTwash-out2 minus MSTbaseline) 
were calculated. Finally, the mean ∆MSTbaseline, mean ∆MSTwash-out1 and mean ∆MSTwash-out2 per VNS 
output current intensity were calculated. 
- Part 2: Effect of various VNS output current intensities on the MST 
Per rat and per VNS output current intensity, the ∆MSTVNS1 (i.e. MSTVNS1 minus MSTbaseline) and 
∆MSTVNS2 (i.e. MSTVNS2 minus MSTbaseline) were calculated. Finally, the mean ∆MSTVNS per VNS output 
current intensity was calculated as the mean of all ∆MSTVNS1 and ∆MSTVNS2 values. 
 
Statistical analysis 
A generalized linear mixed model and post-hoc Bonferroni for multiple comparisons was used to 1) 
compare the mean ∆MSTwash-out1 and the mean ∆MSTwash-out2 with the mean ∆MSTbaseline within each 
VNS output current intensity and 2) to compare the mean ∆MSTVNS at 0.25 mA, 0.5 mA and 1.0 mA 
with the mean ∆MSTVNS at 0.0 mA. Statistical analyses were performed using SPSS 20 for Windows. 
Data are expressed as mean ± standard error of the mean. The significance level for demonstrating 
differences was set at α=0.05.  
Results 
The impedance between the vagus nerve electrode contacts showed normal values in all rats during 
all experiments (1-4 kOhm). Within each VNS output current intensity, no differences were found 
between the mean ∆MSTbaseline, the mean ∆MSTwash-out1 and the mean ∆MSTwash-out2, 
showing that VNS-induced changes in MST were transient and returned to baseline in the inter-
stimulus periods. 
Figure 1| Schematic representation of the experimental design. Vagus nerve stimulation (VNS) at four output current 
intensities was administered randomly in each rat on four consecutive days. Per output current intensity, ﬁve-one-hour 
periods were conducted and the motor seizure threshold (MST) was determined after each period. ΔMST values were 
obtained by comparing the MST values with the baseline MST value. 
104 Chaper 6| Effects of VNS on cortical excitability 
 
The mean ∆MSTVNS as a function of VNS output current intensity is plotted in figure 2. The mean 
∆MSTVNS at 0.0 mA, 0.25 mA, 0.5 mA and 1.0 mA was 15.3 ± 14.6 µA, 101.8 ± 23.5 µA, 108.1 ± 24.4 µA 
and 85.7 ± 18.1 µA respectively. The mean ∆MSTVNS at 0.25 mA, 0.5 mA and 1.0 mA were significantly 
larger compared to the mean ∆MSTVNS at 0.0 mA (p = 0.002 for 0.25 mA; p = 0.001 for 0.5 mA and p = 
0.011 for 1.0 mA). 
 
 
 
 
 
 
 
 
 
No electro-encephalographic, epileptiform discharges were observed in the parietal cortical areas 
during any epileptic seizure, indicating that the elicited epileptiform activity was restricted to the 
motor cortex. Furthermore, no afterdischarges were observed on the EEG after cessation of cortical 
stimulation. 
Discussion 
The main findings of our study in the motor cortex stimulation rat model are that VNS at 0.25 mA, 0.5 
mA and 1.0 mA significantly increases the threshold for evoking focal, motor seizures compared to 
stimulation at 0.0 mA and 2) effects of one hour VNS are no longer present one hour later.  
A previous study by our group showed that acute VNS at 0.75 mA in the motor cortex stimulation rat 
model is effective in decreasing cortical excitability (De Herdt et al. 2010). The findings of De Herdt et 
al. and our findings are in agreement with the reported direct and indirect acute effects of VNS on 
cortical excitability in preclinical and clinical experiments (Woodbury and Woodbury 1991; Naritoku 
et al. 1992; Santiago-Rodriguez et al. 2006).  
Figure 2| Effect of various vagus nerve stimulation (VNS) output current intensities on the motor seizure 
threshold (MST). The mean ΔMSTVNS (SEM) is plotted as a function of the VNS output current intensity. 
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In our study, significant effects of acute VNS on cortical excitability in rats were already observed at 
0.25 mA. Also in other types of preclinical and clinical research, significant effects of low-intensity, 
acute VNS were found. Acute VNS at 0.25 mA in conscious rats increased staining for c-fos, an 
indirect marker of neuronal activity, in the NTS and many regions that receive its projections 
(Cunningham et al. 2008). In a functional neuroimaging study by our group, acute VNS, using an 
output current intensity of 0.25 mA, induced significant cerebral blood flow changes in the human 
brain, particularly in the thalamus and the limbic system (Van Laere et al. 2000). These findings were 
confirmed in a human imaging study by Vonck et al. (Vonck et al. 2008). 
Our observation, together with the observation of De Herdt et al. (De Herdt et al. 2010), that VNS at 
0.25 mA, 0.5 mA, 0.75 mA and 1.0 mA in rats significantly increased the MST supports the theory that 
vagal afferent fibers with low-to-moderate activation thresholds (i.e. A- and B-fibers) may be 
responsible for the antiepileptic effect of VNS. The vagus nerve contains three types of fibers (A-, B- 
and C-fibers), distinguished by their diameter and conduction velocity. In rats, recruited at the lowest 
threshold (0.02-0.2 mA) are the large, myelinated A-fibers. At thresholds of 0.04-0.6 mA, smaller, 
myelinated B-fibers are recruited. C-fibers are small, unmyelinated fibers with the highest stimulation 
threshold of above 2 mA (Groves et al. 2005; Bunch et al. 2007). Initially, it was thought that the 
antiepileptic effect of VNS was directly related to the extent of C-fiber activation (Woodbury and 
Woodbury 1990). This theory was discarded after Krahl et al. demonstrated seizure suppression in 
rats even following selective destruction of C-fibers using capsaicin (Krahl et al. 2001). Furthermore, 
the group of Bunch concluded that therapeutically effective stimulation levels are below the 
threshold for C-fiber activation (Bunch et al. 2007). In an electrophysiological study by Evans et al., a 
C-fiber response was identified in 4 out of 8 patients using therapeutic VNS parameters (Evans et al. 
2004). However, because the C-fiber response (i) was apparent in 2 of the 4 patients only with 2 or 3 
mA stimulation (which is at the upper limit of intensities used clinically) and (ii) was not measured 
consistently, the authors concluded that C-fiber activation is probably not necessary for the 
antiepileptic effect of VNS.  
Additional support that low-to-moderate output current intensities are sufficient to reduce seizure 
activity comes from a study of Woodbury and Woodbury, in which VNS at 0.2-0.5 mA already 
reduced chemically-induced seizures in rats (Woodbury and Woodbury 1990). In vivo intracellular 
recordings in the temporal association cortex in rats showed that stimulus intensities that 
predominantly activate myelinated vagal fibers (≤ 0.20 mA) were already effective in reducing the 
excitability of pyramidal neurons (Zagon et al. 2000). Our low effective current values are even more 
impressive considering that the authors above used a 500 µsec pulse width, which, according to the 
classical strength-duration relationship and according to Takaya et al. (Takaya et al. 1996), is 
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expected to require about half the current to yield the same effect as a 250 µs pulse. Lower output 
current intensities also seemed to be effective in the antidepressant activity of VNS in rats (Manta et 
al. 2009), in the effect of VNS on recognition memory in rats and humans (Clark et al. 1998, 1999) 
and in the effect of VNS on human tolerance for pain (Ness et al. 2000).  
A modeling study on the neurophysiology of the human vagus nerve suggested an output current 
level between 0.75 and 1.75 mA to reach optimal seizure control (Helmers et al. 2012). A direct 
comparison with the results of our study is not possible due to a large number of factors including: 1) 
experimental rats versus humans; 2) much smaller diameter of rat vagus nerve; 3) different 
electrodes (cuff versus helicoïdal); 4) the model does not take surgical neurotrauma into account; 5) 
structural irregularities such as the presence of different nerve vessels modify thresholds but are not 
modeled; 6) tissue conductivities and geometry have a significant influence but are only rough 
approximations in a model. Both the study of Helmers et al. and our study however give insight in 
appropriate ways to optimize the therapeutic output current intensity and save battery-life. Our 
study in particular suggests that output current intensity quickly reaches a saturation level in 
therapeutic effectiveness and that higher output current intensities are not required to reach 
significant effects on cortical excitability. This idea may be extrapolated to human clinical practice in 
future clinical trial design. Due to the lack of prospective clinical trials comparing the effects of lower 
and higher output current intensities on seizure control, it is, even with the knowledge of our study, 
too early to defend convincingly the benefit of lower stimulation currents, although it would save 
battery life and decrease adverse events. However, it is worthwhile to extrapolate the implications of 
our findings to human VNS therapy. Combination of VNS and recording of vagal nerve compound 
action potentials could help to decide at what level this change in strategy should be applied in 
individual patients (El Tahry et al. 2010).  
Taken together, this study confirms efficacy of VNS in the motor cortex stimulation rat model, and 
indicates that, of the VNS output current intensities tested, 0.25 mA is sufficient to decrease cortical 
excitability and higher output current intensities may not be required. Further research is needed to 
determine if even lower output current intensities are sufficient. Preliminary results in our rats, using 
vagal compound action potential recordings with single VNS pulses and a short pulse width, indicate 
that fiber recruitment may reach a saturation level at output current intensities lower than 0.25 mA. 
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Abstract 
Rationale: Vagus nerve stimulation (VNS) is an adjunctive treatment for patients with refractory 
epilepsy. In more than 30% of the patients VNS has no therapeutic effect. The goal of this study was 
to find an objective parameter that can be used as an indicator of effective stimulation of the vagus 
nerve. 
Methods: The electrophysiological response to VNS was recorded from the vagus nerve, recurrent 
laryngeal nerve and larynx muscles. Nerve lesions and muscle relaxing agent were used to find the 
source of the electrophysiological response. A cuff-electrode for chronic stimulation and recording 
was implanted for chronic recording of the VNS-induced electrophysiological response after 
implantation. Dose–response curves were determined daily during a follow-up period of 2 months. 
Results: VNS induced an electrophysiological response around 3 ms after start of the stimulation. This 
response was identified as a larynx compound action potential (LCMAP) LCMAP could be recorded 
immediately after surgery in 11/21 rats, while in the other 10/21 rats, a recovery period with an 
average of 25 days was required. Once the LCAMP could be recorded, the latency and overall 
characteristics of the doses response curves of the LCMAP remained stable during the entire follow-
up period. 
Conclusions: In this study, we provide an objective electrophysiological parameter for vagus nerve 
activation. LCAMP may indicate recovery of the vagus nerve after implantation, which may help to 
determine when uptitration of VNS therapy can be initiated. LCAMP could be of value in future 
experiments for objectification of VNS in animal models for epilepsy. 
Repeated assessment of larynx compound muscle action potentials using a 
self-sizing cuff electrode around the vagus nerve in experimental rats 
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Introduction 
Epilepsy is a neurological disorder characterized by recurrent aberrant electrical activity in the central 
nervous system that typically manifests itself as seizures. It is estimated that 1-2% of the population 
is affected worldwide. About 30% of the patients with epilepsy do not respond to antiepileptic drugs 
and are considered medically refractory (Hauser et al. 1996; Fisher et al. 2005). For these patients, 
alternative treatment modalities such as epilepsy surgery or neurostimulation, such as deep brain 
stimulation or vagus nerve stimulation, may be useful. 
The vagus nerve is a mixed cranial nerve that consists of 80% afferent fibers innervating the heart, 
aorta, lungs and gastro intestinal tract and 20% efferent fibers that provide parasympathetic 
innervations of these structures and innervate the voluntary striated muscles of the larynx and 
pharynx through the recurrent laryngeal nerve, which is similar in rats (Dahlqvist et al. 1982; Paxinos 
2004) and humans (Berthoud and Neuhuber 2000; Jotz et al. 2011). Moreover, the proportion of 
myelinated axons in the cervical left vagus nerve of rats is comparable to humans (Hofmann and 
Schitzlein 1961; Soltanpour and Santer 1996). At last, the left superior laryngeal nerve splits from the 
vagus nerve identically in rats and humans, as it runs back superiorly behind the aortic arch in a 
groove between oesophagus and trachea to finally enter into the larynx (Berthoud and Neuhuber 
2000; Paxinos 2004). 
Electrical stimulation of the left vagus nerve is used as an adjunctive treatment for patients with 
refractory seizures (Holder et al. 1992; BenMenachem et al. 1994; Handforth et al. 1998a,b; 
DeGiorgio et al. 2000; Uthman et al. 2003). The mechanism of action of vagus nerve stimulation 
(VNS) remains incompletely understood. There is little or no information available about the 
electrophysiology of the vagus nerve, although activation of the nerve is essential to its antiepileptic 
effect (Holder et al. 1992; BenMenachem et al. 1994; Handforth et al. 1998a,b). Many questions in 
VNS therapy remain unresolved, for example why some patients experience beneficial effects and 
others do not respond to the treatment. In current clinical epilepsy practice, no investigation is 
available to assess whether the vagus nerve is successfully activated by VNS or not. Defining a 
parameter reflecting stimulation-induced activation of the vagus nerve activation might provide a 
better understanding of the electrophysiological properties of the nerve. This in turn, could lead to 
further optimization of VNS treatment. 
The aim of this study was to identify a marker reflecting effective stimulation of the vagus nerve. In 
the first part of the study an electrophysiological response to VNS was measured using thin-point 
recording electrodes placed near the stimulation cuff electrode. By inducing lesions at various levels 
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along the vagus and recurrent laryngeal nerves, performing simultaneous EMG recording and 
applying a muscle paralyzing agent the electrophysiological response was identified to be a far field 
potential of a VNS-induced larynx compound muscle action potential (LCAMP). During the second 
part of this study a new self-sizing cuff electrode for combined stimulation and recording was 
designed and used to record VNS-induced LCAMP on a daily basis and for several weeks after 
implantation of the stimulation electrode. In humans, intra-operative VNS-induced LCAMP was 
described (Ardesch et al. 2010), but no studies, animal nor human, report chronic LCAMP recordings. 
Materials and methods 
Design of the cuff-electrode 
The self-sizing spiral cuff electrode is composed of two 80 μm thick silicone rubber sheets (Statice 
Santé, France) glued together with an adhesive which polymerizes at room temperature (Parts A and 
B MED 4-4210, Nusil). The internal sheet is stretched during curling (stretch factor of 0.5) in order to 
obtain a self-curling spiral cuff. The cuff has an internal diameter of 1 mm and a total length of 9 mm. 
For the acute experiments two pieces of platinum (Alfa Aesar, 99.9% metal basis, 0.25 mm thick) are 
inserted between the silicone sheets to form the stimulation contacts (Fig. 1b). The inter-electrode 
distance between stimulation of the anode and cathode (each 3 mm × 1 mm) was 1 mm. Windows 
of 500 μm diameter are cut out in the internal silicone sheet in order to give the platinum contacts 
to the nerve. 
For the chronic experiments a cuff electrode was manufactured with an extra contact for recording 
(Fig. 1a and c). Therefore a third piece of platinum (1 mm × 1 mm) was inserted between the 
silicone sheet at 2 mm from the cathode, near the cuff edge directed towards the head. 
Teflon coated stainless steel wires (FWM 1 × 7 × 0.02/316LVM/EFTE, Fort Wayne metals) of 20 cm 
were welded to each platinum contact before their insertion between the electrode silicone sheets. 
Connector pins were soldered at the other extremity of the leads, allowing connection to an external 
stimulator or a recording device. 
Animals 
Adult male Wistar rats (Harlan, The Netherlands), were treated according to the guidelines approved 
by the European Ethics Committee (decree 86/609/EEC). The study protocol was approved by the 
Animal Experimental Ethical Committee of Ghent University hospital (ECP 08/37). All animals were 
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kept under environmentally controlled conditions (12 h light/dark cycles, 20–23 °C and 50% relative 
humidity) with food and water ad libitum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1| Schematic representation of a self-sizing cuff-electrode for combined stimulation and recording 
(A,C) and for stimulation only (B). 
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Surgery 
- Acute experiments 
Wistar rats (250–350 g) (n = 4) were implanted with a spiral cuff stimulation electrode around the left 
vagus nerve. Rats were anesthetized with gas isoflurane anesthesia (5% isoflurane for induction, 2% 
isoflurane for maintenance). An incision was made over the left anterior cervical region. The left 
vagus nerve was carefully dissected from the aortic sheet and the cuff electrode was wound around 
the nerve with the anode placed caudally. To record the electrophysiological response to VNS thin-
point, stainless steel electrodes (125 µm diameter) were placed on different anatomical structures, 
including the vagus nerve, as well as the recurrent laryngeal nerve and the muscles surrounding the 
larynx. An epidural electrode, placed over posterior occipital cortex, was used as reference/ground 
electrode. In order to induce lesions along the nerves a nylon wire was strapped around the nerves. 
Vecuronium (Norcuron, 1 ml of 2 mg/ml solution), a muscle relaxing agent, was applied to paralyze 
the larynx muscles. At the end of each acute experiment, animals were sacrificed with an overdose of 
pentobarbital (180 mg/kg i.p). 
- Chronic experiments 
Wistar rats (250–350 g) (n = 21) were implanted with a spiral cuff electrode for stimulation and 
recording of the left vagus nerve. The rats were anesthetized with a ketamine/xylazine (respectively, 
80 mg/kg and 7.5 mg/kg, i.p.) mixture. For chronic use, the electrode leads were tunnelled to an 
incision made in the skin above the skull. The connector pins were fixed to a skull head stage of 
acrylic cement. Four epidural stainless steel anchor screws were screwed bilaterally into the skull 
above parietal and occipital cortex. The posterior right screw, placed over occipital cortex, served as 
ground/reference for chronic electrophysiological recording. 
Recording of the larynx compound action muscle potential 
The vagus nerve was stimulated with biphasic square wave pulses of 100 µs duration in the acute 
experiments in order to keep stimulation artifact as low as possible and allow recording of possible 
early physiological signals in response to stimulation. For chronic experiments 500 µs block-pulses 
were used because this pulse width is mostly used in chronic studies on efficacy of VNS in humans 
and animals. Stimuli were delivered by a constant current stimulator. Dose–response curves were 
determined using a stimulus intensity ranging between 40 µA and 800 µA. Signals were recorded 
from stainless steel wire point electrodes placed on the vagus nerve, recurrent laryngeal nerve and 
larynx muscle or from the monopolar contact inside the cuff electrode. Signals were amplified 500 
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times before high pass filtering at 0.15 Hz in order to remove DC components. Thereafter, the data 
were digitized using a National Instruments acquisition board (NI DAQ PAD 6259) and finally stored 
on a personal computer. Recording and analysis of signals were done using Matlab (2007a, the 
MathWorks, Natick, Massachusetts  
Data analysis 
Both in the acute and chronic experiments, the latency of the LCAMP was determined. The latency is 
defined as the delay between the onset of the stimulus artifact and the occurrence of the major 
negative peak. In addition, acute and chronic dose response curves of the LCAMP were determined. 
In the chronic experiments LCAMP dose response curves were determined on a daily basis for five 
days per week during a follow-up period of 8 weeks after surgery. At each session, the rats were 
anesthetized using isoflurane (induction 5%, maintenance 2%) in order to reduce movement 
artefacts. The time span, during which vagus nerve was stimulated but no response could be 
recorded, was considered to represent a recovery period after surgery. 
A Boltzmann function: (M = Mmax/1 + e(I50−x)/k) was fitted to the measured dose–response 
curves. Mmax is defined as the maximal muscle potential amplitude. I50 is the intensity needed to 
obtain a response with half the maximal amplitude and slope factor k describes the recruitment 
homogeneity of the vagus nerve fibers (Fig. 2). For each stimulus intensity, 20 sweeps were averaged 
to improve the signal to noise ratio. Besides the latency, I50 and k, the impedance of the stimulation 
contacts was recorded over time. The contact impedance of the stimulation electrodes was 
expressed in kOhms and defined as the voltage to current ratio measured at the end of a stimulation 
pulse of 100 µA amplitude and 500 µs duration. At the end of the 8 week follow-up period animals 
were sacrificed with an overdose of pentobarbital (180 mg/kg i.p). 
Statistical analysis 
From the chronic LCAMP recordings, parameters of the dose–response curves (latency, I50 and k) and 
electrode impedances were averaged for each rat and for each of the eight follow-up weeks. 
Sensitivity analysis showed that there was no bias effect of pooling the results of the animals with a 
recovery period to the results of the rats in which the LCAMP could be recorded from the start of the 
chronic recordings. Therefore, the means and standard errors of the mean (SEM), presented in 
figures, were calculated from all rats in which an LCAMP could be recorded during a specific week. 
Statistical analysis was performed using mixed model linear regression analysis, including random 
intercepts in order to account for dependent observations. A Bonferonni correction was used to 
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correct for type I error in multiple comparisons. Calculated residuals were normally distributed, 
which supports the validity of the used statistical model. 
 
 
 
 
 
 
 
 
 
 
Results 
Acute experiments: identification of the larynx compound muscle action 
potential 
VNS reproducibly induced a large negative peak at 2.6 ms ± 0.2 ms after onset of the stimulation 
artifact (N1) (Fig. 3a). Based on its long latency and large amplitude we hypothesized that this 
response is a far field potential corresponding to larynx muscle activation induced by co-activating of 
the recurrent laryngeal nerve with VNS. The following observations support this hypothesis: (1) A 
lesion of the vagus nerve distal to the stimulation electrode but proximal to the aortic arch, abolished 
the recorded signals (Fig. 3b); (2) A proximal lesion of the vagus nerve did not abolish the signal (Fig. 
3a); (3) An electromyography (EMG) recording of the laryngeal muscles shows a very large response 
at latency of 2.6 ms (Fig. 3c), and (4) Finally, all the signals recorded at the level of the vagus nerve, 
Figure 2| A representative example of a dose response curve of the larynx compound action muscle 
potential (LCAMP) in response to VNS. A Boltzmann function (M = Mmax/1 + e(I50−x)/k) was fitted to the 
dose response curve. Imax is defined as the intensity needed to achieve a response with maximal 
amplitude. I50 is the intensity needed to obtain a response with half of the maximal amplitude and k is the 
slope factor representing recruitment homogeneity of the vagus nerve fibers. 
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recurrent laryngeal nerve and larynx muscle disappeared immediately when applying the muscle 
blocking agent Vecuronium (1 ml of Norcuron, 4 mg/2 ml ampoule) to the larynx muscles. 
 
 
Figure 3| (A) VNS-induced neurophysiological response measured at different locations on the vagus nerve (Ch 1–3), 
characterized by a major negative peak (N1). The response remains preserved after inducing a vagus nerve lesion rostral 
to the stimulation electrode. (B) Lesion of the vagus nerve distal to the stimulation electrode but proximal to the aortic 
arch, abolished all signals recorded at the level the vagus nerve (Ch 1–3). (C) Signals recorded from larynx muscles (Ch 
1), the vagus nerve (Ch 2), the recurrent laryngeal nerve (Ch 3) showed no difference in latency. Moreover, the larynx 
EMG channel (Ch 1) exhibited much larger amplitude than signals recorded from other channels. All signals were 
abolished when applying Vecuronium into the larynx muscles. 
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Acute and chronic recordings of the of the larynx compound muscle action 
potential 
In the acute experiments, latency of N1 of the LCAMP recorded at the level of the vagus nerve, was 
2.6 ms ± 0.2 ms after onset of the stimulation artifact. The I50 and slope factor of acute doses 
response curves were respectively, 125.8 ± 35.7 µA and 28 ± 30 µA. In the chronic experiments, 21 
rats were implanted with a cuff electrode for combined stimulation and recording of the vagus nerve. 
LCMAP could be recorded immediately after surgery in 11/21 rats, while in the other 10/21 rats a 
recovery period ranging between 2 and 7 weeks (mean 25 days) was needed (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
The latency of N1 was 3.2 ms ± 0.1 ms and did not change significantly over time during the 8 weeks 
of follow up (p = 0.88) (Fig. 4a). The I50 calculated from the doses response curves did not 
significantly change over time and varied between 56 µA ± 7 µA and 74 µA ± 18 µA (p = 0.77) 
(p = 0.77) (Fig. 4b). The slope factor of the doses response curves varied between 4.2 µA ± 0.7 µA 
and 6.7 µA ± 2.0 µA, indicating that implanted electrodes were able to activate vagus nerve fibers in 
a stable manner over the entire follow-up period (p = 0.82) (Fig. 4c).  
The impedance of the stimulation contacts significantly increased over time (p < 0.001), values of 
week 4 to week 8 being significantly higher in comparison to the first week (post-hoc analysis with 
bonferonni correction) (Fig. 5). 
 
 
 
Time after surgery (weeks) Amount of rats with recordable LCAMP 
0 11 
1 11 
2 13 
3 13 
4 13 
5 16 
6 20 
7 21 
Table 1| Amount of rats per week after surgery in which an LCAMP could be recorded. In 11/21 rats, 
LCAMP could be measured immediately after implantation. In the remaining rats (10/21), a post-
surgical recovery period was required before LCAMP could be recorded adequately. 
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Figure 4| (A) The latency of N1 was 3.2 ms ± 0.1 ms and did not change significantly over time during the 
8 weeks of follow up. (B) I50 and (C) slope factor (k) deduced from the dose response curves remained 
stable during 8 weeks of follow-up. Means and standard errors of the mean (SEM) presented in figures, 
were calculated from all rats in which an LCAMP could be recorded during a specific week. 
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Discussion 
The primary objective of this study was to identify an objective electrophysiological parameter to 
assess effective vagus nerve stimulation. In the first part of the study, the LCAMP was identified as a 
candidate marker for effective vagus nerve stimulation. In the second part of this study an 
implantable electrode system for chronic stimulation and recording of VNS-induced LCMAP in 
rodents was developed. In half of the rats implanted with this electrode system for chronic 
stimulation and recording a response to VNS could only be measured after delay of several weeks. 
From the moment the LCAMP could be measured up to eight weeks after electrode implantation 
input–output relationship between stimulus intensity and amplitude of the LCAMP remained stable 
over time although the impedance of the stimulation electrodes increased slightly during the eight 
weeks after implantation. 
Characteristics of the LCAMP 
By introducing lesions distal to the stimulation electrode and application of a muscle relaxing agent 
we showed that the measured electrophysiological response to VNS corresponds to muscle 
potentials of the larynx and not to any neural potential originating from the vagus nerve. Most likely 
the LCAMP is evoked by VNS-induced activation of the Aα efferent motor fibers of the vagus nerve. 
In rats but also in other mammals these vagal Aα fibers innervate the laryngeal muscles. The LCAMP 
was recordable in a reproducible manner during a follow-up period of two months, although a 
variable recovery period after surgery was found. The latency of the LCAMP, I50 and slope factor of 
dose response curves remained relatively stable during the follow-up period after electrode 
Figure 5| The impedance of the stimulation contacts increased over time. Values of week 4 to week 8 
were significantly higher in comparison to the first week. * represents a corrected p-value lower than 
0.05. 
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implantation. However, as our experiments count a small group of animals (N = 21), subtle changes 
over time cannot fully be excluded. Nevertheless, our results indicate that once the LCAMP could be 
recorded, the vagus nerve remained excitable, despite the development of a fibrous capsule around 
the electrode–nerve interface ( Grill and Mortimer 2000; Thil et al. 2006). 
The increased impedance values of the stimulation electrodes between 4 and 8 weeks after 
implantation, support the idea that a fibrous encapsulated electrode-nerve interface is formed. 
Importantly, values for the I50 and the slope factor of acutely dose response curves were larger than 
the same results obtained in chronic experiments, but a smaller pulse width was used. In addition, a 
shunting effect of physiological water that was added to the dissection pouch in order to moisturize 
the vagus nerve while performing surgery may also explain the obtained results. 
LCMAP as a marker for vagus nerve stimulation 
Laryngeal activation is the result of efferent stimulation, while VNS in epilepsy is focused on 
stimulating afferents in order to obtain beneficial effects in the brain (Woodbury and Woodbury 
1990, 1991; Krahl et al. 2001). The use of LMCAP as a marker for adequate vagus nerve stimulation 
thus remains an indirect surrogate parameter, as it does not necessarily reflect activation of the 
specific fiber population with antiseizure effect (Zagon and Kemeny 2000; Krahl et al. 2001). 
Nevertheless, Aα fibers, provide motor activation of striated muscles of the larynx and represent a 
relatively low threshold fiber population. Importantly, these fibers are the most sensitive to anoxia 
and injury due to surgical manipulation (Agnew and McCreery 1990; Woodbury and Woodbury 
1991). Consequently, alteration in Aα function may imply damage to other afferent vagus nerve 
fibers which are thought to provide anti seizure effect of VNS. On the other hand, a histological study 
by Evans and Murray (Evans and Murray 1954), in the rabbit vagus nerve showed that myelinated 
motor fibers of the vagus nerve seem to gather in the deep lateral part of the vagus nerve bundle, 
which implicates that damage to these fibers would not necessarily imply injury to the medial 
afferent myelinated fibers. Data about precise configuration of different fibers bundles in the cervical 
vagus nerve in humans is lacking, therefore possible hypothesises in this field remain purely 
speculative. 
VNS induced vocal cord EMG in humans 
A study performed in humans by Ardesh et al, in which intra-operative vocal cord EMG was recorded 
after VNS implantation showed a very similar VNS induced LCMAP. The shape was identical, but 
longer latencies and higher amplitudes were reported (Ardesch et al. 2010). Activation of the larynx 
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in humans was obtained by applying a VNS pulse of 0.5 mA and 130 µs, while in our experiments 
maximal muscle activation was already reached at approximately 65 µA and 100 µs. 
In humans, a temporary paresis of vocal cords after VNS surgery has been described (Zalvan et al. 
2003; Shaffer et al. 2005; Shaw et al. 2006) indicating that the surgical procedure and implantation of 
the electrode often causes a transient vagus nerve failure, hence requiring a recovery period before 
to become functional again. 
Clinical relevance of the VNS induced LCAMP 
In clinical practice, the idea that in some patients there is a delayed effect of VNS might in some 
cases be explained by a temporary failure of VNS-induced activation of the nerve due to nerve 
damage after electrode implantation. In our study, nearly half of the implanted rats required an 
average recovery period of 5 weeks (range 2–7) before VNS could efficiently induce a LCAMP. In 
clinical practice, ramping up of VNS output generally starts two weeks after surgery (Vonck et al. 
2004; De Herdt et al. 2006). Our results and the larynx studies cited above, suggest that an 
individualized approach might be more beneficial, although comparisons between humans and rats 
must be made with caution. Currently, there is no specific investigation indicating whether the vagus 
nerve recovered sufficiently to start up titration of VNS therapy. In this context, recording a VNS-
induced LCAMP by EMG of the larynx before and at different time points after surgery, could possibly 
serve as a new investigative tool in VNS therapy. More research on this topic is needed to confirm 
this idea. 
Future experiments which investigate the relationship between LCAMP occurrence and therapeutic 
response to VNS treatment could be interesting. The lack of therapeutic effect of VNS may not only 
be the result of a lack of VNS effects on the brain, but also simply be the consequence of inadequate 
local recovery of the vagus nerve. 
Conclusion 
Twenty-one rats were successfully implanted with a custom-made self-sizing stimulation/recording 
electrode around the left vagus nerve, allowing repeated recording of the LCMAP over time. Our 
method provides an objective indication of effective vagus nerve activation, which could be of great 
value in all VNS experiments in animal models for epilepsy. 
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Abstract 
The mechanism of action of vagus nerve stimulation (VNS) for pharmacoresistant epilepsy is 
unknown and the therapeutic outcome is highly variable. We investigated stimulation-induced vagus 
nerve electrophysiological responses in rats using various stimulation parameters. Conduction 
velocity, I50, rheobase and chronaxie were calculated. We identified an early and late component 
corresponding to an afferent compound action potential (CAP) and a remote laryngeal motor-evoked 
potential (LMEP), respectively. The conduction velocity (CAP: 26.2 ± 1.4 m/s; LMEP: 32.4 ± 2.4 m/s) 
and I50 (CAP: 2.4 ± 0.3 mA; LMEP: 1.8 ± 0.2 mA) were significantly different for both components, the 
rheobase (CAP: 140 ± 30 μA; LMEP: 110 ± 26 μA) and chronaxie (CAP: 66 ± 7 μs; LMEP: 73 ± 9 μs) 
were not. Using a pulse of 10 μs, the CAP saturated between 4–5 mA. Our method can be used to 
record VNS-induced electrophysiological responses in rats and provides an objective biomarker for 
electrical stimulation with various parameters in an experimental set-up. Our findings are potentially 
useful for clinical purposes in the sense that combination of VNS and recording of vagal nerve CAPs 
may help clinicians to determine the individual optimal intensity required to fully activate fast-
conducting afferent fibers. 
Keywords: Vagus nerve recording; nerve fiber type; laryngeal muscle potential; vagus nerve 
stimulation. 
Introduction 
Vagus nerve stimulation (VNS) is indicated in patients with medically refractory epilepsy who are 
unsuitable candidates for epilepsy surgery (Boon et al. 2009; Ben-Menachem 2002).  
Electrophysiological responses from vagus nerve stimulation in rats 
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A pulse generator is implanted subcutaneously in the left subclavicular area and delivers intermittent 
electrical stimuli via an electrode that is wound around the left vagus nerve at the cervical level 
(Shoeb et al. 2009). Different studies have established the clinical efficacy and safety of VNS both 
during short- and long-term follow-up in various types of epilepsy (Ben-Menachem 2002; Penry and 
Dean 1990; Wilder et al. 1991; Handforth et al. 1998; Vonck et al. 1999; DeGiorgio et al. 2001; 
Schachter 2002).  
The vagus nerve is a mixed cranial nerve consisting of 20% efferent (motor) and 80% afferent 
(sensory) fibers. The efferent fibers of the vagus nerve originate from the dorsal motor nucleus and 
nucleus ambiguus. A fraction of the efferent fibers of the vagus nerve provides parasympathetic 
innervation to the abdominal viscera, while another fraction contributes to the recurrent laryngeal 
nerve. The recurrent laryngeal nerve branches from the vagus nerve at the level of the aortic arch, 
ascends next to the trachea and carries low-threshold vagal motor neurons to the larynx, pharynx 
and vocal cords. The afferent fibers of the vagus nerve originate from the jugular and nodosal 
ganglion and convey visceral information, taste information and somatosensory information to the 
brain. The afferent fibers primarily project to the nucleus of the solitary tract (NTS), but the vagus 
nerve also sends ipsilateral projections to the dorsal motor nucleus, nucleus ambiguus and medullary 
reticular formation (Krahl and Clark 2012). The NTS in turn has widespread projections to numerous 
areas in the brain, including important areas for epileptogenesis such as the amygdala and the 
thalamus (Schachter and Saper 1998; Vonck et al. 2008; Fanselow 2012), structures involved in the 
pathophysiology of epilepsy such as the limbic system (Castle et al. 2005), and monoaminergic 
structures such as the serotonergic dorsal raphe nucleus and the noradrenergic locus coeruleus 
(Herbert and Saper 1992; Van Bockstaele 1999). Finally, the NTS has numerous diffuse cortical 
connections (Jean 1991). 
The antiepileptic mechanism of action of VNS remains incompletely understood. There is convincing 
evidence that VNS acts via activation of afferent vagal fibers (Krahl and Clark 2012; Zabara 1992; 
McLachlan 1993; Rijkers et al. 2010). These afferent fibers may indirectly activate the thalamus and 
thalamocortical projection pathways, thereby causing a desynchronization of the EEG (Aalbers et al. 
2011). In addition, the monoaminergic system may account, at least in part, for the antiepileptic 
effect of VNS (Krahl et al. 1998; Groves et al. 2005; Dorr and Debonnel 2006; Raedt et al. 2011). In 
our group, we demonstrated a positive correlation between the antiepileptic effect of VNS and VNS-
induced increases in hippocampal noradrenaline in the focal pilocarpine model (Raedt et al. 2011). 
Others hypothesize that VNS exerts its antiepileptic effect via nonspecific arousal by activation of the 
reticular system in the brainstem (Aalbers et al. 2011). 
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In VNS therapy for medically refractory epilepsy the large variation in therapeutic outcome remains a 
concern (Handforth et al. 1998; Uthman et al. 1993; Ben-Menachem et al. 1994; Koo et al. 2001). To 
date, VNS is successful in one third of treated patients (Boon et al. 2007). It is unknown why some 
patients experience beneficial effects and others do not respond to the treatment. In current clinical 
practice, physicians are unable to assess effective VNS-induced vagal nerve fiber activation. 
Individualized vagal nerve recordings reflecting stimulation-induced activation of the vagus nerve and 
correlation of these recordings with therapeutic efficacy could lead to the optimization of VNS 
treatment and increase the response rate. 
At the cervical level, the majority of vagus nerve fibers are unmyelinated, high-threshold, slow-
conducting C-type fibers (65–80%) and a smaller proportion are myelinated, low-threshold, fast-
conducting A- and B-type fibers (Erlanger and Gasser 1930; Krahl 2012; Helmers et al. 2012). It is 
believed that afferent, fast-conducting A- and B-type fibers initiate VNS-induced antiepileptic effects 
in the brain (Fanselow 2012). Animal experiments demonstrate that selective destruction of C fibers 
using capsaicin does not abolish VNS-induced seizure suppression (Krahl et al. 2001). Stimulation 
levels that are therapeutically effective for seizure suppression are below the threshold for C fiber 
activation (Bunch et al. 2007). As a result of co-activation of efferent, fast-conducting laryngeal 
motor fibers, side effects such as voice alteration and hoarseness are not uncommon (Ben-
Menachem 2002; Banzett et al. 1999; Kersing et al. 2002; Uthman et al. 2004).  
The aim of the current study was to investigate the feasibility of recording VNS-induced 
electrophysiological responses from fast-conducting vagal fibers in rats, and to determine the 
characteristics of these responses. These recordings can then be applied in an experimental setting 
as a biological marker reflecting effective vagal fiber activation when electrical neurostimulation is 
applied to optimize VNS stimulation parameters. 
Material and Methods 
Animals 
Seven male Wistar rats (Harlan, The Netherlands) weighing 250–275 g were used. Animals were 
treated according to guidelines approved by the European Ethics Committee (decree 86/609/EEC). 
The study protocol was approved by the Animal Experimental Ethical Committee of Ghent University 
Hospital (ECP 08/37). All animals were kept under environmentally controlled conditions (12 h 
light/dark cycles, 20–23◦C and 50% relative humidity) with food and water intake ad libitum. 
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Surgery 
Rats were anesthetized with isoflurane (induction: 5%; maintenance: 1–2%). Buprenorphine 
(Temgesic, 0.03mg/kg subcutaneously) was administered to minimize pain. An incision was made 
over the left, anterior cervical region. The cervical, left vagus nerve was carefully dissected from the 
arteria carotis communis and a bipolar custom-made silicone cuff electrode (platinum contacts, 
3mm2 area each, 1mm space between them) was implanted around the vagus nerve, with the anode 
placed caudally and the cathode placed rostrally (Fig. 1).  
 
 
Animals were sacrificed at the end of each experiment with an overdose of pentobarbital (Nembutal, 
180mg/kg intraperitoneally). 
Electrophysiological recordings 
Electrophysiological recordings were performed under anesthesia using two thin needle electrodes 
(125 μm diameter) consisting of a stainless steel wire (California Fine Wire, California, USA) placed on 
the vagus nerve rostral to the stimulating cathode (Fig. 1). The distance between the stimulating 
cathode and both recording electrodes was determined under microscopic control. A 
Figure 1| Ventral view of the left, anterior cervical region and experimental set-up. 
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reference/ground electrode (also consisting of a stainless steel wire) was placed in contact with the 
surgical field between the stimulation and recording electrodes. 
Experimental set-up and protocol 
The custom-made silicone cuff electrode was connected to a current stimulator (DS4, Digitimer Ltd., 
Hertfordshire, England) (Fig. 1). The vagus nerve was stimulated with biphasic, charge-balanced, 
square-wave pulses. Total pulse duration was 10 μs. Longer stimulus durations, even with sufficient 
length of nerve exposed, led to broader stimulus artifacts, with the risk of masking very fast 
electrophysiological responses.  
Electrophysiological recordings were amplified 500 times and high-pass filtered at 0.15Hz. Data were 
digitized at 100 kHz using a National Instruments acquisition board (NI USB 6259) and stored on a 
personal computer. Matlab (2007b, The Math- Works, Natick, Massachusetts) was used to record 
and analyze the electrophysiological signals.  
In order to investigate the precise origin of different components in the evoked electrophysiological 
response, three different methodological approaches were investigated (Fig. 1): 
(i) The vagus nerve and recurrent laryngeal nerve were ligated using silk wire (lesion 1, 2, 3). 
(ii) The muscle-paralyzing agent vecuronium (Norcuron, 2mg/ml solution, 1ml) was applied 
to the laryngeal muscles. 
(iii) The C fiber-specific neurotoxic agent capsaicin (10% Tween 80, 10% ethanol and 80% 
saline, 0.5mg/ml) was administered locally at the cervical level of the vagus nerve. 
Data analysis 
The response latency and conduction velocity of different components in the evoked 
electrophysiological response were determined. The response latency was defined as the delay 
between the onset of the stimulus and the onset of the evoked electrophysiological component 
measured at the first recording electrode. The conduction velocity was calculated from the distance 
between the two different recording positions divided by the difference in response latency at both 
recording positions.  
Stimulus-response curves were determined by increasing the stimulus intensity from 0 mA to 6 mA in 
steps of 0.3 mA. The upper limit was set at a high intensity level because of the short pulse duration 
that was applied (10 μs). For each stimulus intensity, ten response sweeps (duration/sweep: 25 ms) 
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were averaged. After assessing response onset and response peak of the averaged 
electrophysiological component, a time interval of 50 μs and 200 μs was defined around both, 
wherein the local maximum and minimum was determined, respectively. The mean amplitudes 
within a time interval of 100 μs around the local maximum and minimum were then calculated and 
the absolute difference between the two latter values was retained as the peak amplitude. A 
Boltzmann function (Eq. (1)) was fitted to the recorded stimulus-response curves and its goodness of 
fit was calculated via residual sum of square analysis. Only fittings with a minimum goodness of fit of 
0.90 were retained. 
(1) 
where ymax is the maximal peak amplitude, I50 is the stimulus intensity required to evoke an 
electrophysiological response with half the maximal amplitude and the slope factor k describes the 
steepness of the stimulus-response curve. These parameters were determined based on the fitted 
Boltzmann function.  
Strength-duration curves were determined by defining the minimal current required to evoke an 
electrophysiological response using various pulse widths. Total pulse duration was increased from 10 
μs to 100 μs in steps of 10 μs and from 100 μs to 200 μs in steps of 20 μs. The Lapicque equation (Eq. 
(2)) was fitted to the measured strength-duration curves. 
(2) 
where Istim is the minimum stimulation current required to evoke an electrophysiological response, Irh 
is the rheobase current, Tch is the chronaxie and T is the stimulus duration. Rheobase is the minimal 
electrical current of infinite duration required to activate a single nerve fiber. Chronaxie is the 
stimulus duration required to reach threshold when the current intensity value is twice the rheobase. 
At threshold level, long duration stimulation pulses correspond to larger power consumption and 
hazardous electric charges while voltage and current density becomes prohibitive with very short 
pulses. A commonly accepted optimum for stimulation pulse duration is a value in the range of the 
chronaxie. Both the rheobase and chronaxie characterize the response to our specific stimulation 
configuration and were calculated for all components in the evoked electrophysiological response 
based on the fitted Lapicque function.  
Data is expressed as mean ± standard error of the mean (SEM). Comparisons were made with a 
Student’s t-test. P < 0.05 was assumed to indicate a significant difference. 
y(I) = ymax/(1 + exp(I50−I)/k), 
Istim = Irh(1 + Tch/T ), 
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Results 
In all rats an electrophysiological response to VNS could be recorded from the vagus nerve rostral to 
the stimulating cathode. This electrophysiological response consisted of an early and a late 
component (Fig. 2). The early, but not the late component, disappeared by ligating the vagus nerve 
between the stimulating cathode and the first recording electrode (Fig. 2). A ligation distal to the 
stimulating anode but proximal to the aortic arch abolished only the late component (Fig. 2). The late 
component also disappeared by blocking the recurrent laryngeal nerve and by applying vecuronium 
to the laryngeal muscles (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2| Top: Ventral view of the left, anterior cervical region in rats and experimental set-up. Bottom: Recordings on 
channel 1 are shown. The arrow indicates the stimulation artifact. The evoked electrophysiological response from the 
vagus nerve consisted of an early and a late component. A lesion of the vagus nerve proximal of the stimulation 
electrode (lesion 1) abolished only the early component. The late component was abolished by (i) a distal lesion of the 
vagus nerve (lesion 2), (ii) a lesion of the recurrent laryngeal nerve (lesion 3) and (iii) application of the muscle-
paralyzing agent vecuronium to the laryngeal muscles. 
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The latter provides evidence that the late component reflects laryngeal muscle activity, rather than 
nerve conduction. Taken together, at this point, the early component represented a rostrally 
propagated vagus nerve compound action potential (CAP), while the late component was a remote 
VNS-induced laryngeal motor-evoked potential (LMEP).  
A difference in response latency between both recording positions was found for the CAP, but not for 
the LMEP (Fig. 3(a)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3| (A) Recordings on channel 1 (upper trace) and channel 2 (lower trace) are shown in one rat. The arrow 
indicates the stimulation artifact. A difference in response latency between both recording channels was observed only 
for the CAP. (B) A statistically significant difference in conduction velocity between the CAP and LMEP was observed. 
The conduction velocity for the CAP was calculated based on the distance and latency difference between both 
recording positions. The conduction velocity for the LMEP was calculated using a single latency measurement, 
regardless of recording position, and distance measurement (i.e. nerve length between the stimulating cathode and the 
laryngeal muscles). 
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The presence of a latency difference for the CAP confirmed our hypothesis that the first wave is a 
propagated axonal potential, while the absence of a latency difference for the LMEP confirmed our 
hypothesis that the second wave is a remote VNS induced muscle potential. At 1.5 ± 0.1 mm rostral 
to the stimulating cathode (recording channel 1), the latencies of the CAP and LMEP were 0.18 ± 0.02 
ms and 2.88 ± 0.27 ms, respectively. At 3.4 ± 0.3 mm rostral to the stimulating cathode (recording 
channel 2), the latencies were 0.25 ± 0.03 ms and 2.88 ± 0.27 ms, respectively. Based on the 
difference in response latency for the CAP, conduction velocity was calculated to be 26.2 ± 1.4 m/s. 
Based on the nerve length between the stimulating cathode and the laryngeal muscles (89 ± 2 mm) 
that was measured under microscopic control, conduction velocity of the efferent action potentials 
leading to the LMEP was calculated to be 32.4 ± 2.4 m/s. The observed difference between the 
conduction velocity for the CAP and LMEP was statistically significant (Fig. 3(b)).  
In Fig. 4 the stimulus-response curves for both the CAP and LMEP are shown for individual rats. A 
Boltzmann function was fitted to the curves. The individual and mean (± SEM) I50 values, k values and 
ymax values are shown in Table 1. For each rat, the I50 for the CAP was higher compared to the I50 for 
the LMEP. The mean I50 for the CAP (2.4 ± 0.3 mA) was significantly higher compared to the mean I50 
for the LMEP (1.8 ± 0.2 mA). No differences were found between the mean slope factor k for the CAP 
(0.27 ± 0.03) and the mean slope factor k for the LMEP (0.20 ± 0.04). The mean ymax for the CAP and 
LMEP was 0.08 ± 0.03 mV and 0.21 ± 0.10 mV, respectively.  
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Figure 4| Plots of the amplitude of the CAP (black) and LMEP (grey) as a function of the pulse intensity and fitted 
Boltzmann curves are shown for individual rats. 
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For each component, strength-duration curves were determined and a Lapicque equation was fitted 
to the curves (Fig. 5). The rheobase for the CAP and LMEP was 140 ± 30 μA and 110 ± 26 μA, 
respectively. The chronaxie for the CAP and LMEP was 66 ± 7 μs and 73 ± 9 μs, respectively. The 
differences between the CAP and the LMEP were not significant for either parameter.  
 
Table 1| Individual and mean (±SEM) I50 values, k values and ymax values. For each rat, the I50 for the CAP was higher 
compared to the I50 for the LMEP. The mean I50 for the CAP was significantly higher compared to the mean I50 for the 
LMEP. 
 
 
 
Figure 5| Strength-duration curves for the CAP (black) and LMEP (grey) are shown. The rheobase and chronaxie are 
indicated. No significant differences for the rheobase and chronaxie were found between the CAP and the LMEP. 
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When conducting the strength-duration experiments, it was examined in all rats whether additional 
components could be observed. A third electrophysiological component with a threshold above 1 mA 
was observed in one out of seven rats, when a pulse width of 100 μs was applied (Fig. 6). The latency 
of this component was 2.8 ms, and at a distance of 4 mm between the stimulating cathode and the 
first recording electrode, this latency corresponds to a conduction velocity of 1.4 m/s. Local 
application of the C fiber-specific neurotoxic agent capsaicin to the cervical level of the vagus nerve 
(Fig. 1) abolished this additional electrophysiological component (Fig. 6). 
 
 
 
Figure 6| In addition to the CAP and LMEP, a third electrophysiological component was observed in one out of seven 
rats (upper trace). The arrow indicates the stimulation artifact. This component disappeared by local application of the 
C fiber-specific neurotoxic agent capsaicin (lower trace). The CAP is hidden within the stimulation artifact. 
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Discussion 
The primary objective of this study was to investigate the feasibility of recording VNS-induced 
electrophysiological responses from fast-conducting vagal fibers in rats, and to determine the 
characteristics of these responses. The results indicate that, using our electrode configuration, it is 
feasible to record VNS-induced electrophysiological responses from the vagus nerve in rats. A short 
(10 μs), biphasic, charge-balanced, square-wave stimulus to the vagus nerve with an intensity of 1–6 
mA induces rostrally and caudally propagating action potentials.  
In our study, electrical stimulation of the vagus nerve elicited a bidirectional activation of nerve 
fibers, with the CAP and LMEP reflecting rostrally propagating nerve action potentials and efferent 
laryngeal muscle activation, respectively. Based on the lesion experiments, no distinction can be 
made between retrograde activity in efferent fibers and anterograde activity in afferent fibers with 
regard to the CAP. As a result, both the CAP and LMEP could possibly, but not necessarily, result from 
activation of the same motor fibers, the first reflecting a nerve potential and the second a muscle 
potential. However, we hypothesize that afferent fibers were also recruited, based on a number of 
observations. Firstly, the I50 for the CAP was significantly higher compared to the I50 for the LMEP. It is 
therefore likely that the CAP does not (only) represent activation of the same low-threshold laryngeal 
motor fibers. Secondly, the conduction velocity of the fibers leading to the CAP was significantly 
lower compared to the conduction velocity of the laryngeal motor fibers leading to the LMEP, 
indicating that different fiber types were recruited. Furthermore, the conduction velocity of the 
laryngeal motor fibers calculated in this study is probably an underestimation, as we did not take into 
account an estimated delay for (i) the nerve activation (± 0.32 ms), (ii) the terminal slowing due to 
narrowing and branching of the laryngeal motor fibers (± 0.8 ms) and (iii) the neuromuscular 
transmission (± 1 ms).  
One puzzling finding is the slower conduction velocity in the proximally recorded CAP compared to 
the distal muscle LMEP response, especially taking into account the likely underestimation of the last 
value. A likely hypothesis is that the motor fibers are not numerous enough to be detected as a CAP 
but produce a clear LMEP due to the muscle “amplification” effect. Another hypothesis is local 
damage to the nerve resulting in slowing of the conduction velocity near the implantation site. The 
nerve remains unaffected further away so that the longer path for the LMEP is mostly healthy while 
almost all of the explored conduction path for the CAP would be subjected to slowing. These are 
issues for further research, but this finding indicates that in this kind of work, the observed 
conduction velocities must be interpreted cautiously.  
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If indeed the CAP and LMEP represent activation of different vagal fiber types, one could expect to 
see differences in their strength-duration curves. However, the chronaxie only depends on the 
electrical resistance and capacitance of the axonal membrane and is therefore expected to be similar 
for all myelinated nerve fibers, for all unmyelinated nerve fibers and to be very different for muscles 
(Geddes 2004). The absence of a difference in rheobase on the other hand, can be explained by the 
fact that this is a threshold value, only taking into account the most excitable fibers and not the 
average fiber population. The variability of the fiber characteristics could further obscure the 
difference between the two fiber populations sampled at the lowest threshold. In contrast, the I50 
obtained from the stimulus-response curves concerns fibers with modal characteristics and is 
therefore a more optimal representation of the average fiber population.  
With regard to the afferent CAP, we hypothesize that fast-conducting vagal A, and perhaps B, fibers 
were activated. In other experiments, conduction velocity estimates for vagal A and B afferent fibers 
were in the range of 10-30 m/s (Woodbury and Woodbury 1990; Usami et al. 2012), which is in line 
with the conduction velocity found here. Also in cats and dogs, a similar conduction velocity for type 
A and B fibers was found (Li et al. 1976, 1977; Castoro et al. 2001). The afferent CAP observed in our 
study may therefore reflect activation of the specific fiber population within the vagus nerve that 
addresses the neural pathways involved in the seizure-suppressing effect of VNS. Indeed, vagal 
afferent fibers with low-to-moderate activation thresholds (i.e. A and B fibers) are responsible for 
activating the seizure-suppressing mechanisms of VNS in the brain (Krahl et al. 2001; Bunch et al. 
2007; Groves and Brown 2005). Due to spatial constraints in rats, recording electrodes were placed 
at a small distance from the stimulation electrode. As a consequence, the electrophysiological 
response of A and B afferent fibers were likely superimposed and their contribution to the overall 
electrophysiological response could not be differentiated. Even in dogs, the electrophysiological 
component from small A fibers is clearly superimposed with the component from B fibers for 
conduction distances of 8 cm or less (Castoro et al. 2001).  
A third electrophysiological response was recorded in one out of seven animals. Because the 
conduction velocity is in the range of C fiber conduction velocity and the component disappeared by 
local application of capsaicin, the component was interpreted as a C fiber response. Higher 
stimulation intensities are needed to consistently measure C fiber responses. As levels of VNS that 
are therapeutically effective for seizure suppression are below threshold for C fiber activation (Bunch 
et al. 2007), it was beyond the scope of this study to look for an electrophysiological response from C 
fibers.  
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We suggest that the CAP can be used as an objective biomarker for effective stimulation-induced 
activation of fast-conducting afferent vagal fibers. In a recent study by our group, the LMEP was 
suggested as a marker for adequate VNS (El Tahry et al. 2011). As, however, the LMEP is the result of 
efferent stimulation and VNS in epilepsy is focused on stimulating afferents in order to obtain 
beneficial effects in the brain (Krahl et al. 2001; Woodbury and Woodbury 1990, 1991), the LMEP 
remains an indirect surrogate marker (El Tahry et al. 2011). Furthermore, CAPs of the fast-conducting 
afferent vagal fibers may serve as a new tool to identify more adequate stimulation parameters. In 
clinical practice, one of the most important issues is whether higher output current intensities can 
provide better efficacy (DeGiorgio et al. 2001). VNS is gradually uptitrated according to the reported 
seizure reduction and side effects (Rajdev et al. 2011), due to a lack of electrophysiological 
information about the vagus nerve itself. In this context, the stimulus-response curve for the CAP 
obtained in our study illustrates that recruitment of fast-conducting afferent vagal fibers rapidly 
reaches a saturation level in rats. Using a pulse of 10 μs, saturation was reached between 4 mA and 5 
mA. On the basis of equal pulse charge, these intensities are approximately equivalent to 0.16-0.20 
mA using a pulse of 250 μs. We therefore hypothesize that output current intensities of this order 
should be sufficient to reduce seizure frequency and higher output current intensities should not be 
required in the rat. Our results from rats still have to be translated to humans. Combination of VNS 
and recording of vagal nerve CAPs could help to decide at what level this change in strategy should 
be applied in individual patients. The last years, attention is paid to the development of VNS devices 
that include an electrode for combined stimulation and recording. One feasibility study has shown 
that is it possible to record CAPs using such a VNS device (El Tahry et al. 2010). Recording CAPs 
postoperatively may help clinicians to determine the individual optimal intensity required to fully 
activate fast-conducting afferent vagal nerve fibers, which in turn could be used as a patient-specific 
optimal VNS output current value. In addition, this may lead to more insights in the subpopulations 
to be targeted as, hypothetically, non-responders to the VNS therapy could be those patients in 
whom the vagus nerve does not recover sufficiently from surgery and in whom no CAPs can be 
recorded. Finally, recording from the vagus nerve might help to develop stimulation methods that 
have the potential to reduce the LMEP, which reflects VNS-related throat discomfort, while 
maximizing the CAP. 
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Conclusion 
Successful treatment of patients with medically refractory epilepsy remains a challenge due to the 
inherent intractable nature of the disorder. Electrical stimulation of the left vagus nerve is one of 
several treatment options for these patients. Despite the fact that VNS is accepted in epilepsy 
centers worldwide as a valuable and reliable therapeutic option for patients who are considered 
unsuitable for resective surgery or in whom surgery failed, specific issues remain to counteract its full 
therapeutic application. VNS research comprises 3 major topics: (i) identification of the antiepileptic 
mechanism of action, (ii) identification of the most optimal stimulation parameter settings, and (iii) 
identification of responder characteristics. In this thesis, research was done on these 3 major topics.  
Mechanism of action 
From this thesis we can conclude that: 
1. Afferent A and B fibers at the cervical level of the vagus nerve may be responsible for the 
antiepileptic effect of VNS.  
2. VNS induces an increase in the extracellular hippocampal concentration of noradrenaline, 
which is at least partly responsible for the antiepileptic effect of VNS in the intrahippocampal 
pilocarpine model of acute limbic seizures. 
3. VNS is able to modulate cortical excitability in rats. 
Stimulation parameters 
From this thesis we can conclude that: 
1. VNS at intensities of 0.25 mA, 0.5 mA and 1 mA has similar effects on cortical excitability in 
the motor cortex stimulation rat model. This finding indicates that 0.25 mA is sufficient to 
modulate cortical excitability and higher output current intensities may not be required. 
2. CAP recordings could be used to guide the search for a more appropriate choice of 
stimulation parameters. 
Predictive factors for response 
Conclusion, discussion and future perspectives 
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From this thesis we can conclude that: 
1. Extracellular hippocampal noradrenaline levels/changes are a potential biomarker for the 
efficacy of VNS in MTLE. 
2. VNS-induced electrophysiological responses recorded from the vagus nerve reflect true vagal 
fiber activation. These electrophysiological responses may be used to determine recovery of 
the vagus nerve after implantation, to determine when VNS therapy in a specific experiment 
should be initiated and to optimize VNS parameters in an experimental set-up.  
Discussion  
Mechanism of action 
The antiepileptic mechanism of action of VNS is not completely understood. Nevertheless, 
knowledge of the mechanism of action of a treatment can be crucial to increase its efficacy.  
A first research line consists of investigating the role of the different fiber types that constitute the 
vagus nerve at the cervical level. There is convincing evidence that VNS acts via activation of afferent 
vagal fibers at the cervical level (Zabara 1992; McLachlan 1993). The earliest animal studies 
suggested that the antiepileptic potential of VNS was directly related to the fraction of vagal afferent 
C fibers stimulated. This was based on a maximal evoked response from A, B and C fibers in an 
isolated vagus nerve preparation induced by parameters required to suppress seizures in awake rats 
(Woodbury and Woodbury 1990, 1991). In rats, A fibers are recruited between 0.02-0.2 mA, B fibers 
between 0.04-0.6 mA and C fibers above 1 mA (Groves et al. 2005). The theory supporting C fiber 
involvement was discarded after Krahl et al. demonstrated seizure suppression with VNS in awake 
rats following selective destruction of C fibers using capsaisin (Krahl et al. 2001). The CAP recordings 
conducted by Woodbury and Woodbury (1990, 1991) were performed in anaesthetized animals and 
such a preparation does not take electrical shunting through the body fluid into account. Our 
observation that VNS at 0.25 mA, 0.5 mA and 1 mA has similar effects on cortical excitability in the 
motor cortex stimulation rat model supports the theory that vagal afferent fibers with low-to-
moderate activation thresholds (i.e. A and B fibers) may be responsible for the central antiepileptic 
mechanisms of VNS. 
A second branch of research consists of identifying the potential role of central nervous system 
structures that are located on the anatomical pathways from the cervical part of the vagus nerve up 
to the cortex and their neurotransmitters in the antiepileptic effect of VNS. The vagus nerve 
indirectly projects to the noradrenergic LC via the NTS. Several studies indicate that the 
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noradrenergic LC is a critical structure in the antiepileptic effect of VNS. The seizure suppression 
induced by VNS in the MES model is lost with the bilateral inactivation of the LC (Krahl et al. 1998). 
Single-unit recording experiments in rats have shown that the activity of LC neurons is increased 
upon acute and chronic stimulation of the vagus nerve (Groves et al. 2005; Dorr and Debonnel 2006; 
Manta et al. 2009). Confirming the recruitment of LC neurons during VNS, immediate-early gene 
mRNA’s or their protein transcripts increase within LC neurons in response to VNS, in both rats 
(Naritoku et al. 1995) and rabbits (Gieroba and Blessing 1994; Cunningham et al. 2008). Increases in 
extracellular noradrenaline concentration have been measured by microdialysis in projection areas of 
the LC, such as the prefrontal cortex (Roosevelt et al. 2006; Follesa et al. 2007; Manta et al. 2013), 
hippocampus (Roosevelt et al. 2006; Manta et al. 2013) and amygdala (Hassert et al. 2004) in VNS-
treated rats. Also we found significant increases in the extracellular hippocampal concentration of 
noradrenaline in response to VNS. Based on in vitro studies, we hypothesize that VNS reduces the 
activity of the NTS in a frequency-dependent manner. This should be evidence by in vivo studies in 
future. Our hypothesis further considers the predominantly inhibitory influence of the NTS on LC 
neurons. VNS as a result causes a disinhibition of the LC. The activity of the LC and its widespread 
noradrenergic modulation of various brain regions are now increased. 
Although the above mentioned studies all suggest a role for noradrenaline in the antiepileptic effect 
of VNS, we are the first to show a causal relationship between VNS-induced noradrenaline increases 
and VNS-induced antiepileptic effects. In our hands, VNS suppressed pilocarpine-induced limbic 
seizures only in those rats with a hippocampal noradrenaline increase of at least 70%. Conversely, 
rats in which VNS did not increase hippocampal noradrenaline exhibited the most severe seizures. 
Furthermore, concomitant intrahippocampal administration of a selective α2 adrenorecepor 
antagonist abolished the antiepileptic effects of VNS. These findings strongly support the hypothesis 
that the antiepileptic effect of VNS in MTLE is at least partly mediated by increased hippocampal 
noradrenaline and increased hippocampal α2 adrenorecepor activation.  
The brainstem DRN contains the largest number of serotonergic neurons in the brain. These 
serotonergic neurons represent a diffusely projecting system that innervates virtually all areas of the 
central nervous system (Krahl and Clark 2012). Pharmacological treatments that increase the 
concentration of serotonin (5-HT) at its postsynaptic receptors produce antiepileptic effects in a 
variety of epilepsy models, while treatments that decrease the 5-HT concentration exert 
proconvulsant effects (Przegalinksi 1985; Giorgi et al. 2004). Although less extensively studied 
compared to the effect of VNS on the LC and its noradrenaline transmission, VNS might also suppress 
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seizures through activation of the DRN and its serotonergic transmission. While acute VNS produces 
an increase in c-fos expression in the LC, the gene product specific to delayed and persistent 
neuronal activation, i.e. delta fosB, is expressed in the DRN only after prolonged VNS treatment (≥ 14 
days) (Cunningham et al. 2008). These data are consistent with electrophysiological studies showing 
that VNS increases the firing rate of LC neurons after 1 hour of stimulation (Groves et al. 2005) while 
the firing rate of DRN neurons only increases after 14 days of stimulation (Dorr and Debonnel 2006). 
Interestingly, this last group also demonstrated that the LC must remain intact in order for VNS to 
affect DRN activity (Dorr and Debonnel 2006). LC lesions completely prevented the increase in DRN 
activity in response to chronic VNS. Furthermore, administration of an α1 adrenoreceptor antagonist 
and agonist in the DRN reduced and increased its firing rate, respectively (Manta et al. 2009). The 
levels of 5-HIAA, a metabolite of serotonin, were increased in the cerebrospinal fluid of patients 
receiving VNS (Ben-Menachem et al. 1995) and the VNS-induced suppression of PTZ-induced seizures 
in rats was abolished when serotonergic neurons are destroyed with 5,7-dihydroxytryptamin, a 
selective 5-HT neurotoxin (Browning et al. 1997). Long-term VNS treatment has been shown to 
increase the tonic activation of postsynaptic 5-HT1A receptors and to suppress neuronal firing in the 
hippocampus (Manta et al. 2013).  
Based on the knowledge that seizures are characterized by highly synchronized EEG and on the 
finding that VNS alters EEG activity in animal models (Zabara 1985; Woodbury and Woodbury 1990, 
1991; Sunderam et al. 2001; Sahin et al. 2009), it was initially hypothesized that the main mechanism 
of action of VNS consists of desynchronisation of cortical activity. This desynchronization may be the 
result of the VNS-induced activation of the noradrenergic and serotonergic system, but one report 
also suggests a possible role for acetylcholine (Nichols et al. 2011). The acitivity in the rat auditory 
cortex was suppressed by VNS and the muscarinic receptor antagonist scopolamine attenuated these 
suppressive effects. In addition, desynchronization of cortical activity may also be the result of VNS-
induced activation of brain structures that have been shown to play a role in the regulation of 
seizures such as the amygdala, limbic cortex and thalamus, and that are anatomically connected with 
the vagus nerve (Hopkins and Holstege 1978; Ito and Craig 2005). VNS inhibited cortical responses 
evoked by amygdala stimulation (Lyubashina and Panteleev 2009) and evoked slow hyperpolarization 
in rat cortical neurons (Zagon and Kemeny 2000). In line with these results, VNS has been shown to 
increase the threshold for evoking focal motor seizures in the motor cortex stimulation rat model (De 
Herdt et al. 2010). We confirmed this last finding, indicating that VNS is able to modulate cortical 
excitability.  
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Stimulation parameters 
The currently applied VNS parameters are not evidence based, but supported by a limited number of 
animal studies on efficacy and safety (Zanchetti et al. 1952; Stoica and Tudor 1967; Woodbury and 
Woodbury 1990, 1991; Zabara 1992). VNS is intermittently administered in order to reduce 
stimulation-related nerve damage (Agnew and McCreery 1990) and prolong battery life. In addition 
efficacy studies have shown that the effect of stimulation outlasts the stimulus duration (Zabara 
1992; Takaya et al. 1996; Santiago-Rodriguez et al. 2006; Carrette et al. 2007). Agnew et al. have 
demonstrated in rats that electrically induced damage to the vagus nerve was greatly reduced when 
lower stimulation frequencies (20 Hz versus 50-100 Hz) were used (Agnew et al. 1989). They also 
showed that continuous high-frequency (> 50 Hz) stimulation could cause nerve injury.  
The discovery that intermittent VNS was antiepileptic and safe in animals led to the development of 
intermittent VNS for human use. In many open label studies, the use of different stimulation 
parameters was investigated. Two randomized trials have shown that “high” settings in terms of duty 
cycle, frequency and pulse width (30 s ON, 5 min OFF, 30 Hz, 500 µsec, 0.25 to 3.5 mA) are 
significantly more effective than “low” settings (30 s ON, 180 min OFF, 1 Hz, 130 µsec, 0.25 to 3.5 
mA) (Handforth et al. 1998). When patients originally randomized to “low” settings were crossed 
over to “high” settings, a robust improvement in efficacy resulted (DeGiorigio et al. 2000). 
Furthermore, when the duty cycle was increased above 22% or when the off time was decreased to ≤ 
1.1 min, a significant improvement in efficacy was observed (DeGiorgio et al. 2001). In an 
uncontrolled, open label retrospective Belgian multicenter study, analysis of the used stimulation 
parameters revealed that the efficacy of VNS was comparable between patients with a 10 min OFF 
period and patients with shorter OFF periods (3 or 5 min) (De Herdt et al. 2007). Regarding the pulse 
width, reductions from 500 µs to 250 µs have been shown to increase tolerability (Liporace et al. 
2001). Few data are available describing the use of pulse durations of less than 250 µsec in humans. 
Therefore, the use of such low pulse durations is not recommended (Heck et al. 2002).  
Regarding the output current intensity, several animal and human studies corroborate the possibility 
that less charge density could be sufficient to obtain VNS efficacy. Acute VNS at 0.25 mA in conscious 
rats already increased staining for c-fos, an indirect marker of neuronal activity, in the NTS and many 
regions that receive its projections (Cunningham et al. 2008). In a study of Woodbury and Woodbury, 
VNS at 0.2-0.5 mA already reduced chemically-induced seizures in dogs (Woodbury and Woodbury 
1990). In a functional neuroimaging study by our group, acute VNS, using an output current intensity 
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of 0.25 mA, induced significant cerebral blood flow changes in the human brain, particularly in the 
thalamus and the limbic system (Van Laere et al. 2000). These findings were confirmed in another 
human imaging study by our group (Vonck et al. 2008). In our study, we found that VNS at 0.25 mA, 
0.5 mA and 1 mA has similar effects on cortical excitability in the motor cortex stimulation rat model. 
These results indicate that 0.25 mA is sufficient to decrease cortical excitability in rats and higher 
output current intensities may not be required. A direct translation to clinical practice is hampered 
by a large number of factors: (i) experimental rats versus humans; (ii) much smaller diameter of rat 
vagus nerve and (iii) different electrode configurations. Future prospective clinical studies comparing 
high versus low output current intensities are required to confirm if less charge density is sufficient 
to exert antiepileptic effects in humans. 
The lowest output current intensity tested in the motor cortex stimulation model was 0.25 mA. The 
question remains if even lower output current intensities are sufficient to exert an antiepileptic 
effect. This question could be answered by means of CAP recordings. The stimulus-response curve 
for the afferent CAP described in our study illustrates that recruitment of fast-conducting afferent 
vagal A and B fibers rapidly reaches a saturation level in rats. Using a single pulse of 10 µs, saturation 
was already reached between 4 and 5 mA. On the basis of equal pulse charge, these intensities are 
approximately equivalent to 0.16-0.2 mA using a pulse of 250 µs. We therefore hypothesize that 
output current intensities of this order might be sufficient to reduce seizure frequency and higher 
output current intensities might not be required in the rat.  
A recently developed mathematical model allows achievement of full activation of myelinated A and 
B fibers at the cervical level of the vagus nerve through changes in output current intensity and pulse 
width (Helmers et al. 2012). By adding additional factors that may influence the effectiveness of the 
VNS therapy, such as virtual cathodes and duty cyle and frequency of stimulation, the model could 
give clinicians complete information on how to optimize the VNS parameter settings. 
Predictive factors for response 
Another way to optimize the VNS treatment, apart from defining optimal stimulation paradigms, is 
the search for predictive factors for response. Clinical response to VNS is variable and unpredictable 
(Boon et al. 2007). Treatment with VNS (especially long-term treatment) reduces seizures with ≥ 50% 
in 50% of patients. These patients are defined as responders. In about 30% of patients, there is little 
or no effect. These patients are defined as non-responders. In the other 20% of patients, seizure 
frequency reduction ranges between 30-50%. These patients are defined as partial responders. So 
far, no criteria for success have been identified - despite the growing application of VNS, it is still not 
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possible to predict which patients will respond to what extent to the VNS therapy. Determining the 
success of VNS is important in counseling patients and in optimizing the VNS treatment. Moreover, 
because of the invasive nature of the procedure, the possible hazards of chronic implantation and 
the relatively high costs of the treatment, factors indicating a poor prognosis could favour other 
treatment options, e.g. a ketogenic diet or newly developed AEDs.  
Most studies that attempt to predict the success of VNS are based upon clinical characteristics, the 
localization of the seizure focus or the epilepsy syndrome. However, these predictors for success are 
still elusive. It was found that VNS responsiveness was associated with older age and longer epilepsy 
duration (Labar 2004) or rather to be independent of epilepsy duration (Tecoma and Iragui 2006) and 
associated with younger age (Ghaemi et al. 2010; Marras et al. 2013). Bilateral or multifocal epilepsy 
seems to be associated with a good clinical outcome, while Lennox-Gastaut syndrome typically does 
not benefit from VNS (Labar 2004; Marras et al. 2013). Few studies evaluated whether success of 
VNS can be forecasted using the EEG. Janszky et al. showed that absence of bilateral interictal 
epileptiform discharges in the EEG before VNS implantation was associated with a seizure free 
outcome (Janszky et al. 2005). Elliott et al. noted that patients with focal epilepsy had optimal 
responses to VNS therapy (Elliott et al. 2011). De Vos et al. found that EEG symmetric features, based 
on brain symmetry index, could predict VNS efficacy (De Vos et al. 2011). In their study, the 
asymmetric spectral characteristics of the interictal EEG proved more typical of non-responder than 
responder patients, indicating a role of interictal EEG in predicting the success of VNS. 
Further identification of VNS responders based on clinical and EEG characteristics require large 
prospective studies targeted at specific subpopulations of patients based on their unique 
characteristics. This remains a real challenge in a population as diverse as patients with refractory 
epilepsy. Identification of other, biological, neurochemical or neurophysiological markers may 
represent potential candidates (Janszky et al. 2005). When used in combination with a non-invasive 
technique to deliver VNS (e.g. transcutaneous activation of the vagus nerve (Dietrich et al. 2008)), 
such a biomarker for efficacy of VNS could help clinicians to reliably identify responders prior to 
surgical implantation of a VNS device. 
We are the first to show that the antiepileptic effect of VNS in MTLE is at least partly mediated by 
increased hippocampal noradrenaline and increased hippocampal α2 adrenorecepor activation. 
Noradrenaline levels/changes are therefore a potential biomarker for the efficacy of VNS in MTLE. 
Translation to human MTLE patients is hampered by the fact that limbic seizures in our study are 
acutely evoked. It should therefore be first evaluated if the same type of correlation between the 
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hippocampal noradrenaline content and antiepileptic effects of VNS also exists in a model of 
spontaneous and not acutely evoked limbic seizures (e.g. the post-status model). Furthermore, to 
date no non-invasive techniques are available to directly measure noradrenaline levels/changes in 
the human brain. 
In current clinical practice, physicians are unable to assess true VNS-induced vagal nerve fiber 
activation. In our studies, we focused on the identification of an electrophysiological parameter that 
relfects true activation of the vagus nerve by VNS. Electrophysiological responses to VNS were 
measured using thin-point recording electrodes placed on the vagus nerve near the stimulation 
electrode. In the first study, a remote Larynx Muscle Evoked Potential (LMEP) was recorded. As, 
however, the LMEP is the result of efferent stimulation and VNS in epilepsy is focused on stimulating 
afferents in order to obtain beneficial effects in the brain (Woodbury and Woodbury 1990,1991; 
Krahl et al. 2001), the LMEP remains an indirect surrogate marker for adequate VNS. In the second 
study, CAPs of the fast-conducting afferent vagal A and B fibers were recorded. This CAP may provide 
an objective parameter for adequate VNS. In addition, both the LMEP and the CAP may be used to 
determine recovery of the vagus nerve after implantation and to determine when VNS therapy 
should be initiated.  
Future perspectives 
Mechanism of action 
An important finding of this thesis is the causal relationship between VNS-induced hippocampal 
noradrenaline increases and VNS-induced suppression of limbic seizures in the intrahippocampal 
pilocarpine model. We hypothesize that the VNS-induced hippocampal noradrenaline increases are 
the result of a VNS-induced enhancement of the activity of LC neurons. This hypothesis could be 
evidenced by selective lesioning of the LC noradrenergic neurons in the intrahippocampal pilocarpine 
model. We anticipate that following selective lesioning of the LC noradrenergic neurons in the 
intrahippocampal pilocarpine model, the VNS-induced hippocampal noradrenaline increases will be 
no longer present. If this correlates with a loss of antiepileptic efficacy of VNS, it would be a strong 
evidence for a crucial role of the LC in the antiepileptic effect of VNS in MTLE.  
Different lesioning approaches for selective destruction of LC noradrenergic neurons can be used. 
The LC can be lesioned following intraperitoneal administration of N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine (DSP-4). An alternative, more selective approach makes use of intrahippocampal 
injection with an antiserum against Dopamine-β-Hydroxylase (DbH) conjugated with the neurotoxin 
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saporin. DbH is the enzyme that converts dopamine to noradrenaline at the level of noradrenergic 
nerve terminals. The neurotoxin is taken up retrogradely by noradrenergic neurons that project to 
the hippocampus. Eventually, these neurons will be lesioned. Using intrahippocampal microdialysis 
and the acute pilocarpine model, the impact of LC lesions on the hippocampal noradrenergic 
response following VNS and on the antiepileptic effect of VNS in MTLE can be investigated.  
Limbic seizures in the intrahippocampal pilocarpine model are acutely evoked. A next step is to study 
the role of hippocampal noradrenaline in the antiepileptic effect of VNS in a model of spontaneous 
limbic seizures.  
In our laboratory a rat model of spontaneous limbic seizures is available. In this model, a status 
epilepticus and anatomopathological changes are induced by intraperitoneal injection of kainic acid, 
an analogue of the excitatory neurotransmitter glutamate. A few days to weeks after the status 
epilepticus rats develop spontaneous seizures in which the hippocampus is heavily involved. The 
epileptic rats could be implanted with a VNS electrode, EEG registration electrodes and a 
microdialysis guide cannula in the hippocampus. During two weeks of baseline monitoring the 
frequency, duration and severity of epileptic seizures could be determined. Then VNS could be 
initiated and freely moving animals could be monitored again for two weeks using the video-EEG 
setup to determine the frequency, duration and severity of spontaneous seizures. While continuing 
the VNS treatment, hippocampal perfusion of an α2 adrenorecepor antagonist could now be 
initiated. The influence of the antagonist treatment on the effects of VNS on seizures in the kainic 
acid model could be monitored for 2 weeks. We hypothesize that VNS will reduce limbic seizure 
activity in the kanic acid model and that this antiepileptic effect will be abolished by the antagonist 
treatment. If this is indeed the case, it would provide evidence for a role of hippocampal 
noradrenaline and α2 adrenorecepors in the antiepileptic effect of VNS in a model of spontaneous 
limbic seizures. If this is not the case, spontaneous limbic seizures and entailed anatomopathological 
lesions are likely to compromise noradrenergic neurotransmission. We hypothezise that possible 
antiepileptic effects of VNS are then the result of other, more chronic VNS-induced neuromodulatory 
effects, such as induction of neuronal plasticity and neurogenesis (Revesz et al. 2008).  
We hypothezise that VNS in clinical practice reduces the activity of the NTS neurons. Our hypothesis 
further considers the predominantly inhibitory effect of the NTS on the LC. As a result of VNS, LC 
neurons are relieved from this inhibitory influence of the NTS, and their activity is increased. Our 
hypothesis could be evidenced by determining the effect of NTS antagonism on the LC firing rate. The 
NTS could be inhibited by local application of an AMPA-receptor antagonist. If NTS antagonism 
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increases the firing rate of LC neurons, it would provide direct evidence that NTS inhibition might 
exert antiepileptic effects.  
LC neurons not only contain noradrenaline, but the noradrenaline co-transmitters Neuropeptide Y 
(NP-Y) and galanin are also expressed in LC neurons (Gundlach et al. 1990; Xu et al. 1998). Both 
neuropeptides have shown strong antiepileptic properties when applied locally into the 
hippocampus (Mazarati et al. 2002; Meurs et al. 2007). For these reasons, we hypothesize that 
hippocampal levels of both neuropeptides will increase in response to VNS and that these 
neuropeptides are also active contributors to the antiepileptic effect of VNS.  
The effect of VNS on hippocampal NP-Y and galanin release can be studied in different ways. Post-
mortem analysis of hippocampal NP-Y and galanin expression in VNS-treated rats can be performed 
using immunohistochemistry and ELISA techniques. The results can be compared to data obtained 
from LC-lesioned or sham-treated animals. It is worthwhile to investigate if the same ELISA technique 
can be used to analyze hippocampal microdialysates for NP-Y and galanin contents as well. If VNS 
indeed increases the hippocampal NP-Y and/or galanin concentration, selective antagonists for NP-Y 
and/or galanin receptors can be locally administered into the hippocampus to unravel the potential 
contribution of both neuropeptides to the antiepileptic effect of VNS in the intrahippocampal 
pilocarpine model of acute limbic seizures. 
In this thesis we confirmed that VNS is able to increase the threshold for evoking focal motor seizures 
in the motor cortex stimulation rat model, indicating that VNS is able to modulate cortical 
excitability. Further research may be performed within the motor cortex stimulation rat model to 
explore the detailed underlying mechanisms responsible for the VNS-induced modulation of cortical 
excitability. Using microdialysis, neurochemical effects of VNS could be measured and correlated 
with the VNS-induced increases in seizure threshold. Based on the knowledge that the generalized 
paracrine noradrenaline diffusion affects the entire cortical activity, we hypothesize that 
noradrenaline will be involved in the VNS-induced modulation of cortical excitability. Also SPECT 
imaging studies could identify a neuronal correlate for the attenuation of cortical excitability with 
VNS in this animal model. The SPECT tracer 99mTc-ethyl cysteine dimer is characterized by a high and 
immediate cerebral uptake after intravenous injection (less than 10% of the administered activity 
remains in the blood after 5 minutes) (Shishido et al. 1994), making quick imaging at the moment of 
tracer injection possible. At the end of a VNS trial, the threshold for evoking focal motor seizures 
could be determined, immediately followed by SPECT imaging. In addition to the LC, we hypothezise 
that VNS-induced cerebal blood flow changes will be observed in brain structures that have been 
shown to play a role in the regulation of seizures such as the amygdala, limbic cortex and thalamus, 
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and that these changes will correlate with clinical efficacy of VNS in the motor cortex stimulation 
model.  
Stimulation parameters 
The lowest output current intensity tested in the motor cortex stimulation model, i.e. 0.25 mA, was 
sufficient to affect cortical excitability. Based on the stimulus-response curve for the vagal afferent A 
and B fibers described in our other study, we hypothesize that even lower output current intensities 
may be sufficient to significantly reduce cortical excitability. A combination of CAP recordings and 
threshold determinations in the motor cortex stimulation rat model could give more insight in this 
hypothesis. 
Among the currently applied VNS parameters, many different combinations are optional and the 
efficacy of different paradigms should be investigated in a prospective way to evaluate potential 
superiority of certain paradigms with regards to efficacy as well as battery life. It is however likely to 
assume that not one ultimate set of stimulation parameters will benefit all different types of epilepsy 
and all refractory individuals. Individually guided stimulation parameter titration may be a more 
successful avenue.  
Recording CAPs of afferent A and B fibers at the cervical level of the vagus nerve may represent a 
new tool for guiding individual parameter titration. Over the last years, attention is paid to the 
development of VNS devices that include an electrode for combined stimulation and recording (El 
Tahry et al. 2010). Recording CAPs post-operatively may help clinicians for example to determine the 
individual optimal intensity required to fully activate fast-conducting afferent vagal A and B fibers, 
which in turn could be used as a patient-specific optimal VNS output current value. In addition, this 
tool might help to develop stimulation methods that have the potential to reduce the LMEP, which 
reflects VNS-related throat discomfort, while maximizing the afferent CAP. 
Predictive factors for response 
Based on our rat study, we hypothesize that noradrenaline may be a useful biomarker for the 
efficacy of VNS in human MTLE. Even more, based on the knowledge that the generalized paracrine 
noradrenaline diffusion affects the entire cortical activity, we hypothesize that noradrenaline may be 
a useful biomarker for VNS efficacy in other types of epilepsy as well. The challenge is to measure 
noradrenaline in the human brain. Although no non-invasive techniques are currently available to 
directly measure noradrenaline in the human brain, an increase in noradrenaline may be indirectly 
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evaluated through parameters which are modulated by central noradrenergic signalization, such as 
the pupil diameter and the P300 component of event-related potentials. Recently, a retrospective 
clinical trial, including patients with diverse seizure foci, has been successfully performed at the 
Center for Neurophysiological Monitoring (CNM) at Ghent University Hospital. Patients with a good 
therapeutic response to VNS showed an increase in the amplitude of the P300 component of event-
related potentials during the VNS ON phase compared to the VNS OFF phase. As the amplitude of the 
P300 component of event-related potentials is modulated by central noradrenergic signalization, 
these results indirectly indicate that VNS in these patients increases the noradrenaline levels and that 
the P300 component of event-related potentials can be used a biomarker for efficacy of VNS. A 
prospective clinical study is currently being conducted on this topic.  
Another non-invasive and indirect technique to assess changes in central noradrenaline release could 
be the use of radioligands. Recently, it was shown that the PET tracer 11C-yohimbine, an α2 
adrenoreceptor antagonist, can be used to picture pharmacologically-induced changes in 
noradrenaline in the pig brain (Landau et al. 2012). Based on this study, a pilot trial is currently being 
performed in our laboratory to evaluate if 11C-yohimbine can be used to picture changes in 
noradrenaline concentration in the rat brain during VNS. If the results are satisfactory and can be 
correlated with seizure reduction in the intrahippocampal pilocarpine model, clinical trials could be 
initiated to evaluate if the PET tracer 11C-yohimbine can be used as a surrogate biomarker for the 
efficacy of VNS in human epilepsy.  
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Summary 
Epilepsy is a frequently occurring chronic neurological disorder, characterized by the spontaneous 
and recurrent occurrence of epileptic seizures. Epilepsy affects approximately 0.5-1% of the 
population. Despite adequate antiepileptic treatment, 30-40% of patients continue to have seizures 
or experience unacceptable pharmacological side effects. These patients have medically refractory 
epilepsy and require a thorough diagnostic and therapeutic evaluation in a specialized epilepsy 
center. Epilepsy surgery is an invasive but often curative treatment option that aims at removing the 
ictal onset zone believed to be responsible for seizure occurrence. A substantial number of patients is 
however rejected from surgery due to the fact that a well circumscribed, unifocal ictal onset zone 
cannot be identified or due to the fact that the ictal onset zone is located in functional brain tissue. 
Unsuitable candidates for resective surgery have few options left. Administration of newly developed 
antiepileptic drugs (AEDs) leads to seizure freedom in only a small number of patients. The inability 
to adequately treat all patients with refractory epilepsy provides a continuous impetus to investigate 
novel forms of treatment. One novel treatment option is neuromodulation by electrical stimulation 
of central nervous system structures. One type of neuromodulation is vagus nerve stimulation (VNS).  
VNS involves stimulation of the tenth cranial nerve by means of a spiral stimulation electrode, wound 
around the vagus nerve at the cervical level and connected to a subclavicularly implanted pulse 
generator. The first human implant was performed in 1990. Now, over 60,000 patients are treated 
with VNS worldwide. Despite the established efficacy and safety, the large number of treated 
patients and more than 20 years of experience with VNS, some specific issues about this treatment 
remain to be established. The currently existing drawbacks of clinical application of VNS are the lack 
of responder identification prior to implantation and the insufficient knowledge about the most 
appropriate stimulation parameters. Improved knowledge of the antiepileptic mechanism of action 
of VNS may support the solution for these drawbacks. This thesis focused on these unresolved VNS-
related topics with the aim of discovering new insights in the treatment modality of VNS for 
refractory epilepsy.  
Several studies indicate that the noradrenergic brainstem nucleus locus coeruleus (LC) is a critical 
structure in the antiepileptic effect of VNS. Presumably as a result of enhancement of the activity of 
LC neurons, we observed an increase in the extracellular hippocampal noradrenaline concentration 
in VNS-treated rats. A strong positive correlation was found between the noradrenergic and 
antiepileptic effects of VNS in the focal pilocarpine limbic seizure model and blockade of 
hippocampal α2 receptors reversed the antiepileptic effect of VNS. These findings 
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strongly suggest that VNS-induced increases in extracellular hippocampal noradrenaline are at least 
partly responsible for the antiepileptic effect of VNS in a model for limbic seizures, and constitute a 
potential biomarker for the efficacy of VNS in temporal lobe epilepsy. When used in combination 
with a non-invasive technique to deliver VNS (e.g. transcutaneous activation of the vagus nerve), 
noradrenaline as a biomarker for the efficacy of VNS could help clinicians to reliably identify 
responders prior to surgical implantation of a VNS device, and to determine optimal stimulation 
parameters in a more rational way. 
With regards to stimulation parameters, we found that VNS at 0.25 mA, 0.5 mA and 1 mA increased 
the threshold for evoking focal, motor seizures compared to sham stimulation in rats. These results 
indicate that, of the VNS output current intensities tested, 0.25 mA is sufficient to decrease cortical 
excitability and higher output current intensities may not be required. Our results are supported by 
several animal and human studies and support the theory that vagal afferent fibers with low-to-
moderate activation thresholds may be responsible for addressing the antiepileptic mechanisms of 
VNS. Future prospective clinical trials comparing high versus low output current intensities are 
required to confirm these findings, as low output current intensities significantly increase battery life 
and improve tolerability.  
In current clinical practice, physicians are unable to assess effective VNS-induced vagal nerve fiber 
activation. In this thesis, we focused on the identification of an electrophysiological parameter that 
reflects adequate VNS. Therefore, electrophysiological responses to VNS were measured using thin-
point recording electrodes placed on the vagus nerve near the stimulation electrode. The 
electrophysiological response to VNS consisted of an early and a late component, identified as a 
compound action potential (CAP) of fast-conducing afferent vagal fibers and a remote laryngeal 
motor-evoked potential (LMEP), respectively. As the LMEP is the result of efferent co-stimulation, 
and VNS in epilepsy is focused on stimulating fast-conducting vagal afferents in order to obtain 
beneficial effects in the brain, the CAP may provide the best objective parameter for adequate VNS. 
Both the LMEP and CAP may be used to determine the recovery of the vagus nerve after 
implantation and to determine when VNS therapy can be initiated. In addition, recording CAPs of 
fast-conducting afferent vagal A and B fibers may represent a new tool for guiding individual 
parameter titration and might help to develop stimulation methods that have the potentials to 
reduce the efferent LMEP, which reflects VNS-related throat discomfort, while maximizing the 
afferent CAP. 
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Résumé 
L’épilepsie est une affection neurologique chronique fréquente, caractérisée par l’apparition 
spontanée et récurrente des crises d’épilepsie. Malgré les traitements antiépileptiques adéquats, 30 
à 40% des patients continuent d’avoir des convulsions ou des effets secondaires pharmaceutiques 
inacceptables. Ces patients souffrent d'épilepsie réfractaire au traitement médical et nécessitent une 
évaluation diagnostique et thérapeutique approfondie dans un centre spécialisé. La chirurgie 
d'épilepsie est une option invasive mais souvent curative qui vise à éliminer la zone ictale qui est 
responsable de la survenance de crises. Un nombre important de patients est cependant rejeté pour 
la chirurgie en raison du fait qu’une zone ictale unifocale et bien circonscrit ne peut être identifiée ou 
en raison du fait que la zone ictale se trouve dans le tissu cérébral fonctionnel. Candidats 
inappropriés pour une chirurgie d'exérèse ont peu d'autres options. Administration nouvellement 
mis au point des médicaments antiépileptiques (AEDs) conduit à la contrôle que dans un petit 
nombre de patients. L'incapacité à traiter correctement tous les patients souffrant d'épilepsie 
réfractaire fournit une impulsion continue à enquêter sur de nouvelles formes de traitement. Une 
nouvelle option de traitement est la neuromodulation par stimulation électrique des structures du 
système nerveux central. Un type de neuromodulation est la stimulation du nerf vague (VNS). 
VNS implique la stimulation du dixième nerf crânien au moyen d'une électrode de stimulation en 
spirale, enroulée autour du nerf vague, au niveau du col et reliée à un générateur d'impulsions 
implanté dans la région sous-claviculaire. Le premier implant humain a été réalisé en 1990. 
Maintenant, plus de 60000 patients sont traités par la VNS dans le monde entier. Malgré l'efficacité, 
la sécurité établie, le grand nombre de patients traités et plus de 20 ans d'expérience avec le système 
de la VNS, certaines questions spécifiques au sujet de ce traitement restent à établir. Les 
inconvénients existant actuellement à l’application clinique de la VNS sont le manque d'identification 
répondeur avant l'implantation et l'insuffisance des connaissances sur les paramètres de stimulation 
les plus appropriés. Une meilleure connaissance du mécanisme antiépileptique de l'action de la VNS 
peut soutenir la solution pour ces inconvénients. Cette thèse a porté sur ces sujets non résolus de la 
VNS liées dans le but de découvrir de nouvelles perspectives dans la modalité de traitement de la 
VNS pour l'épilepsie réfractaire. 
Plusieurs études indiquent que le noyau locus coeruleus (LC) est une structure située dans le tronc 
cérébral noradrénergique essentielle à l'effet antiepileptique de la VNS. Probablement en raison de 
l'amélioration de l'activité des neurones LC, nous avons observé une augmentation de la 
concentration de noradrénaline extracellulaire dans l'hippocampe de rats traités par VNS. Une forte
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 corrélation a été trouvée entre les effets noradrénergiques et antiepileptique de la VNS dans le 
modèle limbique pilocarpine focal. En plus, le blocus des récepteurs α2 de l'hippocampe annulait 
l'effet antiepileptique de la VNS. Ces résultats suggèrent fortement que les augmentations de la 
noradrénaline hippocampe extracellulaire induites par la VNS sont au moins partiellement 
responsable de l'effet antiepileptique de la VNS dans un modèle de crises limbiques, et constituent 
un bio marqueur potentiel pour l'efficacité de la VNS dans l'épilepsie du lobe temporal. S'il est utilisé 
en combinaison avec une technique non-invasive pour fournir une VNS (par exemple l’activation 
transcutanée du nerf vague), la noradrénaline comme un bio marqueur de l'efficacité de la VNS 
pourrait aider les cliniciens à identifier de manière fiable les respondeurs avant l'implantation 
chirurgicale d'un dispositif VNS, et à déterminer les paramètres de stimulation optimale d'une 
manière rationnelle. 
En ce qui concerne les paramètres de stimulation, nous avons constaté que la VNS à 0,25 mA, 0,5 mA 
et 1 mA également augmente le seuil pour évoquer des convulsions moteur focales par rapport à 
sham stimulation des rats. Ces résultats indiquent que, sur les intensités actuellement testés, 0,25 
mA est suffisant pour diminuer l'excitabilité corticale et des intensités de courant plus élevés ne 
peuvent pas être nécessaire. Nos résultats sont supportés par plusieurs études animales et humaines 
et soutiennent la théorie selon laquelle les fibres afférentes vagales avec des seuils d'activation faible 
à modéré jouent un rôle important dans le mécanisme antiépileptique de l'action de la VNS. Essais 
cliniques prospectifs futurs comparant les intensités de courant élevées par rapport à faible 
rendement sont nécessaires pour confirmer ces résultats, comme intensités faibles augmentent 
considérablement l'autonomie de la batterie et améliorent la tolérance. 
Dans la pratique clinique actuelle, les médecins sont incapables d'évaluer l'activation des fibres du 
nerf vague induite par la VNS. Dans cette thèse, nous nous sommes concentrés sur l'identification 
d'un paramètre électrophysiologique qui reflète une VNS adéquate. Les réponses 
électrophysiologiques à la VNS ont été mesurées à l'aide des électrodes d'enregistrement mince 
placées sur le nerf vague près de l'électrode de stimulation. La réponse électrophysiologique à la VNS 
se composait d'une composante tôt et d’une composante tard, identifié comme un potentiel d'action 
composite (CAP) de fibres vagales afférentes rapide conducteurs et un potentiel laryngeal évoqué 
moteur à distance (LMEP), respectivement. Comme le LMEP est le résultat de co-stimulation 
efférente, et la VNS dans l'épilepsie est axée sur la stimulation rapide conducteur afférences vagales 
afin d'obtenir des effets bénéfiques dans le cerveau, la CAP peut offrir le meilleur paramètre objectif 
pour une VNS adéquate. Le LMEP et la CAP peuvent être utilisés les deux pour déterminer le temps 
de récupération du nerf vague après l'implantation et pour déterminer quand une titration de la 
thérapie de VNS peut être initiée. En outre, l'enregistrement CAP de rapide conducteur afférente 
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vagale A et fibres B peut représenter un nouvel outil pour guider le titrage des paramètres 
individuels et pourraient aider à développer des méthodes de stimulation qui ont le potentiel de 
réduire le LMEP efferent. 
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Samenvatting 
Epilepsie is een frequent voorkomende chronische neurologische aandoening die gekenmerkt wordt 
door het herhaaldelijk en episodisch optreden van epileptische aanvallen. Epilepsie komt voor bij 0.5-
1% van de bevolking. De meeste patiënten reageren goed op een medicamenteuze behandeling. Bij 
30-40% van de epilepsiepatiënten komen de epileptische aanvallen niet of slechts gedeeltelijk onder 
controle ondanks een optimale behandeling met antiepileptica. Deze patiënten hebben refractaire 
epilepsie en vereisen een meer uitgebreide diagnostische en therapeutische evaluatie in een 
gespecialiseerd epilepsiecentrum. De behandelingsmogelijkheden bestaan uit epilepsiechirurgie 
en/of toediening van recent ontwikkelde antiepileptica in het kader van fase-III klinische studies. Het 
relatief groot aantal refractaire patiënten en de beperkte beschikbaarheid van middelen om 
refractaire epilepsie te behandelen onderstreept de nood tot het ontwikkelen van nieuwe 
behandelingsmodaliteiten. Neuromodulatie door elektrische stimulatie van zenuwstructuren 
(neurostimulatie) met de bedoeling epileptische aanvallen te onderbreken vormt hiervan een 
voorbeeld. Concreet betreft het stimulatie van de tiende craniale zenuw, nl. “nervus vagus 
stimulatie” (NVS). 
Bij NVS wordt een spiraalvormige stimulatie elektrode rond de linker nervus vagus in de halsregio 
gewonden en verbonden met een kleine pulsgenerator die subcutaan thv het sleutelbeen geplaatst 
wordt. De eerste implantatie in een epilepsiepatiënt vond plaats in 1990. Ondertussen worden 
wereldwijd reeds meer dan 60000 patiënten behandeld met NVS. Ondanks de doeltreffendheid en 
veiligheid van de NVS behandeling, het groot aantal behandelde patiënten en meer dan 20 jaar 
ervaring met NVS, dienen nog een aantal aspecten opgehelderd te worden. De factoren die de 
klinische doeltreffendheid van NVS in een individuele patient bepalen zijn momenteel ongekend. 
Daarnaast is er nood aan een identificatie van de meest optimale stimulatie parameters en aan een 
gedetailleerde kennis van het anti-epileptisch werkingsmechanisme van NVS. Dit proefschrift richt 
zich op deze NVS-gerelateerde onderwerpen met het oog op het aantonen van nieuwe inzichten in 
de NVS therapie voor refractaire epilepsie. 
Het anti-epileptisch effect van NVS wordt toegeschreven aan de activatie van afferente vezels van de 
nervus vagus. Een zenuwkern van de nervus vagus die een belangrijke rol lijkt te spelen in het 
aanvalsonderdrukkend effect van NVS is de locus coeruleus (LC). Deze kern, gelegen in de pons, is rijk 
aan noradrenerge neuronen en is de voornaamste bron van noradrenaline in de hersenen. 
Vermoedelijk als gevolg van een verhoogde activiteit van LC neuronen, toonde onze eerste studie 
een toename van de noradrenaline concentratie in de hippocampus in VNS-behandelde dieren. Deze 
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studie toonde bovendien aanvalsonderdrukkende effecten van NVS in een diermodel voor temporale 
kwab epilepsie. De mate van aanvalsonderdrukking bleek positief gecorreleerd te zijn met de 
toename van de hippocampale noradrenaline concentratie en de anticonvulsieve effecten van NVS 
werden opgeheven door intrahippocampale toediening van een α2 adrenoreceptor antagonist. Deze 
bevindingen suggereren dat de NVS-geïnduceerde toename van de hippocampale noradrenaline 
concentratie minstens gedeeltelijk verantwoordelijk is voor de aanvalsonderdrukkende effecten in 
een diermodel voor temporale kwab epilepsie. Hippocampaal noradrenaline zou aldus een potentiële 
biomarker kunnen zijn voor de potentie van NVS om limbische aanvallen te onderdrukken. 
In een tweede studie werd het effect van verschillende NVS intensiteiten op de corticale 
exciteerbaarheid in ratten geëvalueerd. NVS aan 0.25 mA, 0.5 mA en 1 mA verhoogde de drempel 
voor het uitlokken van focaal, motorische aanvallen in gelijke mate. Deze resultaten wijzen erop dat 
NVS aan 0.25 mA volstaat om de corticale exciteerbaarheid in ratten te verlagen, en dat hogere 
stimulatie intensiteiten niet vereist zijn. Onze resultaten worden ondersteund door verschillende 
dierexperimentele en humane studies, en ondersteunen de theorie dat vagale afferente vezels met 
een lage tot matige activeringsdrempel verantwoordelijk zijn voor het activeren van het 
aanvalsonderdrukkend werkingsmechanisme van NVS. Prospectieve klinische studies zijn nodig om 
deze bevindingen te bevestigen, aangezien lagere NVS intensiteiten de levensduur van de batterij 
aanzienlijk verhogen en de bijwerkingen van de NVS therapie aanzienlijk reduceren. 
In de huidige klinische praktijk zijn neurologen niet in staat om werkelijke NVS-geïnduceerde activatie 
van de nervus vagus te beoordelen. In dit proefschrift hebben we ons gericht op de identificatie van 
een elektrofysiologische parameter die effectieve NVS weerspiegelt. Hiertoe werden NVS-
geïnduceerde elektrofysiologische responsen gemeten met behulp van puntelektroden die geplaatst 
werden op de nervus vagus in de buurt van de stimulatie elektrode. De elektrofysiologische 
responsen bestonden uit een vroege en een late component, geïdentificeerd als respectievelijk een 
“compound action potential” (CAP) van de snelgeleidende afferente vagale vezels en een op afstand 
gemeten “larynx motor-evoked potential” (LMEP). Aangezien de LMEP het resultaat is van efferente 
co-stimulatie en VNS in epilepsie gericht is op het stimuleren van snelgeleidende afferente vagale 
vezels, kan de CAP beschouwd worden als de beste objectieve biomarker voor adequate NVS. Zowel 
de LMEP als de CAP kunnen gebruikt worden om het herstel van de nervus vagus na implantatie te 
bepalen en om te bepalen wanneer uptitratie van de NVS therapie kan gestart worden. Daarnaast 
zouden CAP registraties kunnen gebruikt worden als een nieuwe methode om op individuele basis te 
zoeken naar de meest adequate NVS parameters. 
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Dankwoord 
Dit doctoraatswerk bleek een werk van lange adem te zijn, een weg van mooie ups, maar toch ook 
downs, eigen aan het voltooien van een dergelijke onderneming. Ongetwijfeld clichés die menig 
doctoraatstudent zich al bedacht heeft. Hierbij wil ik graag even de tijd nemen om een aantal 
personen in de bloemetjes te zetten die een belangrijke rol hebben gespeeld bij het voltooien van dit 
proefschrift. 
Als eerste had ik graag Prof. Dr. Paul Boon bedankt om mij een plaats te bieden binnen zijn 
laboratorium. Prof. Boon zorgde en zorgt nog steeds voor een uitstekend kader waarin naar hartelust 
aan onderzoek kan gedaan worden.  
Dankzij de kritische en wetenschappelijke bijdrage van mijn promotor Prof. Dr. Kristl Vonck heb ik 
mijn interesse voor de neurowetenschappen verder kunnen uitbouwen tot een passie, die niet meer 
weg te denken is uit mijn professionele leven. De regelmatige peilingen naar nieuwe 
onderzoeksresultaten en het aanwenden van nieuwe nuttige experimenten hebben zeker hun nut 
bewezen bij het tot stand brengen van dit doctoraatswerk.  
Ook zonder mijn co-promotor Prof. Dr. Robrecht Raedt had ik dit punt waarschijnlijk nooit bereikt. 
Zijn bereidheid tot het nalezen van manuscripten, projecten, data en zoveel meer kende de 
afgelopen jaren geen grenzen. Hij leerde me dat wat moeilijk en onmogelijk lijkt niet altijd 
onhaalbaar is. Bedankt, Prof. Raedt, voor de professionele ondersteuning, intensieve en 
stimulerende begeleiding en de waardevolle en kritische wetenschappelijke input. 
Prof. Dr. Delbeke en Prof. Wadman, jullie zijn voor mij speciale leermeesters geweest. Bedankt voor 
de vele leerrijke woorden over elektroden en stimulatie. 
Doctoreren en eenzaamheid zouden hand in hand kunnen gaan. Maar dat is, op zijn zachtst 
uitgedrukt, buiten ons labo gerekend. De aangename werkomgeving, waarin naast het druk in de 
weer zijn ook altijd tijd en ruimte was voor een babbeltje/lolletje over niet-neurologische zaken, 
zorgde voor een unieke groepsgeest, en vele collega’s zijn de afgelopen jaren dan ook in de eerste 
plaats vrienden geworden. Bedankt Bregt, Annelies, Lars, Ine, Ine, Lisa, Mathieu en Leen! In het 
bijzonder wens ik mijn jaargenoten Ine en Bregt veel succes met het weldra voltooien van hun 
doctoraat. De jongere garde wens ik ook heel veel succes, mooie resultaten en veel 
doorzettingsvermogen. Ook een dikke merci aan de immer sympathieke Corine. Dankzij jou konden 
we toch steeds een gaatje vinden in die drukke agenda! 
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Een woordje van dank is er zeker ook voor de dierenarts Dr. Ingrid Van Overbeke en de 
dierenverzorgers van het animalarium voor hun geduld bij het verzorgen van de (niet altijd 
gemakkelijke) proefdieren. 
Gelukkig bleef er ook nog wat vrije tijd over. Bedankt fantastische vrienden voor alle toffe momenten 
tijdens etentjes, spelletjesavonden, weekenden, reisjes of gewoon op café: Ilse-Mien, Marlies, Iris, 
Katrijn, Ine, Kirsten, Thierry, Wendy, Bert, Evelyne, Pieter, Sara, Webbey, Annelies, Christophe, 
Fanie, Dominique, Debbie, Arvid,…! Ook een dikke dankjewel voor alle begeleiders en leden van 
Abajaa! Het jaarlijks zomerkamp was steeds fantastisch! 
Mijn grootste supporters wil ik hier uiteraard ook bedanken. In de eerste plaats wens ik mijn lieve 
ouders van harte te bedanken voor hun onvoorwaardelijke steun. Bedankt mama en papa voor de 
geweldige jeugd, het geven van alles kansen waarvan ik kon dromen en de blijvende interesse in mijn 
onderzoek. Wat er ook moge gebeuren, jullie bereidheid om alles te laten vallen voor jullie kinderen 
kent geen grenzen. Ook een dikke merci aan Karen, Karel, Pieter, Karolien, Bart en An om mij op te 
peppen wanneer nodig en voor de vele leuke momenten. Ik kan mij geen betere (schoon)zussen en 
(schoon)broers voorstellen! Een dikke zoen ook voor de allerkleinste Molletjes! Ook mijn 
schoonmama Thérèse en Mammoe wil ik graag in de bloemetjes zetten. Dank je wel!  
En als laatste, maar absoluut niet in het minste, wil ik mijn allerliefste schat bedanken. Karel(tje), 
liefje, merci voor je opkikkertalent, luisterend oor, geduld, eindeloze humor en de enorme vreugde 
die je brengt in mijn leven! Je bent er altijd om mij op te vangen, letterlijk en figuurlijk. Ik hoop dat 
we lang van elkaar kunnen genieten!  
 
Dit werk kwam tot stand dankzij de financiële steun van het Fonds voor Wetenschappelijk Onderzoek 
Vlaanderen. 
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